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Rh(III)-Catalyzed Alkene Difunctionalization for the Synthesis of Nitrogen-Containing Compounds 
Sumin Lee 
 
 Nitrogen-containing compounds are essential structural units in a myriad of biologically 
active molecules including pharmaceuticals. Although numerous synthetic methods have been 
developed over the last few decades, new methods constructing them in an efficient way from 
readily accessible starting material are still great of interest. As a coupling partner of the reaction, 
alkenes are abundant, general, and therefore ideal starting materials to synthesize a variety of 
complex, value-added products. In this thesis, we have utilized Rh(III) catalysis to develop 
efficient synthetic methodologies for nitrogen-containing compounds using alkenes as coupling 
partners. In Chapter 2, we developed a unique disconnection approach to pyrrolidines using -
olefins as a 4-carbon source and hydroxylamine derivatives as a nitrogen source of the reaction. In 
Chapter 3, regio- and diastereoselective synthesis of ,-unsaturated--lactams from acrylamide 
and unactivated alkenes initiated from C-H activation are discussed. In Chapters 4 and 5, three-
component alkene difunctionalization of alkenes delivering acyclic aminated products including 
-amino acids are described. 
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Chapter 1: An Introduction to the Synthesis of Nitrogen-Containing 
Heterocycles 
1.1 N-heterocycles in FDA approved drugs 
Nitrogen-containing organic molecules are ubiquitous in a myriad of biologically active 
compounds including natural products, nucleic acids, proteins, and pharmaceuticals. An in-depth 
analysis of FDA-approved drugs reported in 2014 reveals that among the 1086 unique small-
molecule drugs, 910 (84%) contain at least one nitrogen atom far surpassing the numbers for sulfur 
(26%) and fluorine (13%) (Scheme 1.1).1 Nitrogen is the most commonly observed element in 




Scheme 1.1: Frequency of elements in FDA-approved drugs. 
 
Among these unique small molecule drugs containing nitrogen, around 60% of them 
possess at least one nitrogen-containing heterocycles (Scheme 1.2).1 Piperidine is the most 
commonly observed N-heterocycles, followed by pyridine, piperazine, cephem, and pyrrolidine, 
etc. Even though it is exceedingly difficult to identify the single reason why nitrogens are prevalent 
in drugs due to the large diversity of their function in our biological system, in general, nitrogen 
heterocycles accept or donate a proton readily, form diverse weak interactions such as hydrogen 
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bonding, dipole interactions, etc., which allows them to bind with a variety of enzymes and 
receptors in biological targets with high affinity.1-3 Although significant efforts have been devoted 
to the development of synthetic methodologies for nitrogen-containing heterocycles over the last 
few decades, developing efficient routes to them with easily accessible starting material is still of 








1.2 Transition metal-catalyzed C-H aminations 
The importance of the nitrogen heterocycles has motivated synthetic chemists to develop 
a new way of constructing them. Especially, transition-metal catalysis has played an essential role 
in the progress of the field since it provides unique and efficient routes to form a new carbon-
nitrogen bond.4, 5 In this context, one of the classical methods to build a C-N bond is through cross-
coupling reactions such as Ullman reaction with Cu catalyst6 or more recently developed Pd-
catalyzed Buchwald-Hartwig reaction7 to give aniline derivatives (Scheme 1.3).  
 
 
Scheme 1.3: Transition metal-catalyzed C-H aminations. 
 
Such cross-coupling reactions between aryl (pseudo)halides and amines are well-studied, 
and, are widely used in a variety of research fields including medicinal chemistry. However, the 
reaction requires pre-functionalized substrates as coupling partners of the reactions and inherently 
generates halide salt as a side product. Alternatively, the direct functionalization of inert and 
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ubiquitous C-H bonds has received great attention (Scheme 1.3). Compared to cross-coupling 
reactions, the biggest advantage is the rapid access to value-added amine products from readily 
accessible substrates although this approach invokes the selectivity issue when multiple C-H bonds 
are electronically and sterically similar. 
The mechanism of transition metal-catalyzed C-H amination can be categorized into three 
different classes (Scheme 1.3).5, 8-11 First, a transition metal catalyst “activates” the C-H bond in a 
molecule and the resulting organometallic complex subsequently reacts with an external nitrogen 
source to give the desired amination product. Second, the metal catalyst generates a metal-
nitrenoid intermediate that undergoes outer-sphere C-H insertion to form a C-N bond. Last, 
photoredox catalysis has been utilized to generate a radical intermediate through the hydrogen 
atom transfer and the resulting radical reacts with nitrogen source to give an aminated product.  
 
1.3 C-H aminations with Cp* group 9 metal catalysis 
As mentioned above, one of the challenges of C-H functionalization is the selectivity due 
to the presence of multiple indistinguishable C-H bonds in a molecule. One solution to this 
problem is using a functional group that can coordinate to the metal center, then the metal complex 
undergoes selective C-H activation on the basis of proximity. Numerous first and second-row 
transition metal complexes including Pd, Cu, Fe, Mn, and Ru, etc. have been developed to achieve 
this transformation.12 For Cp* group 9 metal catalysis, several directing groups have been also 
utilized for the C-H amination chemistry with a variety of aminating reagents (Scheme 1.4).4 As 
a key intermediate of the reaction, Cp*M(V)-imido complexes were proposed. Although this 
intermediate has never been isolated or detected yet, computational studies support Cp*M(V)-





Scheme 1.4: Cp*M(III) catalysis for directing group-assisted C-H amination. 
 
While the directing group-assisted C-H amination provides excellent chemoselectivity, the 
installation and/or removal of often unnecessary directing groups limits its synthetic application. 
As a part of efforts to develop directing group-free C-H amination with Cp* group 9 metal 
catalysis, In 2019, Rovis group reported Ir(III)-catalyzed branch selective allylic amination of -
olefins (Scheme 1.5a).15 Slightly after this report, Glorius and Blakey groups also reported the 
same transformation independently.16, 17 Again, the key intermediate was Ir(V)-imido complexes 
that undergo C-N bond formation. Later, we expanded this chemistry to more challenging internal 
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alkenes (Scheme 1.5b) that contain almost indistinguishable allylic C-H bonds to achieve site-




Scheme 1.5: Selective allylic amination of alkenes. 
 
1.4 Alkene aminations with Cp* group 9 catalysis 
Previously, Rovis group utilized the Rh(III)-catalyzed Csp2-H activation/annulation 
strategy for the synthesis of a variety of nitrogen-containing heterocycles with alkenes as coupling 
partners (Scheme 1.6a).19 The general mechanism of these transformations is Rh(III) catalyst 
activates a Csp2-H bond through concerted-metalation-deprotonation (CMD), the resulting 
rhodacycle undergoes migratory insertion with an alkene and subsequently forms a C-N bond to 
deliver a cyclized product.  
In addition to N-heterocycle syntheses, we also reported Rh(III)-catalyzed stereospecific 
syn-carboamination of activated alkenes that give acyclic aminated products.20 As a part of the 
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alkene difunctionalization chemistry, more recently we published Ir(III)-catalyzed regio-divergent 
synthesis of - and -lactams through intramolecular diamination and oxyamination.21, 22  
As an extension of this previous work mentioned above, in this thesis, Rh(III)-catalyzed 
alkene difunctionalization for the synthesis of N-heterocycles such as pyrrolidines (Chapter 2), 
,-unsaturated--lactams (Chapter 3), and carboamination (Chapter 4) and diamination (Chapter 
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Chapter 2: A Formal [4+1] Approach to Pyrrolidines from 
Unactivated Terminal Alkenes and Nitrene Sources 
2.1 Current methods for pyrrolidine synthesis 
Pyrrolidine is a prevalent structural unit in biologically active molecules such as 
pharmaceuticals and natural products. According to an analysis conducted in 2014 by Njardarson 
et al.,1 pyrrolidine is one of the top 5 nitrogen-containing heterocycles in FDA-approved drugs, 
and the most commonly observed 5-membered nitrogen heterocycle. It is also the structural core 
of various organocatalysts including proline analogs that enable important synthetic 
transformations.2-5 Not surprisingly, significant efforts have been devoted to the development of 
efficient routes to pyrrolidines and early examples can be traced back to the classical 
Hofmann−Löffler−Freytag reaction in the 19th century.6, 7 Since then, a myriad of intramolecular 
cyclization methods has been developed for the synthesis of this saturated 5-membered nitrogen 
heterocycle. A SciFinder search on pyrrolidine cyclization involving three different disconnections 
results in more than 5 million reactions, which emphasizes the importance of this structural unit 
and a diversity of approaches to this heterocycle. 
For the recent progress of the field, intramolecular alkene difunctionalization with tethered 
amine nucleophile is one of the well-established ways of constructing a 5-membered nitrogen ring 
with various transition metal catalysts.8 (Scheme 2.1a). Recently, Knowles group also utilized 
photoredox catalysis to achieve this transformation through a proton-coupled electron transfer 
(PCET) mechanism.9 Alternatively, intramolecular amination of sp3 C-H bond through metal 
nitrene insertion with Rh, Fe, Co, and Ni have been reported for the synthesis of pyrrolidines 
(Scheme 2.1b).10-13 Although the reactions deliver saturated pyrrolidine derivatives, the 
disconnection of C3-C4 bond of pyrrolidine is also well-studied and olefin metathesis or 1,6-enyne 
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cyclization can be categorized into this approach (Scheme 2.1c and 2.1d).14, 15 While all of these 
reactions mentioned above are efficient approaches to pyrrolidines with interesting reaction 
mechanisms, they require the preparation of acyclic precursors before the cyclization that might 
need multi-step syntheses. 
 
 
Scheme 2.1: Intramolecular cyclization methods. 
 
Alternatively, intermolecular, convergent synthetic strategies involving two or three 
unique components have also received great attention. Among potential reaction partners, olefins 
are perhaps the most abundant, general, and desirable. For the synthesis of pyrrolidines, alkenes 
are most frequently used as two carbon sources of the reaction and the [3+2] cycloaddition between 
azomethine ylides and alkenes represents a well-studied method among them (Scheme 2.2).16-18 
Other recent examples also include the reaction of β-amino aldehydes, protected cinnamyl amines, 





Scheme 2.2: Intermolecular approaches using alkenes as coupling partners. 
 
Strategies utilizing alkenes as three-carbon coupling partners are relatively rare and often 
require pre-functionalization. For example, 2-((trimethylsilyl)-methyl) allyl acetate has been 
reported as a three-carbon source for the palladium-catalyzed formal [3+2] cycloaddition with 
imines (Scheme 2.2).24-26 Most recently, a visible light-mediated photoredox catalyzed synthesis 
of spiro-pyrrolidines was reported using homoallylic amines as 3-carbon/1-nitrogen sources with 
aliphatic ketones as 1-carbon partners.27 Until we developed this method,28 the synthesis of 
pyrrolidines using alkene as a 4-carbon source of the reaction was unprecedented. Such a strategy 
13 
 
would be complementary to current methods with the advantage of providing direct access to 
pyrrolidines from easily accessible terminal olefins.  
 
 
Scheme 2.3: Formal [4+1] approach to pyrrolidine using alkenes as 4-carbon sources. 
 
2.2 Reaction development 
We serendipitously discovered this reactivity during the development of two separate 
research projects. I was trying to develop Rh(III)-catalyzed diamination of unactivated alkenes 
using 1-hexene (1a), and a former group member Dr. Honghui Lei was investigating the 
mechanism of allylic amination with -olefins.29  
Surprisingly, we noted that heptamethylindenyl (Ind*) Rh(III) catalyst30 delivers the 
pyrrolidine side product (3aa) and linear allylic amination product (4) in low yield from 1-hexene 
(1a) and N-pivalolyloxy tosylamide (2a) (Table 2.1, entry 1). Inspired by this preliminary result 
and the rapid access to pyrrolidines, we sought to optimize the transformation. Although desired 
product could be formed by Rh(III) alone, we found that the yield of pyrrolidine (3aa) is greatly 
improved by pre-stirring the reaction mixture until full consumption of 1-hexene (1a) and then 
subjecting the reaction mixture with AgOTf at 80 °C (entry 2). Systematic examination of acid 
additives revealed that Sc(OTf)3 is more effective than AgOTf, promoting the cyclization even at 





Table 2.1: Reaction optimization. 
 
Eventually, TfOH was chosen as an optimal additive, delivering 66% yield of desired 2-
ethyl-1 tosylpyrrolidine (3aa) (entry 4). The electron-deficient heptamethylindenyl (Ind*) ligand 
on the Rh(III) catalyst is crucial with the more common [Cp*RhCl2]2 providing product in a much 
lower yield (entry 5).31 Moreover, other nitrene precursors previously used for the amination 
chemistry with Cp* group 9 catalysis such as dioxazolone or tosyl azide (entry 6, 7) lead to no 




2.3 Alkene substrate scope 
We next sought to examine the scope of this method with various terminal alkenes 
(Scheme 2.4). The reaction proceeds smoothly with alkenes containing substituents at C4 and C5 
positions, giving desired products (3aa−3da) in good yield. Interestingly, in the case of 4,4-
dimethyl-1-pentene (1e) where the C4 position is blocked, one of the methyl groups migrates to 
the C3 position, forming 2,2,3-trimethyl-1-tosylpyrrolidine (3ea) selectively. Additionally, a 
variety of functional groups such as −Br, −OAc, −OTs, −NPhth, −CONR2 and −CO2R are tolerated 
when located far from the reaction center, providing corresponding products (3fa−3ka) in 
moderate to good yield.  
 
Scheme 2.4: Linear alkene substrate scope. 
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The presence of proximal nucleophilic functional groups leads to their interception of the 
cationic intermediates formed in the reaction. For example, benzyl hexenyl ether forms amino 
methyl tetrahydropyran in good yield under these reaction conditions. 
In consideration of the importance of spirocyclic pyrrolidines among pharmaceuticals, we 
tested synthetic utility of this method for the synthesis of spiro-pyrrolidines with a variety of allyl 
cyclohexane substrates (Scheme 2.5).  
 
Scheme 2.5: Allyl cyclohexane substrate scope. 
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Allyl cyclohexane (1l) was successfully converted to the 1-tosyl-1-azaspiro[4.5]decane 
(3la) product in excellent yield. A conformational bias in the cyclohexane ring (4-tert-butyl, 4-
phenyl, 3-methyl and 3-trifluoromethyl) produced corresponding spiro-pyrrolidine products with 
excellent diastereoselectivity (3na, 3oa, 3pa, and 3qa). It is also worth noting that >20:1 
diastereoselectivities are achieved regardless of the trans/cis ratio of the starting cyclohexane. The 
relative stereochemistry of 3na and 3pa was unambiguously determined by X-ray crystallography. 
Interestingly, the reaction with 2-allyl adamantane (1r) causes a 1,2-hydride shift before 
cyclization, leading to the formation of an unprecedented structure 3ra. A similar hydride shift 
event was also observed with 1-allyl-2-methylcyclohexane (1s), giving rise to 6,6-fused bicyclic, 
decahydroquinoline (3sa). Moreover, naphthyl sulfonyl group was introduced as an alternative 
tosyl protecting group due to its milder deprotection conditions (3nb). Last, regiodivergent 
synthesis of pyrrolidine-based spirocycle (3la) and fused bicyclic compound (5la) was achieved 
from allyl cyclohexane (1l) with exquisite selectivity by simply changing reaction temperature 
(Scheme 2.6). As a control experiment, we subjected 3la to triflic acid at elevated temperature (60 
°C) and as a result, we observed that 3la was converted to 5la which suggests 5la is formed from 




Scheme 2.6: Regiodivergent synthesis of spirocyclic and fused bicyclic compound. 
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2.4. Mechanistic investigation 
To obtain mechanistic insights, we first conducted the reaction with 1-hexene (1a) using 
the standard reaction conditions without the sequential treatment of TfOH (Scheme 2.7). As a 
result, N-Tosyl aziridine (6aa) was isolated in quantitative yield. Further subjecting the resulting 
aziridine (6aa) to TfOH leads to pyrrolidine product in 75% yield (3aa). These results suggest that 
the Rh(III)-catalyzed intermolecular aziridination of the alkene and subsequent acid-promoted ring 




Scheme 2.7: Mechanistic investigation. 
 
The aziridination of unactivated alkenes catalyzed by Ind*Rh(III) is unprecedented, 
although it is a well-explored research area. The unexpected and novel part of the reaction 
mechanism is the ring expansion from aziridine to pyrrolidine through remote C-H amination. 




Scheme 2.8: Mechanistic investigation on aziridine ring expansion. 
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First, the aziridine ring is opened by forming allylic tosylamide and undergoes the alkene 
chain walking presumably through protonation/elimination pathway. Then, homoallylic tosyl 
amide will be cyclized to give pyrrolidines in acidic condition. In order to test this mechanism, 
allylic and homoallylic tosyl amides (4 and 7) were prepared and subjected to TfOH (Scheme 
2,8a). Allylic amine (4) does not lead to pyrrolidine product, while a quantitative yield was 
achieved from homoallylic amine (7). These experiments indicate that the alkene chain walking 
mechanism is unlikely although homoallylic tosyl amide could be one of the reaction 
intermediates. 
The second pathway that we considered was the sequential hydride shift mechanism. To 
test this idea, we conducted deuterium labeling experiments with C3 and C4 deuterated aziridines 
(Scheme 2,8b, for C1 and C2 deuterated aziridines, see Appendix A). In the case of C3 deuterated 
aziridine (6ca-C3-d2), extensive deuterium incorporation is observed at the C2 position which 
suggests the aziridine ring-opening is initiated by 1,2-hydride shift. The reaction with C4 
deuterated aziridine (6ca-C4-d2) also shows deuterium migration from C4 to C3 position with the 
significant erosion of deuterium that can be attributed to the formation of homoallylic tosyl amide.  
 
2.5 Proposed mechanism 
Taken together, these experiments suggest a plausible reaction mechanism (Scheme 2,9). 
N-Pivalolyloxy tosylamide (2a) first coordinates to the Rh(III) catalyst and undergoes Rh-nitrene 
formation (II). Alkene aziridination proceeds subsequently to form N-tosyl aziridine (6aa). It is 
also possible that the aziridine (6aa) is formed through the alkene migratory insertion of 
intermediate I, followed by a concerted C−N bond formation and N−O bond cleavage. Upon 
treatment with triflic acid, aziridine ring expansion is initiated by 1,2-hydride shift, followed by a 
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combination of 1,2-hydride shift and elimination/protonation pathways, and eventually quenches 
the carbocation at C4 position to form the pyrrolidine product (3aa). The possible intervention of 
homoallylic amide VI explains the modest loss of deuteration in the deuterium labeling 




Scheme 2.9: Proposed mechanism. 
 
2.6 Summary 
In summary, we have developed a Rh(III)-catalyzed formal [4+1] synthesis of pyrrolidines 
from readily available unactivated alkenes. Mechanistic studies show that the reaction proceeds 
through a Rh(III)-catalyzed aziridination of the alkene and subsequent ring expansion from 
aziridine to pyrrolidine promoted by the acid. This method offers a new strategy for pyrrolidine 
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synthesis by employing a simple alkene as a four-carbon source. With this method, various types 
of pyrrolidines, especially spiro-pyrrolidines, were rapidly constructed.28  
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Chapter 3: Direct Regio- and Diastereoselective Synthesis of -
Lactams from Acrylamides and Unactivated Alkenes 
3.1 Introduction 
Nitrogen heterocycles are an essential structural unit found in a variety of biologically 
active molecules. FDA-approved drug analysis shows that around 60% of unique small molecule 
drugs contain at least one nitrogen heterocycle.1 Among them, the piperidine ring is the most 
prevalent N-heterocycle found in FDA-approved drugs (Scheme 3.1). 
 
Scheme 3.1: Synthesis of piperidines. 
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Consequently, numerous synthetic methods have been developed for the synthesis of 
piperidines including both intra- and intermolecular pathways. Convergent synthetic strategies 
involving two different components have received great attention.2-8 While these strategies are 
useful, they are often limited to specific classes of coupling partners and deliver products with a 
narrow range of substitution patterns. We envisioned direct access to ,-unsaturated--lactams 
from simple precursors would prove useful since they can be easily converted into piperidines 
through well-established reduction reactions.  
In this context, Rh(III)-catalyzed C-H activation/annulation strategy has been utilized to 
synthesize related N-heterocycles (Scheme 3.2). Pioneering work by the groups of Fagnou,9 
Miura/Satoh,10 Li,11, and our group,12 has demonstrated the directed C-H activation of benzamides 
with alkynes to yield isoquinolones (Scheme 3.2a). Significantly, the Fagnou group installed the 
N-OMe group as an oxidizing directing group that delivers unprotected isoquinolone products 
without an external oxidant. Later, Fagnou13 and Glorius14 groups introduced the N-acyloxy 
hydroxamate directing group, which allows alkene insertion to deliver dihydroisoquinolone 
(Scheme 3.2b). 
The key to the success of the reaction with alkene was the discovery of the N-OPiv 
oxidizing directing group that resulted in milder reaction conditions and broader substrate scope. 
Later, the asymmetric variant of this process has been developed by Rovis/Ward using artificial 
metalloenzyme,15 and Cramer with chiral Cp ligand.16 However, related vinyl C-H activation is 
much less explored and only two examples of transition-metal-catalyzed vinyl C-H activation of 
acrylamides and the coupling with alkenes are documented. Specifically, the Daugulis group has 
utilized the aminoquinoline directing group in the presence of a Co catalyst and a stoichiometric 
amount of oxidant (Scheme 3.2c).7 Recently, we reported asymmetric -lactam synthesis from N-
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(pivaloyloxy)acrylamides using a monomeric streptavidin artificial metalloenzyme (Scheme 
3.2d).17 In both cases, only reactions with styrene-type alkenes are reported. For example, in our 
reaction with the artificial metalloenzyme, the reactions with unactivated alkenes such as 
cyclopentene and vinyl cyclohexane result in low yield and enantioselectivity.  
 
 
Scheme 3.2: C-H activation and annulation strategy. 
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3.2 Reaction development 
A former graduate student of the Rovis group, Dr. Natthawat Semakul, commenced the 
reaction development by examining the coupling of 2-benzyl-N-(pivaloyloxy)acrylamide (1a) and 
vinyl cyclopentane (2a) as model substrates. When he conducted the reaction in the presence of 
[Cp*RhCl2]2 and CsOAc in trifluoroethanol (TFE), almost 1:1 regioselectivity was observed with 




Scheme 3.3: Improving regioselectivity with Cp ligand modification. 
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Inspired by previous work on the modification of Cp ligands on Rh(III) catalyst to improve 
regioselectivity,18-24 we conducted a Cp ligand screen and found that the regioselectivity could be 
significantly improved with commercially available Cpt ligand (Cpt = 1,3-di-tert-
butylcyclopentadienyl). After his graduation, I took over this project and continued to optimize the 
reaction conditions, explore the substrate scope, and investigate the reaction mechanism motivated 
by the relevance of the target -lactams, rapid access to the structure from readily available starting 
materials, and the potential to achieve diverse substitution patterns on piperidines. 
For the reaction optimization, when [Cp*RhCl2]2 is used as a catalyst, a nearly 1:1 mixture 
of regioisomers is formed in polar protic solvents (Table 3.1, entry 1–3).  
 
 




As mentioned above, the regioselectivity could be significantly improved with Cpt ligand 
(entry 4–6). The regioisomers 3aa and 4 are easily separable by column chromatography and the 
improved regioselectivity can be rationalized as a consequence of the steric repulsion between 
bulky Cpt ligand and the substituent on the alkene coupling partner based on previous work with 
benzamides.20-23 TFE was selected as a solvent for the optimized condition since it gives both good 
regioselectivity and good reaction yield compared to MeOH and HFIP. Other catalysts such as 
[Cp*CoCl2]2 and [Cp*IrCl2]2 fail to yield the desired product (entry 7). The reaction with styrene 
gives the opposite regioisomer (substituent close to new C-N bond) with both [Cp*RhCl2]2 (64%, 
>15:1 dr) and [CptRhCl2]2 (63%, >15:1 dr) catalysts. 
 
3.3 Substrate scope 
Having optimized the reaction conditions, we next explored the terminal alkene substrate 
scope using (1a) as an acrylamide coupling partner (Scheme 3.4). The reaction proceeds smoothly 
with terminal aliphatic alkenes such as 1-heptene (2b), allyl cyclohexane (2c), and gaseous 
propene (2d), giving the desired -lactam products in good yield and regioselectivity (3aa–3ad). 
A variety of functional groups such as phenyl, benzyl, protected alcohol or amine, bromide, and 
ester groups are all well tolerated (3ae–3ak). In the case of 2-methyl-1,5-hexadiene (2l), insertion 
occurs exclusively to give the mono-substituted terminal alkene over the gem-disubstituted alkene. 
Interestingly, vinyl cyclohexane (2m) and 4,4-dimethyl-1-pentene (2n) gave opposite 
regioisomers as the major product when [Cp*RhCl2]2 was used as a catalyst. Next, the substrate 
scope with respect to internal alkenes was investigated (Scheme 3.5). For internal alkenes, 
[Cp*RhCl2]2 was used as a catalyst instead of [Cp
tRhCl2]2 due to the lower yield observed with 





Scheme 3.4: Terminal alkene substrate scope. 
 
Complex tricyclic structures are successfully constructed in a single step with excellent 
yields when norbornene (2o) and norbornadiene (2p) are used as coupling partners. [6,3,0] and 
[4.3.0] fused bicyclic -lactams are also formed with good yields when cis-cyclo-octene (2q) or 




Scheme 3.5: Internal alkene substrate scope. 
 
Excellent regioselectivity is observed for the reactions with cyclo-hexa-1,3-diene (2s), 1,2-
dihydronaphthalene (2t), and 1H-indene (2u). Acyclic internal olefins containing cis or trans 
configurations, such as (E)-oct-4-ene (2v) and (Z)-but-2-ene (2w), also provide the desired product 
(3av, 3aw) in good yield. All reactions with internal alkenes are highly diastereoselective and 
relative stereochemistry of 3aq and 3av were unambiguously determined by X-ray 





Scheme 3.6: Acrylamide substrate scope. 
 
Finally, we investigated the scope with respect to acrylamides using vinyl cyclopentane 
(2a) as a coupling partner (Scheme 3.6). N-(pivaloyloxy)acrylamides containing ester (1c), 
protected amine (1d), aryl (1e), and halide (1f–1h) groups delivered corresponding -lactam 
products with good yields and regioselectivities. 2-Methylene-N-(pivaloyloxy)-pent-4-enamide 
(1i), which contains two different terminal alkenes, gives -lactam exclusively, presumably due to 
the favored 5-membered rhodacycle formation after the C-H activation step. When 1 atm of 
ethylene (2x) is used as an alkene coupling partner of the reaction with acrylamides, the reactions 
give excellent yield with broad functional group tolerance (Scheme 3.7). This reaction could be 






Scheme 3.7: Acrylamide substrate scope with ethylene. 
 
3.4 Mechanistic investigation 
To obtain mechanistic insight, we first investigated the C-H activation step of the reaction 
(Scheme 3.8a). The reaction was conducted in TFE-d1 and quenched when around 50% of the 
acrylamide substrate was consumed. Interestingly, the reversibility of the C-H activation depends 
on the Cp ligand on the Rh(III) catalyst. When [CptRhCl2]2 was used as catalyst, deuterium 




Scheme 3.8: Mechanistic investigation. 
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irreversible. In the case of [Cp*RhCl2]2, the C-H activation is reversible, showing 27% deuterium 
incorporation on the recovered acrylamide. Next, the kinetic isotope effect (KIE) was measured 
from two separate reactions, one with a normal substrate containing a C-H bond and one with an 
analogous C-D bond (Scheme 3.8b).25 The reaction was conducted in an NMR tube and the 
reaction progress was monitored in situ by 1H NMR. The KIE value was calculated by comparing 
the initial reaction rate (slope) of each reaction. The observed primary KIE (kH/kD) value of 6.31 
suggests that C-H bond cleavage occurs during the turnover limiting step. Overall, both 
experiments indicate that C-H activation is irreversible and the turnover-limiting step when 
CptRh(III) is used as a catalyst. 
 
3.5 Proposed mechanism 
Based on previous work and our mechanistic investigation, we propose the following 
mechanism for the reaction (Scheme 3.9). First, coordination of the acrylamide substrate to active 
Rh(III) catalyst I generates intermediate II. At this stage, turnover-limiting irreversible C-H 
activation occurs to form 5-membered rhodacycle III. Subsequently, an alkene coupling partner 
coordinates and forms 7-membered rhodacycle V through regioselective migratory insertion. After 
C-N bond formation/N-O bond cleavage steps, intermediate VI releases the -lactam product with 




                   
Scheme 3.9: Proposed mechanism. 
 
3.6 Product derivatization 
The utility of the developed method was demonstrated by the rapid synthesis of 
trisubstituted piperidine 6, a potential drug candidate for cardiovascular disorders and tumors 
(Scheme 3.10).26 The coupling reaction between 2-bromo-N-(pivaloyloxy)acrylamide (1h) and N-
allylmethanesulfonamide (2w) gives the corresponding -lactam product (3hw) in a single step. 
The aryl moiety was installed through a Suzuki–Miyaura coupling reaction with 4-
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(trifluoromethyl)-phenylboronic acid, and subsequent alkene hydrogenation resulted in compound 
5. After amide reduction and N-acylation, trisubstituted piperidine 6 was successfully prepared.  
 
 
Scheme 3.10: Product derivatization. 
 
3.7 Summary 
In summary, we have developed a Rh(III)-catalyzed synthesis of ,-unsaturated--
lactams from N-(pivaloyloxy)- acrylamides and unactivated alkenes. With this method, various -
lactams containing a wide array of functional groups and complex bi/tricyclic structures were 
synthesized with good yield and regio/diastereoselectivity. Mechanistic investigation suggests 
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turnover-limiting irreversible C-H activation, subsequent regioselective migratory insertion, and 
C-N bond formation/N-O bond cleavage for the mechanism of the reaction.27 
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Chapter 4: Three-component Syn-Carboamination of Alkenes Using 
Arylboronic Acids and Dioxazolones 
4.1 Introduction 
Alkenes are ubiquitous functional groups in a myriad of organic compounds. Therefore the 
simultaneous installation of two functional groups across the alkene double bond in a 
stereoselective manner is one of the most powerful transformations in organic synthesis.1-6 It 
provides an efficient way of rapidly increasing molecular complexity from readily available 
starting materials. Among various potential alkene difunctionalizations, the carboamination of 
alkenes offers direct access to valuable and pharmaceutically important amine products by forming 
both C-C and C-N bonds in a single step (Scheme 4.1).7, 8  
 
                           
Scheme 4.1: Alkene difunctionalization. 
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A handful of powerful annulations9, 10 or intramolecular carboaminations with tethered 
amine nucleophile11-13 have been developed, which are currently limited to the synthesis of cyclic 
products (Scheme 4.2). Intermolecular carboamination of alkenes delivering acyclic amine 
products is relatively rare. In 2015, Rovis group described the first example of intermolecular, 
stereospecific, syn-carboamination of activated alkenes using N-enoxyphthalimide as both carbon 
and nitrogen source of the reaction to furnish acyclic amine products (Scheme 4.2c).14 Since then, 
plenty of intermolecular carboamination papers have been reported and there are generally two 
approaches (Scheme 4.3). 
 
 




The first approach is directing group-assisted carboaminations. In 2016, Glorius group 
reported the carboamination of acrylates initiated by Cp*Co(III)-catalyzed Csp2−H activation of 
N-phenoxyamides15 followed more recently by Cramer’s demonstration of an asymmetric version 
of this reaction (Scheme 4.3a).16 N-phenoxyamide acts as an oxidizing directing group that enables 
selective ortho C-H activation of aryl ring and makes the overall process redox neutral. However, 
the necessity of directing functionality, and specific aryl substitution patterns (ortho hydroxyl 
group) of the carboamination products remain limitations. 
 
Scheme 4.3: Approaches to intermolecular carboamination of alkenes. 
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Recently, Ellman reported the synthesis of an -branched amine (Scheme 4.3b) through 
the Rh(III)-catalyzed three-component 1,1-carboamination of terminal alkenes that was also 
initiated by directing group assisted C-H activation.17 Other significant contributions towards the 
linear carboamination of alkenes have been made utilizing Pd or Ni catalysis with olefins bearing 
covalently linked aminoquinoline directing groups (Scheme 4.3c).18, 19 Alternative approaches to 
intermolecular carboamination is through single electron pathways involving nitrogen or carbon-
centered radicals.20-22  
 
 




Despite recent progress in the field, the current state-of-the-art in carboamination involves 
additional steps to install and remove the often undesired directing functionality, an inherent loss 
in stereocontrol imparted through open shell intermediates, or synthetically taxing substrates that 
limit the chemical space available to their practical application.  
In searching for a more general solution to this problem, we became interested in 
developing an intermolecular 3-component carboamination that uses readily accessible carbon and 
nitrogen sources. Such a modular approach would enable the rapid synthesis of a diverse library 
of functionalized amine products by simply switching coupling partners (Scheme 4.4). 
As a reaction design to achieve this goal, we envisioned that a carbon nucleophile 
coordinates to Cp*Rh(III) complex after transmetalation or ligand displacement then undergoes 
highly regioselective migratory insertion with activated alkenes in the absence of directing group. 
Subsequent reaction with nitrene precursors forms Rh-nitrene intermediates which will undergo 
reductive elimination to form a C-N bond and deliver desired carboamination products. 
The challenge is that there are several undesired side product pathways as the reaction 
becomes a multi-component system. For example, after transmetalation, it can undergo 
dimerization of carbon source or direct C-N coupling if subsequent alkene migratory insertion is 
slow. Also, after migratory insertion of an alkene into a Rh-carbon bond, undesired -hydride 
elimination or protodemetalation will result in Heck-type and hydroarylation products. Last, 
hydroamination side product also can be formed if the nitrogen source of the reaction directly 




4.2 Reaction development 
With this hypothesis in mind, we initiated a systematic investigation of carbon nucleophiles 
such as organoboron and organostannanes, with nitrene precursors such as azides, hydroxamates, 
and dioxazolones, under various reaction conditions. An initial hit was identified when we 
combined phenylboronic acid (1a), benzyl acrylate (2a), and 3-methyl-1,4,2-dioxazol-5-one (3a) 
with [Cp*RhCl2]2 as a catalyst in methanol at room temperature delivering the desired 
carboamination product (4a) in 8% yield, with the mass balance comprised of Heck-type, 
hydroamination, and direct C-N coupling products. Inspired by a large library of commercially 
available boronic acids and readily accessible dioxazolones which can be easily prepared from 
carboxylic acids,23 we decided to optimize the reaction and gratifyingly, achieved a 77% yield of 
the desired carboamination product (4a) (Table 1, entry 1, see Appendix C for details).  
 
 
Table 4.1: Reaction optimization. 
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Other nitrene precursors10, 24-26 that are frequently used for amination chemistry with Cp* 
group 9 catalysis are completely ineffective for this chemistry. In the cases of Ts-N3, Ts-NH-OPiv, 
5,5-dimethyl-1,4,2-dioxazole, and 1,4,2-dioxazol-5-thione, no conversion of starting materials is 
observed. When N-(pivaloyloxy)amides are used as nitrogen source of the reaction, direct C-N 
coupling product was observed as a major side product and N-(tetrafluorophenoxy)amides give 
Heck-type and hydroarylation side products in high yield. (entry 2, see Appendix C for details).  
Also, the choice of the catalyst is important since cationic Rh(III) catalysts, such as 
[Cp*Rh(MeCN)3](SbF6)2 (entry 3) or an in situ generated cationic Rh(III) complex, do not lead to 
the desired product. Several Rh(I) catalysts such as [Rh(COD)2Cl]2 (entry 4) that are commonly 
used for conjugate addition chemistry with arylboronic acids,27-29 or other Cp* group 9 catalysts 
such as [Cp*CoCl2]2 or [Cp*IrCl2]2, failed to deliver the carboamination products. Screening of 
base additives shows that bicarbonate, carbonate, or fluoride generally gives a higher reaction yield 
compared to acetates, and NaHCO3 was selected as the optimal additive. When acetates are used 
as an additive, the reaction yield is significantly decreased and the Heck-type product becomes a 
major product of the reaction in low yield. One possible explanation is that acetates act as a 
bidentate ligand and prevent the coordination of dioxazolone (entry 5).  
The reaction proceeds smoothly at room temperature and tends to give a lower yield at a 
higher temperature, as shown with the 42% yield obtained when the reaction was conducted at 60 
°C (entry 6). When both alkene (2a) and dioxazolone (3a) are used as the limiting reagent of the 
reaction, the reaction gives a synthetically useful 64% yield (entry 7), and a 77% yield was 
achieved when 1a (2.5 equiv), 2a (3 equiv), and 3a (1 equiv) were used for the reaction (See 
Appendix C for details). Lastly, the reaction can be performed on a 1.0 mmol scale with 2.5 mol% 
catalyst loading without loss of the product yield (entry 8). 
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4.3 Reaction scope 
 
Scheme 4.5: Boronic acid substrate scope. 
Having optimized the reaction conditions, we next sought to explore the scope of the 
transformation. The reaction with aryl boronic acids containing a variety of functional groups at 
the para position of phenyl ring proceeds smoothly, delivering products with -CF3 (4b), -F (4c), -
Br (4d), -OMe (4e), hydroxy (4f), silyl ether (4g), alkene (4h), alkyl (4i), nitrile (4j), and aldehyde 
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(4k) functional groups in good yield (Scheme 4.5). Aryl boronic acids with a substituent in the 
meta position (4l), having multiple substituents (4o, 4p), naphthyl boronic acid (4q), and 3,4-
methylenedioxyphenylboronic acid (4r) also work well in this reaction. In the case of vinyl boronic 
acids (such as 1-penten-1-ylboronic acid) or alkyl boronic acids the reactions are unsuccessful. 
(see Appendix C for limitations). 
For alkene substrate scope, the reaction with monosubstituted acrylates gives 
corresponding phenylalanine derivatives (5b-5d) in good yield (Scheme 4.6).  
 
Scheme 4.6: Alkene substrate scope. 
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Acrylonitrile (2e) also works well in this reaction, providing a potential for further 
functional group derivatization. Secondary acrylamides are also good alkene coupling partners, 
delivering carboamination products (5f-5h) containing two amide bonds. The reaction with 
bridged bicyclic alkenes such as norbornene (2i), oxabenzonorbornadiene (2j), and aza-
benzonorbornadiene (2k) gives syn-carboamination products (5i-5k) in good yield and excellent 
diastereoselectivity. In the case of the reactions with cyclopropenes (2l-2m), the reaction occurs 
cis to the methyl group, presumably because of a smaller steric demand during the alkene 
migratory insertion step, giving cyclopropyl amine products (5l-5m) in high diastereoselectivity.  
 
 
Scheme 4.7: Styrene scope. 
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Internal alkenes such as ethyl crotonate, ethyl cinnamate, cyclopentenone, or styrene do 
not lead to the product formation and direct N-phenylation products are observed as a major side 
product of the reaction, presumably due to a slow alkene migratory insertion (see Appendix C for 
details). In the case of the reaction with styrene (Scheme 4.7), the overall yield for the 
carboamination can be improved by using an electron-deficient CpiPrRh(III) catalyst with an access 
amount of dioxazolones. However, a mixture of two regioisomers (1,1- and 1,2-carboamination) 
is observed with low selectivity. We believe this system accelerates the alkene migratory insertion 
step with styrenes, but -hydride elimination/Rh-hydride re-insertion occurs before Rh-nitrene 
formation to give a mixture of regioisomers. 
Lastly, a variety of functional groups can be installed at the amide side chain using 
dioxazolones with different substituents at the 3 positions (3b-3h) prepared from corresponding 
carboxylic acids (Scheme 4.8).  
 




The reactions with dioxazolone 3d or 3f containing allylic or benzylic C-H bonds give the 
carboamination products selectively (6d, 6f). These are noteworthy as they have been used for 
intramolecular C-H amination chemistry.30 The carboamination occurs intermolecularly in 
preference to an intramolecular C-H insertion suggesting a mechanistic dichotomy with Chang’s 
Ir-based system. 
 
4.4 Mechanistic investigation 
We next designed a series of experiments to interrogate the mechanism of the reaction. 
First, we conducted the reaction under standard conditions, but without phenylboronic acid 
(Scheme 4.9a). As a result, neither N-acyl aziridine nor aziridine ring-opening products26 is 
observed after the reaction. This strongly indicates that the Rh(III)-catalyzed alkene aziridination 
and subsequent ring-opening with phenylboronic acid is unlikely as the mechanism of the reaction.  
During the optimization study, we observed Heck-type (7) and hydroarylation products (8) 
as side products of the reaction, presumably formed through -hydride elimination and proto-
demetallation after the alkene migratory insertion (Scheme 4.10). To determine whether these side 
products give the desired carboamination product (4), we separately synthesized both benzyl 
cinnamate (7) and benzyl 3-phenylpropanoate (8) and they were subjected to the reaction using 1-
naphthyl boronic acid (2q) as the carbon source of the reaction (Scheme 4.9b). While both 
reactions give the desired product (4q) from 1-naphthyl boronic acid (2q) in good yield, 
carboamination products (4a) from these side products (7 or 8) are not observed. These 
experiments suggest 7 and 8 are off-cycle side products that do not re-enter the catalytic cycle. In 
addition, monitoring the reaction progress with 1H NMR indicates that the reaction with 
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dioxazolone that leads to product formation is faster than -hydride elimination at the beginning 
of the reaction. The amount of -hydride elimination product increases after consumption of 
limiting dioxazolone (3a) (see Appendix C for the details). 
 
 




In order to determine the turnover limiting step of the reaction, we investigated the alkene 
migratory insertion step with benzyl acrylate (2a) and deuterated benzyl acrylate (2a-d2). The 
inverse secondary kinetic isotope effect (KIE) value of 0.72 measured from the intermolecular 
competition experiment (Scheme 4.9c) or 0.55 calculated by comparing the initial rate of two 
separate reactions, one with benzyl acrylate (2a) and one with deuterated benzyl acrylate (2a-d2) 
(see Appendix C for details) suggest sp2 to sp3 hybridization change occurs during the turnover 
limiting step of the reaction.31, 32 
In order to determine the relative stereochemistry of the product, we conducted the reaction 
with mono-deuterated benzyl acrylate (2a-d1, 85:14 E/Z) (Scheme 4.9d). Interestingly, the 
reaction gives the product (4a-d1) containing almost identical deuterium incorporation with 
starting alkene (2a-d1) which suggests the carboamination is highly diastereoselective. The product 
was cyclized by Pd-catalyzed intramolecular C-H amidation,33 which confirmed syn-
carboamination of the alkene. 
 
4.5 Proposed mechanism 
Based on these experiments, we propose the following mechanism for the reaction 
(Scheme 4.10). First, the active monomeric Rh complex I undergoes transmetalation with 
phenylboronic acid (1a) to give Rh-phenyl complex II. Next, turnover limiting migratory insertion 
into the Rh-aryl bond forms Rh(III) intermediate IV. Subsequently, dioxazolone (3a) coordinates 
to the electron-rich alkyl Rh(III) complex (IV) followed by Rh-nitrene formation with the 
exclusion of CO2. The desired syn-carboamination product (4a) is formed after reductive 







Scheme 4.10: Proposed mechanism. 
 
4.6 Application to peptide synthesis 
As a potential application of the newly developed methodology, we synthesized peptide 
chains using dioxazolones and alkenes prepared from natural amino acids (Scheme 4.11). The 
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reaction with glycine-derived dioxazolone (3e), alkene (2n) synthesized from L-leucine, and 
phenylboronic acid (1a) delivers tripeptide, PhthN-(Gly)-(Phe)-(Leu)-OEt (10) in 43% yield albeit 
low diastereoselectivity. Using 4-hydroxyphenylboronic acid (1f), tyrosine residue was 
successfully formed to synthesize PhthN-(Gly)-(Tyr)-(Ala)-Ot-Bu (11). Currently, a 2nd-year 
graduate student of the lab, Chris Lamartina, is trying to improve the reaction yield and 
diastereoselectivity to achieve a diastereoselective synthesis of longer and general peptide chains 




Scheme 4.11: Application to peptide synthesis. 
 
4.7 Summary 
In summary, we have developed Rh(III)-catalyzed 3-component regioselective syn-
carboamination of alkenes. The reaction shows a broad scope with a variety of commercially 
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available arylboronic acids and dioxazolones easily prepared from carboxylic acids. Mechanistic 
investigations suggest alkene migratory insertion to be the turnover limiting step supported by 
secondary KIE. In addition, deuterium labeling experiments provide experimental evidence for 
stereoselective syn-carboamination process. This method provides a rapid access to valuable 
amines including non-natural -amino acids from abundant alkenes with excellent regioselectivity 
and high diastereoselectivity with internal cyclic alkenes.  
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Chapter 5: Three-component Diamination of Unactivated Alkenes 
5.1 Introduction 
The 1,2-vicinal diamine is a prevalent structural motif in natural products and 
pharmaceuticals. Moreover, they are commonly utilized as ligands on various metal complexes 
that catalyze essential organic transformations.1-3 Owing to the high demand, the development of 
efficient synthetic strategies for the synthesis of 1,2-diamines has been actively pursued (Scheme 
5.1).2, 4 Several notable synthetic approaches exist including aza-Henry reaction,5-7 Mannich 
reaction between α-amino-compounds and imines,8, 9  and the addition of nucleophile onto α-amino 
imines.10  
 
Scheme 5.1: Synthesis of vicinal diamines. 
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Among the potential synthetic precursors for the synthesis of vicinal amines, alkenes are 
ideal – they are ubiquitous feedstock materials, and unreactive enough to the other transformations. 
Thus, the simultaneous addition of two nitrogen functionalities to the alkene double bond is a 
straightforward and useful way to access 1,2-vicinal diamines (Scheme 5.2).  
 
 
Scheme 5.2: Transition metal-catalyzed alkene diaminations. 
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However, aside from some prominent successes (Scheme 5.2),11-19  transition-metal-
catalyzed 1,2-diamination of alkenes is significantly underdeveloped compared to the much better-
established dihydroxylation and aminohydroxylation of alkenes. Presumably, this is because 1,2-
diamines are generally good ligands and can act as a chelating ligand for the metal complex. 
Alternatively, the nucleophilic ring-opening of aziridines by amines is an efficient strategy 
to access diamines from readily available starting materials.20-23 Recently, we reported a Rh(III)-
catalyzed formal [4+1] approach to pyrrolidines from simple unactivated terminal alkenes and 
nitrene sources.24 Mechanistic investigations led us to propose a Rh-catalyzed intermolecular 
aziridination with subsequent ring expansion by triflic acid for the synthesis of 5-membered 
saturated N-heterocycle. Motivated by the fact that aziridine formation is highly efficient in this 
system, we envisioned that this intermediate can be utilized for the one-pot synthesis of vicinal 
diamines in the presence of exogenous nitrogen nucleophiles. 
 
5.2 Reaction development 
In order to test this idea, we added morpholine (2a) as amine nucleophile after the initial 
aziridination of 1-hexene (1a) and 4-methyl-N-(pivaloyloxy)benzenesulfonamide (Ts-NH-OPiv) 
in the presence of a catalytic amount of Cs2CO3 (0.1 equiv) and [Ind*RhCl2]2 catalyst (2.5 mol%) 
in HFIP. Preliminary results showed that when 2 equiv. of morpholine was added and stirred at 
room temperature and 40 °C, desired diamination products were formed as a single regioisomer 
albeit low yield (Table 5.1. entry 1, 2). Increasing reaction temperature to 80 °C further improved 
the reaction yield to 63% (entry 3). Since we observed unreacted aziridine on workup, longer 
reaction time and higher concentration were applied to complete the reaction, and the yield of 3aa 
improved to 87% when the reaction was conducted at 80 °C for 16 hours in 0.2 M of HFIP (entry 
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6). Lewis acid-promoted aziridine ring opening by amines is well-known;20-23 however, adding 
AgSbF6 together with morpholine after aziridination gives a lower yield of 3aa (entry 4). Finally, 
a quantitative yield of the desired product is observed at 0.2 M with 3 equiv. of morpholine (entry 
7).  
 
Table 5.1: Optimization table. 
 
5.3 Reaction scope 
Having optimized the reaction conditions, we next sought to explore the scope of this 
methodology. First, various commercially available primary and secondary amines were examined 
using 1-hexene as an alkene coupling partner (Scheme 5.3). Cyclic secondary amines such as 
65 
 
pyrrolidine (2b) and piperidine (2c) provide diamination products with good yield (3ab, 3ac).  
Bicyclic 1,2,3,4-tetrahydroisoquinoline (2d) also works well as a nucleophile giving 65% of 
corresponding 1,2-diamine (3ad). The reaction with dibutyl amine also delivers 1,2-vicinal 
diamine product with a good yield (3ae). The reaction also proceeds smoothly with primary 
amines, giving desired products (3af-3ai) in good yield. When aniline (2h) and 4-methoxyaniline 
(2i) are used as a nucleophile, the minor regioisomer is also observed in small amounts. Hydrazine-
type nucleophile (1-aminopyrrolidine) was also tested but only trace amount of desired product 








Next, we tested the synthetic utility of this method with a variety of terminal unactivated 
alkene substrates (Scheme 5.4). Allyl cyclohexane and 2-allyladamantane are successfully 
converted to the corresponding diamination products in good yield (3ba, 3ca). A variety of 
functional groups such as phenyl (3da), tert-butyldiphenylsilyl protected alcohol (3ea), ethyl ester 
(3fa), and protected amine (3ga) are all well tolerated, giving the desired 1,2-diamination product 









5.4 Proposed mechanism 
Based on our previous work24 and aziridine ring-opening precedent,20-23 we propose the 
following mechanism for the reaction. First, [Ind*RhCl2]2 catalyst metalates Ts-NH-OPiv to 
generate Rh complex II, which undergoes Rh-nitrene formation to yield intermediate III. 
Subsequent aziridination with an unactivated alkene coupling partner (1a) would give aziridine 
intermediate with the regeneration of active Rh(III) catalyst. Alternatively, the alkene coupling 
partner (1a) can coordinate with Rh complex II and undergoes alkene migratory insertion to form 
complex IV. Subsequent C-N bond formation and N-O bond cleavage would generate an aziridine 
intermediate. Nucleophilic attack of primary and/or secondary amines on the less hindered 









In summary, we demonstrate the one-pot synthesis of vicinal diamines from readily 
available -olefins through Rh(III)-catalyzed aziridination and subsequent nucleophilic attack by 
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1. General Information  
All reactions were carried out using oven-dried glassware with magnetic stirring unless otherwise noted. 
Anhydrous solvents and reagents were purchased from commercial sources and used without further 
purification except HFIP which was distilled with 3 Å molecular sieves. Flash chromatography was 
conducted either manually on SiliCycle® SilicaFlash® P60 (230-400 mesh) silica gel, SiliCycle® prep TLC 
(TLG-R10011B-341, thickness 1000um) or automatically via a Teledyne Isco Lumen CombiFlash with 
RediSep Rf Disposable Flash columns. Thin layer chromatography (TLC) was performed on Silicycle 
250μm silica gel 60 Å plates. Visualization was accomplished with UV light (254 nm) and KMnO4. 1H, 19F 
NMR and 13C NMR spectra were collected at ambient temperature on Bruker 400 MHz and Bruker Avance 
III 500 MHz spectrometers unless otherwise noted. Chemical shifts (δ) are reported in parts per million 
(ppm), coupling constants (J) are reported in Hz, and multiplicity is described using the following 
abbreviations: singlet (s), broad (b), multiplet (m), doublet (d), triplet (t), quartet (q), or combinations 
thereof. 1H NMR spectra were referenced to 7.26 ppm (CHCl3). 13C NMR spectra were referenced to 77.16 
ppm (CDCl3) and all peaks given are singlet unless otherwise noted. Diastereomeric and regioisomeric 
ratios were measured by integration of 1H NMR spectra of product mixtures prior to purification. Low 
resolution mass spectra were recorded on a Waters Acquity HuPLC-MS or Agilent 5977B GC/MS. Infrared 
spectra were collected on a Perkin Elmer Spectrum Two FT-IR Spectrometer. Melting point were measured 
by Stanford Research System MPA160 melting point apparatus. 
 
2. Preparation of Starting Materials 
1a, 1b, 1c, 1e, 1f and 1l were purchased from Sigma Aldrich and used without further purification. 1d,1 1g-
i,2 1j,3 1k,4 2a-b,5 and [Ind*RhCl2]2 catalyst6 were synthesized following literatures. Allyl cyclohexanes 









General Procedure: synthesis of allyl cyclohexanes 
 
To a suspension of LiCl (1.42 equiv) in MeCN (1.0 M) were added DBU (1.21 equiv) and triethyl 
phosphonoacetate (1.30 equiv) at 0 °C. The mixture was stirred at 0 °C for 30 minutes, before 
cyclohexanone (S1m-s) (1 equiv) was added. The reaction was stirred at room temperature overnight and 
quenched by the addition of saturated aqueous solution of NaHCO3. The mixture was extracted with ethyl 
acetate three times. The combined extracts were washed with brine, dried over anhydrous MgSO4 and 
concentrated. The residue was purified by chromatography on silica gel (hexane/ethyl acetate) to afford the 
corresponding ,-unsaturated ester (S2m-s).  
The , -unsaturated ester (S2m-s) was then dissolved in MeOH (0.3 M) and Pd/C (10% wt) was added at 
room temperature. The reaction mixture was stirred under atmospheric H2 overnight before filtered through 
celite and concentrated under vacuum. The crude product was used without further purification.  
Ester (S2m-s) was added dropwise to a suspension of LiAlH4 (2 equiv) in THF (0.2 M) at 0 oC. The reaction 
mixture was warmed to room temperature and stirred for 2 - 4 hours. After completion of the reaction, the 
mixture was subsequently added x mL water, x mL 15% aqueous solution of NaOH and 3x mL additional 
water (x = g of LiAlH4 used). The resulting mixture was then dried with anhydrous MgSO4, filtered through 
celite and concentrated to give the crude alcohol. 
To a solution of oxalyl chloride (1.3 equiv) in DCM (0.2 M) at -78 oC was added DMSO (2 equiv) and the 
crude alcohol (1 equiv). The solution was stirred for 30 min before Et3N (3 equiv) was added slowly over 
30 minutes. The mixture was warmed to room temperature and stirred for additional 30 minutes. The 
reaction was quenched with water and extracted with DCM. The combined organic layers were washed 
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with brine, dried over anhydrous MgSO4, filtered through celite and concentrated. The resulting aldehyde 
(S3m-s) was used without further purification.  
Potassium tert-butoxide (1.7 equiv) was added to a suspension of methyltriphenylphosphonium bromide (2 
equiv) in THF (0.2 M) at 0 oC. After the solution was stirred for 1 hour at this temperature, the crude 
aldehyde (S2m-s) in THF was added dropwise. The reaction was warmed to room temperature and stirred 
overnight. Pentane was added to the reaction mixture and the suspension was filtered through a short plug 
of silica. The mixture was purified by chromatography on silica gel (pentane) to afford the corresponding 




1H NMR (500 MHz, CDCl3) δ 5.77 (ddt, J = 16.3, 11.0, 7.1 Hz, 1H), 5.09 – 4.90 (m, 2H), 2.11 – 1.97 (m, 
4H), 1.81 – 1.61 (m, 4H), 1.47 – 1.34 (m, 1H), 1.32 – 1.20 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 136.9, 123.9 (dd, J = 241.9, 239.6 Hz), 116.3, 40.3 (d, J = 2.7 Hz), 35.8 (d, 
J = 1.5 Hz), 33.6 (dd, J = 25.4, 22.4 Hz), 28.8 (d, J = 9.5 Hz). 
19F NMR (471 MHz, CDCl3) δ -90.7 (d, J = 234.8 Hz), -100.9 (d, J = 236.3 Hz). 
 
IR (CDCl3, cm-1) ν 3078, 2939, 2866, 2254, 1835, 1651, 1448, 1114, 963, 906, 728, 650, 605. 







1H NMR (500 MHz, CDCl3) δ 5.85 – 5.72 (m, 1H, 2 dias.), 5.04 – 4.92 (m, 2H, 2 dias.), 2.12 – 2.07 (m, 
2H, minor), 1.97 – 1.91 (m, 2H, major),  1.83 – 1.70 (m, 4H, major, 1H, minor), 1.69 – 1.63 (m, 2H, minor), 
1.52 – 1.47 (m, 2H, minor), 1.46 – 1.38 (m, 2H, minor), 1.29 – 1.17 (m, 1H, major), 1.12 (qd, J = 12.5, 3.3 
Hz, 2H, minor), 1.02 – 0.88 (m, 5H, major, 1H, minor), 0.84 (s, 9H, minor), 0.83 (s, 9H, major). 
13C NMR (126 MHz, CDCl3) δ 138.8, 138.0, 115.3, 115.1, 48.6, 48.3, 42.0, 38.0, 35.8, 33.7, 32.7, 32.6, 
32.5, 30.3, 27.8, 27.7, 27.4, 21.7. 
IR (CDCl3, cm-1) ν 3076, 2938, 2917, 2856, 2251, 1822, 1650, 1448, 1365, 1236, 993, 906, 733, 650. 





1H NMR (500 MHz, CDCl3) δ 7.33 – 7.15 (m, 5H, 2 dias.), 5.89 – 5.76 (m, 1H, 2 dias.), 5.07 – 4.97 (m, 
2H, 2 dias.),  2.59 (tt, J = 9.4, 4.9 Hz, 1H, Minor), 2.47 (tt, J = 12.3, 3.3 Hz, 1H, major), 2.19 (tt, J = 7.4, 
1.3 Hz, 2H, minor), 2.02 (tt, J = 7.0, 1.3 Hz, 2H, major), 1.96 – 1.85 (m, 4H, major), 1.84 – 1.77 (m, 1H, 
minor), 1.74 – 1.59 (m, 8H, minor), 1.54 -1.43 (m, 2H, major), 1.43 – 1.35 (m, 1H, major) 1.15 – 1.04 (m, 
2H, major) 
13C NMR (126 MHz, CDCl3) δ 147.9, 147.6, 138.3, 137.7, 128.4, 128.4, 127.1, 127.0, 126.0, 125.9, 
115.6, 115.5, 44.6, 43.6, 42.0, 37.5, 36.6, 34.4, 33.4, 33.0, 29.8, 28.9. 
IR (CDCl3, cm-1) ν 3076, 3061, 3026, 2976, 2920, 2851, 2248, 1638, 1601, 1492, 1447, 1080, 1066, 1030, 
995, 969, 905, 728, 698, 649, 584, 530.  







1H NMR (500 MHz, CDCl3) δ 5.85 – 5.73 (m, 1H, 2 dias.), 5.01 – 4.93 (m, 2H, 2dias.), 2.04 – 1.99 (m, 
2H, minor), 1.99 – 1.89 (m, 2H, major), 1.79 – 1.08 (m, 8H, 2dias.), 0.89 (d, J = 6.9 Hz, 3H, minor), 0.87 
(d, J = 6.5 Hz, 3H, major), 0.79 (m, 2H, major), 0.54 (m, 2H, minor). 
13C NMR (126 MHz, CDCl3) δ 138.4, 137.9, 115.3, 115.2, 42.2, 42.1, 39.4, 39.0, 37.9, 35.4, 33.9, 32.9, 
32.8, 32.5, 31.4, 27.3, 26.5, 23.1, 20.9, 20.9. 
IR (CDCl3, cm-1) ν 3075, 2920, 2853, 1639, 1456, 1376, 995, 906, 733, 650. 





1H NMR (500 MHz, CDCl3) δ 5.82 – 5.69 (m, 1H, 2 dias.), 5.05 – 4.97 (m, 2H, 2dias.), 2.25 – 1.73 (m, 
7H), 1.67 – 1.30 (m, 2H), 1.29 – 0.82 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ 137.3, 136.7, 128.5 (q, J = 279.3 Hz), 127.9 (q, J = 278.6 Hz), 116.3, 116.1, 
42.2 (q, J = 26.4 Hz), 41.7, 37.3, 36.9 (q, J = 26.0 Hz), 36.7, 32.2, 31.9, 31.2 (q, J = 2.6 Hz), 29.5, 28.8 (q, 
J = 2.4 Hz), 25.1 (q, J = 2.6 Hz), 25.0 (q, J = 2.5 Hz), 24.9, 20.0. 
19F NMR (376 MHz, CDCl3) δ -72.2 (d, J = 9.3 Hz), -74.0 (d, J = 8.5 Hz). 
IR (CDCl3, cm-1) ν 3078, 2938, 2863, 2254, 1641, 1465, 1448, 1391, 1323, 1285, 1258, 1202, 1167, 995, 
907, 732, 650. 






1H NMR (500 MHz, CDCl3) δ 5.78 (ddt, J = 17.1, 10.1, 7.1 Hz, 1H), 5.04 – 4.93 (m, 2H), 2.20 (tt, J = 7.2, 
1.4 Hz, 2H), 1.91 – 1.78 (m, 6H), 1.76 – 1.67 (m, 7H), 1.54 – 1.47 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 138.5, 115.0, 44.3, 39.4, 38.6, 37.5, 31.6, 28.5, 28.23. 
IR (CDCl3, cm-1) ν 3074, 2973, 2904, 2850, 2661, 2250, 1638, 1454, 1100, 994, 904, 728, 650, 607. 





1H NMR (500 MHz, CDCl3) δ 5.83 – 5.72 (m, 1H, 2 dias.), 5.04 – 4.92 (m, 2H, 2 dias.), 2.33 – 2.26 (m, 
1H, minor), 2.20 – 0.93 (m, 11H, 2 dias.), 1.84 – 1.76 (m, 1H, major), 0.91 (d, J = 6.4 Hz, 3H, major.), 0.84 
(d, J = 7.1 Hz, 3H, major). 
13C NMR (126 MHz, CDCl3) δ 138.4, 137.9, 115.3, 115.2, 42.2, 42.1, 39.4, 39.0, 37.9, 35.4, 33.9, 32.9, 
32.8, 32.5, 31.4, 27.3, 26.5, 23.1, 20.9, 20.9. 
IR (CDCl3, cm-1) ν 3080, 2923, 2853, 1639, 1447, 1382, 996, 907, 734, 650. 







3. Detailed Optimization Table 
 
Reactions were conducted on a 0.1 mmol scale using 1a (1.0 equiv). Additive was added after 24 h. 
aDetermined by analysis of 1H NMR of the unpurified reaction mixture. bReaction was conducted at 40 °C 
with 1 equiv of 2a and the additive (40 mol%) was added initially. cReaction temperature increased to 80 °C 
after addition of additive. Ind* = heptamethylindenyl, Cpt = di-tert-butylcyclopentadienyl, Cp*CF3 = 





Optimization Table-2: from aziridine to pyrrolidine: 
 
4. General Procedure for Pyrrolidine Synthesis 
Cesium carbonate (0.01 mmol, 0.1 equiv), N-(pivaloyloxy)sulfonamide (0.13 mmol, 1.3 equiv) were 
measured in an oven-dried 1 dram vial with a magnetic stir bar in the glovebox. In a separate vial, alkene 
(0.1 mmol, 1 equiv) was dissolved in 0.35 mL of HFIP and transferred to the first vial. It was rinsed with 
additional 0.35 mL of HFIP and transferred again to the first vial. (In case of volatile alkenes 1a, 1b, and 
1e, Cesium carbonate and N-(pivaloyloxy)sulfonamide were dissolved in 0.7 mL of HFIP and the alkene 
was added directly using micropipette). [Ind*RhCl2]2 (0.0025 mmol, 2.5 mol%) in 0.3 mL of HFIP was 
added to the first vial and stirred at 22 oC for 24 hours. Triflic acid (0.2 mmol, 2 equiv) was added to the 
reaction mixture and stirred for additional 24 hours. Reaction mixture was quenched with saturated aqueous 
solution of NaHCO3 and extracted 3 times with DCM. The combined organic layers were washed with 
brine and dried over anhydrous MgSO4. The solid was filtered and the filtrate was concentrated by rotary 
evaporator. A crude 1H NMR spectrum was collected with 1,3,5-trimethoxybenzene as the internal 
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standard. Purification was performed by flash chromatography or preparational TLC using ethyl acetate 
and hexane as the eluent. 
 
5. Product Characterization 
2-Ethyl-1-tosylpyrrolidine (3aa) 
 
Yield: 61%, white solid. m.p. 72 – 74 °C 
Rf = 0.26 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.69 (m, 2H), 7.33 – 7.28 (m, 2H), 3.57 – 3.50 (m, 1H), 3.37 (ddd, J 
= 10.4, 7.1, 5.2 Hz, 1H), 3.18 (dt, J = 10.4, 7.2 Hz, 1H), 2.42 (s, 3H), 1.89 – 1.81 (m, 1H), 1.80 – 1.72 (m, 
1H), 1.60 – 1.52 (m, 2H), 1.52 – 1.43 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 143.3, 135.2, 129.7, 127.6, 62.0, 49.1, 30.3, 29.3, 24.3, 21.7, 10.5. 
The spectral data are consistent with those reported in the literature7 
IR (CDCl3, cm-1) ν 3059, 2969, 2933, 2876, 1341, 1159, 1093, 737, 663, 587, 550. 
LRMS (ESI+APCI) m/z [C13H20NO2S]+ ([M+H]+ ) calculated 254.1, found 254.1. 
2,2-Dimethyl-1-tosylpyrrolidine (3ba) 
 
Yield: 63%, white solid. m.p. 80 – 82 °C 
Rf = 0.20 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.76 – 7.70 (m, 2H), 7.28 – 7.23 (m, 2H), 3.38 (t, J = 6.5 Hz, 2H), 2.40 (s, 
3H), 1.83 – 1.74 (m, 4H), 1.43 (s, 6H). 
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13C NMR (126 MHz, CDCl3) δ 142.6, 138.9, 129.5, 127.3, 65.2, 49.5, 43.1, 28.4, 22.6, 21.6. 
The spectral data are consistent with those reported in the literature8 
IR (CDCl3, cm-1) ν 2969, 2873, 1599, 1333, 1153, 1095, 1008, 816, 678, 591, 549. 




Yield: 54%, yellowish oil. 
Rf = 0.29 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.68 (m, 2H), 7.32 – 7.27 (m, 2H), 3.59 (dq, J = 11.9, 4.9 Hz, 1H), 
3.37 (ddd, J = 11.1, 7.0, 5.4 Hz, 1H), 3.18 (dt, J = 10.5, 7.2 Hz, 1H), 2.42 (s, 3H), 1.87 – 1.71 (m, 2H), 1.60 
– 1.51 (m, 2H), 1.51 – 1.39 (m, 2H), 1.37 – 1.23 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 143.3, 135.2, 129.7, 127.6, 60.8, 49.0, 36.6, 31.9, 30.8, 26.0, 24.3, 22.8, 
21.7, 14.2. 
IR (CDCl3, cm-1) ν 2956, 2928, 2860, 2255, 1598, 1494, 1458, 1339, 1197, 1159, 1093, 906, 815, 730. 




Yield: 49%, white solid. m.p. 113 – 115 °C 
Rf = 0.25 (EA/Hex 1:9). 
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1H NMR (500 MHz, CDCl3) δ 7.73 – 7.69 (m, 2H), 7.32 – 7.27 (m, 2H), 3.56 – 3.48 (m, 1H), 3.27 (t, J = 
6.5 Hz, 2H), 2.42 (s, 3H), 1.79 – 1.61 (m, 8H), 1.45 – 1.32 (m, 2H), 1.28 – 1.06 (m, 3H), 1.03 – 0.86 (m, 
2H). 
13C NMR (126 MHz, CDCl3) δ 143.2, 135.4, 129.7, 127.7, 65.3, 49.3, 42.4, 30.6, 27.7, 27.1, 26.7, 26.5, 
26.3, 24.7, 21.7. 
The spectral data are consistent with those reported in the literature9 
IR (CDCl3, cm-1) ν 3056, 2927, 2853, 1598, 1340, 1265, 1158, 1092, 735, 665. 




Yield: 75%, white solid. m.p. 92 – 94 °C 
Rf = 0.22 (EA/Hex 1:15). 
1H NMR (400 MHz, CDCl3) δ 7.77 – 7.68 (m, 2H), 7.28 – 7.21 (m, 2H), 3.54 – 3.47 (m, 1H), 3.18 (ddd, J 
= 10.3, 9.1, 6.6 Hz, 1H), 2.40 (s, 3H), 1.88 – 1.78 (m, 2H), 1.57 – 1.46 (m, 1H), 1.40 (s, 3H), 1.18 (s, 3H), 
0.88 (d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 142.6, 139.1, 129.4, 127.2, 67.2, 47.2, 45.7, 30.1, 26.8, 22.5, 21.6, 13.9. 
IR (CDCl3, cm-1) ν 3057, 2971, 2879, 1330, 1266, 1154, 1094, 737, 705, 676, 600, 550. 






Yield: 55%, yellow oil. 
Rf = 0.29 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.68 (m, 2H), 7.32 – 7.28 (d, J = 8.0 Hz, 2H), 3.63 – 3.54 (m, 1H), 
3.41 (t, J = 6.8 Hz, 2H), 3.37 (ddd, J = 10.4, 7.0, 5.1 Hz, 1H), 3.18 (dt, J = 10.4, 7.2 Hz, 1H), 2.42 (s, 3H), 
1.90 – 1.70 (m, 4H), 1.62 – 1.51 (m, 2H), 1.51 – 1.38 (m, 4H), 1.37 – 1.26 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 143.3, 135.1, 129.7, 127.6, 60.7, 49.0, 36.5, 34.2, 32.9, 30.8, 29.4, 28.8, 
28.2, 26.1, 24.3, 21.7. 
IR (CDCl3, cm-1) ν 2928, 2856, 1597, 1461, 1343, 1159, 1092, 815, 736, 664, 587, 551. 
LRMS (ESI+APCI) m/z [C18H29BrNO2S]+ ([M+H]+ ) calculated 402.1 & 404.1, found 402.1 & 404.1. 
 
7-(1-tosylpyrrolidin-2-yl)heptyl acetate (3ga) 
 
Yield: 55%, yellow oil. 
Rf = 0.38 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 7.73 – 7.68 (m, 2H), 7.32 – 7.28 (m, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.61 – 
3.55 (m, 1H), 3.36 (ddd, J = 10.4, 7.1, 5.1 Hz, 1H), 3.18 (dt, J = 10.4, 7.2 Hz, 1H), 2.42 (s, 3H), 2.04 (s, 
3H), 1.85 – 1.70 (m, 2H), 1.66 – 1.58 (m, 2H), 1.58 – 1.51 (m, 2H), 1.51 – 1.39 (m, 2H), 1.38 – 1.26 (m, 
8H). 
13C NMR (126 MHz, CDCl3) δ 171.4, 143.3, 135.2, 129.7, 127.6, 64.7, 60.7, 49.0, 36.6, 30.8, 29.6, 29.3, 
28.7, 26.2, 26.0, 24.3, 21.6, 21.2. 
IR (CDCl3, cm-1) ν 3057, 2931, 2858, 1733, 1598, 1342, 1265, 1247, 1159, 1092, 816, 736, 664.  
LRMS (ESI+APCI) m/z [C20H32NO4S]+ ([M+H]+ ) calculated 382.2, found 382.2. 
 




Yield: 57%, yellow oil. 
Rf = 0.12 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.81 – 7.77 (m, 2H), 7.72 – 7.68 (m, 2H), 7.37 – 7.33 (m, 2H), 7.32 – 7.28 
(m, 2H), 4.02 (t, J = 6.5 Hz, 2H), 3.60 – 3.53 (m, 1H), 3.36 (ddd, J = 10.4, 7.1, 5.1 Hz, 1H), 3.17 (dt, J = 
10.4, 7.2 Hz, 1H), 2.45 (s, 3H), 2.42 (s, 3H), 1.83 – 1.70 (m, 2H), 1.67 – 1.59 (m, 2H), 1.58 – 1.50 (m, 2H), 
1.50 – 1.37 (m, 2H), 1.32 – 1.20 (m, 8H). 
13C NMR (126 MHz, CDCl3) δ 144.8, 143.3, 135.1, 133.3, 130.0, 129.7, 128.0, 127.6, 70.8, 60.6, 49.0, 
36.5, 30.8, 29.4, 29.0, 28.9, 26.0, 25.4, 24.2, 21.8, 21.6. 
IR (CDCl3, cm-1) ν 3061, 2928, 2858, 1598, 1461, 1343, 1188, 1176, 1158, 1095, 815, 736, 664, 587, 553. 




Yield: 52%, yellow oil. 
Rf = 0.16 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.75 – 7.65 (m, 4H), 7.32 – 7.27 (m, 2H), 3.72 – 3.63 
(m, 2H), 3.61 – 3.53 (m, 1H), 3.35 (ddd, J = 10.4, 7.0, 5.1 Hz, 1H), 3.18 (dt, J = 10.4, 7.1 Hz, 1H), 2.41 (s, 
3H), 1.86 – 1.71 (m, 2H), 1.71 – 1.61 (m, 2H), 1.60 – 1.50 (m, 2H), 1.50 – 1.38 (m, 2H), 1.37 – 1.23 (m, 
8H) 
13C NMR (126 MHz, CDCl3) δ 168.6, 143.2, 135.2, 134.0, 132.3, 129.7, 127.6, 123.3, 60.7, 49.0, 38.2, 
36.5, 30.8, 29.5, 29.3, 28.7, 26.9, 26.2, 24.3, 21.6. 
IR (CDCl3, cm-1) ν 2931, 2858, 2255, 1771, 1709, 1598, 1397, 1337, 1158, 1092, 907, 727, 664, 649. 






Yield: 53%, yellow oil. 
Rf = 0.33 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.75 – 7.70 (m, 2H), 7.33 – 7.27 (m, 2H), 3.68 (s, 3H), 3.60 – 3.53 (m, 1H), 
3.36 (ddd, J = 10.4, 7.1, 5.1 Hz, 1H), 3.21 – 3.12 (m, 4H), 2.42 (s, 5H), 1.87 – 1.78 (m, 1H), 1.78 – 1.70 
(m, 1H), 1.68 – 1.57 (m, 2H), 1.57 – 1.50 (m, 2H), 1.49 – 1.40 (m, 2H), 1.38 – 1.26 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 174.9, 143.3, 135.1, 129.7, 127.6, 61.4, 60.7, 49.0, 36.5, 32.3, 32.0, 30.8, 
29.5, 29.4, 26.1, 24.7, 24.2, 21.6. 
IR (CDCl3, cm-1) ν 3054, 2936, 2858, 1657, 1341, 1265, 1159, 1092, 736, 703, 664. 
LRMS (ESI+APCI) m/z [C20H33N2O4S]+ ([M+H]+ ) calculated 397.2, found 397.3. 
 
1,1,1,3,3,3-hexafluoropropan-2-yl 7-(1-tosylpyrrolidin-2-yl)heptanoate (3ka) 
 
Yield: 44%, yellow oil. 
Rf = 0.33 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.68 (m, 2H), 7.32 – 7.28 (m, 2H), 5.77 (hept, J = 6.2 Hz, 1H), 3.62 
– 3.56 (m, 1H), 3.37 (ddd, J = 10.4, 7.1, 5.1 Hz, 1H), 3.18 (dt, J = 10.4, 7.2 Hz, 1H), 2.52 (t, J = 7.5 Hz, 
2H), 2.42 (s, 3H), 1.85 – 1.65 (m, 4H), 1.60 – 1.51 (m, 2H), 1.51 – 1.41 (m, 2H), 1.40 – 1.27 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 143.3, 135.1, 129.7, 127.6, 120.6 (q, J = 283.31 Hz), 120.6 (q, J = 
282.00 Hz), 66.4 (hept, J = 34.29 Hz), 60.6, 49.0, 36.5, 33.4, 30.8, 29.1, 28.9, 26.0, 24.6, 24.3, 21.6. 
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19F NMR (282 MHz, CDCl3) δ -72.47 (d, J = 6.2 Hz). 
IR (CDCl3, cm-1) ν 3059, 2932, 2861, 1780, 1344, 1289, 1266, 1231, 1200, 1159, 1109, 738. 




Yield: 71%, white solid. m.p. 105 – 107 °C 
Rf = 0.30 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.75 – 7.70 (m, 2H), 7.28 – 7.23 (m, 2H), 3.37 (t, J = 6.5 Hz, 2H), 2.40 (s, 
3H), 2.37 – 2.28 (m, 2H), 1.86 – 1.81 (m, 2H), 1.78 – 1.73 (m, 2H), 1.73 – 1.65 (m, 2H), 1.62 – 1.56 (m, 
1H), 1.53 – 1.46 (m, 2H), 1.28 – 1.18 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ 142.5, 139.4, 129.4, 127.2, 69.8, 49.3, 36.6, 36.6, 25.1, 24.8, 22.9, 21.6. 
The spectral data are consistent with those reported in the literature10 
IR (CDCl3, cm-1) ν 3057, 2932, 2864, 1452, 1329, 1265, 1152, 1095, 737, 589. 




Yield: 40%, colorless oil. 
Rf = 0.28 (EA/Hex 1:4). 
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1H NMR (400 MHz, CDCl3) δ 7.76 – 7.69 (m, 2H), 7.30 – 7.24 (m, 2H), 3.42 (t, J = 6.5 Hz, 2H), 2.71 (td, 
J = 13.7, 4.0 Hz, 2H), 2.41 (s, 3H), 2.17 – 2.05 (m, 2H), 1.95 – 1.87 (m, 2H), 1.86 – 1.80 (m, 2H),  1.79 – 
1.62 (m, 2H), 1.58 – 1.48 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 143.0, 138.8, 129.6, 127.2, 122.23 (t, J = 241.62 Hz), 67.4, 49.4, 36.1, 32.3 
(dd, J = 25.9, 23.6 Hz), 32.1 (d, J = 9.9 Hz), 22.7, 21.6. 
19F NMR (471 MHz, CDCl3) δ -92.40 (d, J = 236.8 Hz), -101.74 (dtt, J = 236.6, 34.2, 11.1 Hz). 
IR (CDCl3, cm-1) ν 2977, 2877, 2256, 1743, 1718, 1453, 1375, 1279, 1120, 908, 732. 




Yield: 73%, white solid. m.p. 103 – 105 °C 
Rf = 0.14 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.72 (m, 2H), 7.26 – 7.24 (m, 2H), 3.38 (t, J = 6.4 Hz, 2H), 2.44 – 
2.29 (m, 5H), 1.85 – 1.67 (m, 6H), 1.58 – 1.49 (m, 2H), 1.17 – 1.07 (m, 1H), 1.06 – 0.94 (m, 2H), 0.83 (s, 
9H). 
13C NMR (126 MHz, CDCl3) δ 142.5, 139.3, 129.4, 127.2, 69.7, 49.4, 46.8, 36.8, 36.7, 32.4, 27.7, 25.5, 
22.8, 21.6. 
IR (CDCl3, cm-1) ν 2955, 2867, 1367, 1321, 1265, 1154, 1095, 738, 656, 591, 548. 






Yield: 55%, white solid. m.p. 144 – 146 °C 
Rf = 0.24 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.80 – 7.74 (m, 2H), 7.33 – 7.25 (m, 4H), 7.22- 7.16 (m, 3H), 3.42 (t, J = 
6.6 Hz, 2H), 2.70 – 2.54 (m, 3H), 2.42 (s, 3H), 2.00 – 1.93 (m, 2H), 1.93 – 1.86 (m, 2H), 1.86 – 1.78 (m, 
2H), 1.68 – 1.61 (m, 2H), 1.56 – 1.45 (m,  2H). 
13C NMR (126 MHz, CDCl3) δ 146.8, 142.6, 139.2, 129.5, 128.5, 127.2, 126.8, 126.2, 69.2, 49.3, 43.1, 
36.9, 36.5, 32.4, 22.9, 21.6. 
IR (CDCl3, cm-1) ν 3028, 3059, 2929, 2866, 1599, 1494, 1452, 1343, 1325, 1154, 1095, 736, 702, 659, 588. 




Yield: 60%, white solid. m.p. 71 – 73 °C 
Rf = 0.17 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.75 – 7.70 (m, 2H), 7.28 – 7.23 (m, 2H), 3.35 (t, J = 6.9 Hz, 2H), 2.40 (s, 
3H), 2.26 (td, J = 13.1, 4.3 Hz, 1H), 2.03 (t, J = 12.3 Hz, 1H), 1.85 – 1.79 (m, 2H), 1.79 – 1.73 (m, 2H), 
1.72 – 1.66 (m, 1H), 1.63 – 1.54 (m, 1H), 1.53 – 1.44 (m, 2H), 1.44 – 1.34 (m, 1H), 1.31 – 1.19 (m, 1H), 
0.98 – 0.90 (m, 1H), 0.89 (d, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 142.5, 139.2, 129.4, 127.2, 70.0, 49.2, 45.3, 37.3, 35.9, 33.9, 31.2, 24.3, 
23.0, 22.7, 21.6. 
IR (CDCl3, cm-1) ν 3056, 2952, 2925, 2867, 1598, 1455, 1330, 1265, 1152, 815, 735, 660, 592. 
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Yield: 53%, white solid. m.p. 130 – 132 °C 
Rf = 0.25 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.69 (m, 2H), 7.30 – 7.25 (m, 2H), 3.46 – 3.31 (m, 2H), 2.48 – 2.32 
(m, 5H), 2.09 – 1.98 (m, 1H), 1.91 – 1.80 (m, 3H), 1.83 – 1.71 (m, 3H), 1.74 – 1.68 (m, 1H), 1.58 – 1.50 
(m, 1H), 1.41 – 1.22 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 143.0, 138.8, 129.6, 127.4 (q, J = 278.7 Hz), 127.2, 68.3, 49.2, 41.0 (q, J = 
26.8 Hz), 37.0, 35.4, 35.1 (q, J = 2.4 Hz), 23.9 (q, J = 2.4 Hz), 22.9, 22.8, 21.6. 
19F NMR (471 MHz, CDCl3) δ -72.5 (d, J = 8.1 Hz). 
IR (CDCl3, cm-1) ν 2949, 2873, 1598, 1454, 1151, 1119, 1090, 1011, 679, 591, 548  




Yield: 71%, white solid. m.p. 146 – 148 °C 
Rf = 0.24 (EA/Hex 1:15). 
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1H NMR (500 MHz, CDCl3) δ 7.71 – 7.66 (m, 2H), 7.25 (d, J = 8.0 Hz, 2H), 4.13 – 4.05 (m, 1H), 3.14 (td, 
J = 12.8, 2.4 Hz, 1H), 2.58 (dd, J = 12.1, 3.5 Hz, 1H), 2.41 (s, 3H), 2.28 (dt, J = 12.5, 3.3 Hz, 1H), 2.05 – 
1.99 (m, 1H), 1.98 – 1.92 (m, 1H), 1.82 – 1.52 (m, 12H), 1.44 – 1.33 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 142.4, 141.6, 129.4, 126.7, 60.6, 47.5, 42.9, 42.8, 38.1, 37.1, 35.4, 32.7, 
30.6, 30.4, 30.0, 26.5, 26.4, 21.5. 
IR (CDCl3, cm-1) ν 3056, 2916, 2868, 1456, 1316, 1265, 1150, 1092, 800, 736, 665, 653, 580.  
LRMS (ESI+APCI) m/z [C20H28NO2S]+ ([M+H]+ ) calculated 346.2, found 346.2. 
 
8a-methyl-1-tosyldecahydroquinoline (3sa)  
 
Yield: 60%, colorless oil. 
Rf = 0.24 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.70 – 7.65 (m, 2H), 7.29 – 7.23 (m, 2H), 4.10 (dddd, J = 13.1, 4.5, 2.9, 1.2 
Hz, 1H), 3.13 (td, J = 12.8, 3.3 Hz, 1H), 2.41 (s, 3H), 2.35 – 2.28 (m, 1H), 1.77 – 1.62 (m, 2H), 1.61 – 1.55 
(m, 3H), 1.54 – 1.47 (m, 1H), 1.40 – 1.14 (m, 5H), 1.07 (s, 3H), 1.15 – 1.04 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 142.5, 141.0, 129.4, 126.8, 63.5, 45.8, 43.8, 38.0, 30.0, 27.6, 26.4, 25.6, 
23.3, 21.5, 13.7. 
IR (CDCl3, cm-1) ν 2927, 2859, 1453, 1320, 1151, 1089, 1033, 998, 904, 728, 679, 649, 582. 






Yield: 60%, white solid. m.p. 153 – 155 °C 
Rf = 0.35 (EA/Hex 1:8). 
1H NMR (500 MHz, CDCl3) δ 8.40 (s, 1H), 7.99 – 7.83 (m, 4H), 7.65 – 7.55 (m, 2H), 3.45 (t, J = 6.4 Hz, 
2H), 2.44 (td, J = 13.1, 3.9 Hz, 2H), 1.86 – 1.70 (m, 6H), 1.63 – 1.55 (m, 2H), 1.16 (tt, J = 12.1, 3.1 Hz, 
1H), 1.07 – 0.96 (m, 2H), 0.84 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 139.1, 134.6, 132.3, 129.3, 129.01, 128.5, 128.1, 127.9, 127.4, 122.9, 69.9, 
49.5, 46.8, 36.8, 36.8, 32.4, 27.7, 25.5, 22.9. 
IR (CDCl3, cm-1) ν 3058, 2957, 2869, 2254, 1591, 1504, 1367, 1321, 1264, 1152, 1078, 907, 732, 654. 
LRMS (ESI+APCI) m/z [C23H32NO2S]+ ([M+H]+ ) calculated 386.2, found 386.2. 
 
1-tosyldecahydroquinoline (5la)  
 
Yield: 66%, white solid. m.p. 81 – 83 °C 
Rf = 0.17 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.77 – 7.65 (m, 2H), 7.28 – 7.25 (m, 2H), 3.97 (dt, J = 12.3, 4.6 Hz, 1H), 
3.74 – 3.64 (m, 1H), 2.91 (td, J = 13.2, 2.8 Hz, 1H), 2.41 (s, 3H), 1.79 – 1.49 (m, 7H), 1.43 – 1.19 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 142.8, 139.0, 129.7, 127.0, 55.4, 40.5, 35.1, 31.7, 25.7, 25.6, 24.0, 23.6, 
21.7, 20.1. 
IR (CDCl3, cm-1) ν 2930, 2863, 2255, 1598, 1329, 1171, 1150, 1091, 1008, 984, 908, 731, 660, 586. 
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LRMS (ESI+APCI) m/z [C16H24NO2S]+ ([M+H]+ ) calculated 294.1, found 294.1. 
Representative example of NTs deprotection: 
 
To a solution of naphthalene (151 mg, 30 equiv) in DME (4.0 mL) at room temperature was add sodium 
metal (18 mg, 20 equiv). The reaction mixture was stirred for 1 h, until a dark green color solution was 
formed. In a 1 dr vial, NTs-pyrrolidine 3ga (15 mg, 0.039 mmol) was dissolved in DME (0.5 mL) and 
cooled to -78 oC. Na-naphthalenide solution was then added dropwise until a dark green color was persisted. 
The reaction mixture was stirred for 5 min at -78 oC and then it was quenched by adding several drops of 
water to discharge the green color. The reaction mixture was diluted with water and extracted with EtOAc. 
The organic layer was dried over anhydrous Na2SO4, concentrated under vacuum and further purified by 
the column chromatography (basic aluminium oxide) to give pyrrolidine 3ga-2 (7.6 mg, 85%). 
Rf: 0.35 (MeOH/DCM 1:9) 
1H NMR (500 MHz, CDCl3) δ 4.07 (t, J = 6.8 Hz, 2H), 3.03 (ddd, J = 10.4, 7.6, 5.3 Hz, 1H), 2.95 (p, J = 
7.4, 6.9 Hz, 1H), 2.84 (dt, J = 10.3, 7.4 Hz, 1H), 2.07 (s, 3H), 1.94 – 1.87 (m, 2H), 1.80 – 1.70 (m, 2H), 
1.66 – 1.60 (m, 2H), 1.49 – 1.23 (m, 10H). 
13C NMR (125 MHz, CDCl3) δ 171.3, 64.6, 59.4, 46.5, 36.4, 31.9, 29.7, 29.2, 28.6, 27.4, 25.9, 25.4, 21.0. 
IR (CDCl3, cm-1) ν 3340, 2926, 2855, 1738, 1401, 1365, 1238, 1038. 
HRMS (ASAP+) m/z [C13H26NO2] calculated 228.1958, found 228.1968. 
 
6. Mechanistic Studies 
Allylic amine 6,11 homo allylic amine 7,12 deuterated alkenes (1c-C1-d2,13 1c-C2-d1,14 1c-C3-d2,15 1c-C4-d214) 
were prepared according to literature procedures. 
 
General procedure for synthesis of aziridines (6ca, 6ca-C1-d2, 6ca-C2-d1, 6ca-C3-d2, 6ca-C4-d2) 
Cesium carbonate (0.01 mmol, 0.1 equiv), 2a (0.13 mmol, 1.3 equiv) were measured in an oven-dried 1 
dram vial with a magnetic stir bar in the glovebox. In a separate vial, the deuterated alkene (0.1 mmol, 1 
equiv) was dissolved in 0.35 mL of HFIP and transferred to the first vial. It was rinsed with additional 0.35 
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mL of HFIP and transferred again to the first vial. [Ind*RhCl2]2 (0.0025 mmol, 2.5 mol%) in 0.3 mL of 
HFIP was added to the first vial and stirred at 22 oC. After 24 hours, the reaction mixture was concentrated 




Yield: 95%, colorless oil. 
Rf = 0.28 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.89 – 7.75 (m, 2H), 7.35 – 7.30 (m, 2H), 2.73 – 2.66 (m, 1H), 2.62 (d, J = 
7.0 Hz, 1H), 2.43 (s, 3H), 2.05 (d, J = 4.6 Hz, 1H), 1.56 – 1.48 (m, 1H), 1.34 – 1.10 (m, 11H), 0.85 (t, J = 
7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.5, 135.3, 129.7, 128.1, 40.6, 33.9, 31.7, 31.4, 29.2, 29.1, 26.9, 22.7, 
21.7, 14.2. 
IR (CDCl3, cm-1) ν 2956, 2928, 2857, 2255, 1597, 1456, 1321, 1304, 1160, 1092, 905, 814, 727, 648, 569.  




Yield: 99%, colorless oil. 
Rf = 0.28 (EA/Hex 1:15). 
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1H NMR (500 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.37 – 7.31 (m, 2H), 2.70 (dd, J = 6.9, 4.6 Hz, 1H), 
2.64 (d, J = 6.9 Hz, 1H), 2.44 (s, 3H), 2.06 (d, J = 4.6 Hz, 1H), 1.30 – 1.22 (m, 2H), 1.22 – 1.14 (m, 8H), 
0.87 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.5, 135.4, 129.8, 128.1, 40.6, 33.9, 31.8, 30.7 (p, J = 19.3 Hz), 29.2, 
29.1, 26.7, 22.8, 21.8, 14.2. 
IR (CDCl3, cm-1) ν 2957, 2926, 2857, 2256, 1597, 1495, 1455, 1385, 1321, 1160, 1090, 906, 813, 730. 




Yield: 91%, yellow oil. 
Rf = 0.28 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.37 – 7.30 (m, 2H), 2.71 (m, 1H), 2.64 (d, J = 7.0 
Hz, 1H), 2.44 (s, 3H), 2.05 (d, J = 4.6 Hz, 1H), 1.52 (dd, J = 14.0, 5.0 Hz, 1H), 1.34 – 1.22 (m, 3H), 1.22 
– 1.13 (m, 6H), 0.86 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.5, 135.4, 129.8, 128.1, 40.3, 33.2, 31.8, 31.3, 29.2, 28.9, 26.12 (p, J = 
19.3 Hz), 22.8, 21.8, 14.2. 
IR (CDCl3, cm-1) ν 2956, 2923, 2855, 2257, 1597, 1455, 1324, 1305, 1229, 1162, 1092, 907, 815, 731, 715, 
695.  






Yield: 95%, colorless oil. 
Rf = 0.28 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.36 – 7.30 (m, 2H), 2.70 (dd, J = 7.6, 5.0 Hz, 1H), 
2.44 (s, 3H), 1.58 – 1.49 (m, 1H), 1.37 – 1.14 (m, 11H), 0.86 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.5, 135.4, 129.7, 128.1, 40.5, 31.8, 31.4, 29.2, 29.1, 26.9, 22.8, 21.8, 
14.2. 
IR (CDCl3, cm-1) ν 2957, 2926, 2957, 2256, 2598, 1160, 1092, 905, 730, 649, 568.  




Yield: 95%, yellow oil. 
Rf = 0.28 (EA/Hex 1:15). 
1H NMR (500 MHz, CDCl3) δ 7.89 – 7.77 (m, 2H), 7.35 – 7.31 (m, 2H), 2.63 (s, 1H), 2.43 (s, 3H), 2.05 (s, 
1H), 1.57 – 1.48 (m, 1H), 1.36 – 1.12 (m, 11H), 0.86 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.5, 135.4, 129.7, 128.1, 40.3 (t, J = 25.6 Hz), 33.8, 31.8, 31.3, 29.2, 
29.1, 26.9, 22.7, 21.7, 14.2. 
IR (CDCl3, cm-1) ν 2932, 2860, 2257, 1454, 1321, 1162, 1051, 1032, 1015, 908, 815, 732, 648.  




General Procedure for the Treatment of the Aziridine/Tosyl-Amide with Triflic Acid: 
 
To a solution of the aziridine/tosyl amide (1 equiv, 0.1 mmol) in HFIP (1.0 mL), triflic acid (2 equiv, 0.2 
mmol) was added and stirred at 22 °C for 24 hours. Reaction mixture was quenched with saturated aqueous 
solution of NaHCO3 and extracted 3 times with DCM. The combined organic layers were washed with 
brine and dried over anhydrous MgSO4. The solid was filtered and the filtrate was concentrated by rotary 
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8. Robustness Screening Test 
A robustness screen has been conducted to evaluate the tolerance of this reaction to the given functionalities 
and chemical motifs, as well as the stability of these additives to the reaction conditions.16 The standard 
reaction was performed using 1a as unactivated alkene substrate in the presence of one molar equivalent of 
the specified additive. After the reaction, the yield of the product and the additive remaining is determined 





9. X-ray Crystal Structure 
Single crystal X-ray diffraction was performed at the Shared Materials Characterization Laboratory at 
Columbia University. Use of the SMCL was made possible by funding from Columbia University. 
A chloroform solution of 3na was diluted with pentanes by vapor diffusion, then cooled at -4 oC to afford 
large, colorless shards. A large fragment (.64 x .46 x .11 mm) was separated carefully, mounted on a 
Mitegen mount with Paratone oil, and cooled to 100 K on the diffractometer. Complete data (99.5%) were 
collected to 0.8 Å using Mo radiation. 16080 reflections were collected (4620 unique, 3470 observed) with 
R(int) 5.9% and R(sigma) 6.6% after Gaussian absorption and beam profile correction (largest correction 
factor 1.49).  
The space group was assigned as Pbca based on the systematic absences. The structure solved readily using 
ShelXT with 1 molecule in the asymmetric unit. All non-H atoms were located in the initial solution and 
refined anisotropically with no restraints. C-H hydrogens were placed in calculated positions and refined 
with riding coordinates and ADPs; the hydrogens of the aryl-CH3 group were disordered over two positions 
in a 57:43 ratio. 
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The final refinement (4620 data, 0 restraints, 222 parameters) converged with R1 (Fo > 4σ(Fo)) = 5.4%, wR2 
= 11.7%, S = 1.05. The largest Fourier features were 0.28 and -0.36 e- A-3.  
 
Figure S1. Molecular structure of 3na. Black, carbon; blue, nitrogen; red, oxygen; yellow, sulfur. 
Hydrogen atoms are omitted for clarity. 
 
A chloroform solution of 3pa was diluted with pentane by vapor diffusion to afford a jumble of flaky 
colorless blocks. With difficulty, a single-crystalline fragment (.27 x .14 x .05 mm) was separated carefully, 
mounted on a glass fiber with Paratone oil, and cooled to 100 K on the diffractometer. Complete data were 
collected to 0.8 Å. 18219 reflections were collected (5874 unique, 5812 observed) with R(int) 4.5% and 
R(sigma) 4.6% after analytical absorption correction (maximum correction factor 1.23).  
Based on the systematic absences, the space group was Cc or C2/c. Using ShelXT, the structure solved 
readily in Cc with 2 molecules in the asymmetric unit. The space group was correct because the Flack 
parameter was near 0 and no (pseudo-)symmetry was detected by Platon. All non-H atoms were located in 
the initial solution and refined anisotropically with no restraints. C-H hydrogens were placed in calculated 
positions and refined with riding coordinates and ADPs.  
The final refinement (5874 data, 2 restraints, 383 parameters) converged with R1 (Fo > 4σ(Fo)) = 4.6%, wR2 





Figure S2. Molecular structure of 3pa. Both independent molecules are shown but their relative 
orientation is arbitrary. 
 
A benzene solution of 3ra was diluted with pentane by vapor diffusion to afford large, colorless blocks. 
Part of a crystal (.67 x .52 x .23 mm) was separated carefully, mounted with Paratone oil, and cooled to 100 
K on the diffractometer. The crystal was a triclinic, nonmerohedral twin with a twofold rotation around the 
reciprocal axis 010 as the twin law. Complete data were collected to 0.8 Å resolution. The second twin 
component was somewhat weaker and its isolated reflections were omitted; the data set contained 6772 
overlapped reflections and 6803 isolated reflections for the first component. R(int) was 5.3% and R(sigma) 
11.7% after Gaussian absorption correction and beam profile correction (max. correction factor 3.9). 
The structure solved readily in P-1 with two molecules in the asymmetric unit. Subsequent refinement was 
against the twinned data (HKLF 5 format). C-H hydrogens were placed in calculated positions and refined 
with riding coordinates and ADPs.  
The final refinement (8426 data, 0 restraints, 436 parameters) converged with R1 (Fo > 4σ(Fo)) = 6.0%, wR2 




   
 
 Figure S3. Molecular structure of 3ra. One of the two independent molecules is shown. Black, carbon; 
blue, nitrogen; red, oxygen; yellow, sulfur. Hydrogen atoms are omitted for clarity. 
 
A benzene solution of 5la was diluted with pentane by vapor diffusion and cooled at -4 deg. C to afford one 
large, irregular block. A fragment (.68 x .32 x .21 mm) was separated carefully, mounted on Mitegen loop 
with Paratone oil, and cooled to 100 K on the diffractometer. Complete data were collected to 0.8 Å. 29503 
reflections were collected (3926 unique, 3379 observed) with R(int) 5.8% and R(sigma) 3.7% after 
Gaussian absorption and beam profile correction (maximum correction factor 2.58). The space group was 
assigned as P4 2 /n based on the systematic absences and confirmed by solution in ShelXT. The structure 
solved readily with all non-H atoms located in the initial solution and refined anisotropically with no 
restraints. C-H hydrogens were placed in calculated positions and refined with riding coordinates and 
ADPs. 
The final refinement (3926 data, 0 restraints, 182 parameters) converged with R1 (Fo > 4σ(Fo)) =  5.0%, 





Figure S4. Molecular structure of 5la. One of the two independent molecules is shown. Black, carbon; 
blue, nitrogen; red, oxygen; yellow, sulfur. Hydrogen atoms are omitted for clarity. 
Compound 3na 3pa 3ra 5la 
Formula C20H31NO2S C20H27NO2S C17H25NO2S C16H23NO2S 
MW 349.52 345.48 307.44 293.41 
Space group Pbca P-1 Cc P42/n 
a (Å) 9.7111(4) 6.4929(6) 11.6792(2) 15.6435(2) 
b (Å) 11.8859(6) 10.1262(15) 11.2211(2) 15.6435(2) 
c (Å) 33.1687(11) 26.330(2) 24.8608(4) 12.4533(3) 
α (°) 90 89.500(11) 90 90 
β (°) 90 84.004(7) 99.2204(16) 90 
γ (°) 90 88.445(11) 90 90 
V (Å3) 3828.5(3) 1721.0(3) 3215.98(10) 3047.56(11) 
Z 8 4 8 8 
ρcalc (g cm-3) 1.213 1.333 1.27 1.279 
T (K) 100 100 100 100 
λ (Å) 0.71073 0.71073 1.54184 0.71073 
2θmin, 2θmax 7, 59 7, 59 7, 146 7, 59 
Nref 16080 13575 18219 29503 
R(int), R(σ) .0592, .0665 .053, .137 .0448, .0464 .0578, .0374 
μ(mm-1) 0.181 0.201 1.815 0.214 
Size (mm) .64 x .46 x .11 .67 x .52 x .23 .27 x .14 x .05 .68 x .32 x .21 
Tmax / Tmin 1.48 3.9 1.23 2.58 
Data 4620 8426 5874 3926 
Restraints 0 0 2 0 
Parameters 222 436 383 182 
R1(obs) 0.0543 0.0601 0.0457 0.0502 
wR2(all) 0.1172 0.1116 0.1187 0.1128 
S 1.050 1.043 1.053 1.125 
Peak, hole (e- Å-3) 0.28, -0.36 0.74, -0.53 0.40, -0.39 0.33, -0.40 
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1. General Information  
All reactions were carried out using oven-dried glassware with magnetic stirring unless otherwise noted. 
Anhydrous solvents and reagents were purchased from commercial sources and used without further 
purification. Flash chromatography was conducted either manually on SiliCycle® SilicaFlash® P60 (230-
400 mesh) silica gel or automatically via a Teledyne Isco Lumen CombiFlash with RediSep Rf Disposable 
Flash columns. Thin layer chromatography (TLC) was performed on Silicycle 250μm silica gel 60 Å plates. 
Visualization was accomplished with UV light (254 nm) and KMnO4. 1H, 19F NMR and 13C NMR spectra 
were collected at ambient temperature on Bruker 400 MHz and Bruker Avance III 500 MHz spectrometers 
unless otherwise noted. Chemical shifts (δ) are reported in parts per million (ppm), coupling constants (J) 
are reported in Hz, and multiplicity is described using the following abbreviations: singlet (s), multiplet 
(m), doublet (d), triplet (t), quartet (q), or combinations thereof. 1H NMR spectra were referenced to 7.26 
ppm (CHCl3). 13C NMR spectra were referenced to 77.16 ppm (CDCl3) and all peaks given are singlet 
unless otherwise noted. Regioisomeric ratios were measured by integration of 1H NMR spectra of product 
mixtures prior to purification. High resolution mass spectra (HRMS) were obtained from Columbia 
University Mass Spectrometry Facility on a JOEL JMSHX110HF mass spectrometer using ASAP 
ionization model. Infrared spectra were collected on a Perkin Elmer Spectrum Two FT-IR Spectrometer. 
 
2. Preparation of Starting Materials 
2a, 2b, 2c, 2d, 2e, 2f, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 2q, 2r, 2s, 2t, 2u, 2v and 2w were purchased from Sigma 
Aldrich and used without further purification. 2g,[1] 2h,[2] and 2i[3] were synthesized following literature 
procedures. Acrylamides (1a – 1i) were synthesized following general procedures below. 
 
General Procedure: synthesis of acrylamides 
 
 
Oxalyl chloride (1.2 equiv.) and catalytic amount of DMF were added dropwise at 0 °C to a solution of 
acrylic acid (1.5 equiv.) in CH2Cl2 (0.25 M). The reaction mixture was warmed to room temperature and 
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stirred for 3 hours. After completion, volatiles were removed by rotary evaporator and crude material was 
used without further purification. 
PivO-NH2·TfOH (1.1 equiv.)[4] was dissolved in 0.1 M of ethyl acetate/H2O 2:1 biphasic mixture. K2CO3 
was added to the solution and cooled to 0 °C. The corresponding acid chloride was added dropwise to the 
mixture and stirred for 1 hour at 0 °C. After completion of the reaction, the reaction mixture was extracted 
with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous MgSO4, 
filtered and concentrated. The residue was purified by chromatography on silica gel (hexane/ethyl acetate) 
to afford the corresponding N-(pivaloyloxy)acrylamides (1a-k). 
For the synthesis of 1f, 1g, and 1h, the first step was conducted in THF. After full conversion of acid, the 




Prepared according to general procedure from commercially available 2-benzylacrylic acid (2.00 g, 12.3 
mmol). 
Yield: 82%, 2.62 g (over 2 steps), white solid.  
Rf = 0.47 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 8.97 (s, 1H), 7.36 – 7.29 (m, 2H), 7.28 – 7.19 (m, 3H), 5.93 (s, 1H), 5.39 – 
5.34 (m, 1H), 3.67 (s, 2H), 1.31 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.9, 167.1, 141.2, 137.6, 129.1, 128.9, 127.0, 122.6, 38.5, 38.2, 27.1. 
IR (CDCl3, cm-1) ν 3231, 2977, 2252, 1777, 1674, 1625, 1480, 1455, 1269, 1081, 1032, 906, 729, 703, 648. 






Prepared according to general procedure from commercially available methacryloyl chloride (260 mg, 2.49 
mmol). 
Yield: 75%, 345 mg, white solid.  
Rf = 0.38 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.12 (s, 1H), 5.84 – 5.80 (m, 1H), 5.50 – 5.45 (m, 1H), 1.99 – 19.7 (m, 3H), 
1.32 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 177.1, 167.4, 137.1, 122.1, 38.5, 27.1, 18.4. 
IR (CDCl3, cm-1) ν 3222, 2977, 2936, 2253, 1776, 1677, 1629, 1480, 1457, 1081, 905, 727, 648. 
HRMS (ASAP) m/z [C9H16NO3]+ ([M+H]+ ) calculated 186.1130, found 186.1130. 
 
methyl 3-((pivaloyloxy)carbamoyl)but-3-enoate (1c) 
 
Prepared according to general procedure from 4-methoxy-2-methylene-4-oxobutanoic acid[5] (432 mg, 3.00 
mmol). 
Yield: 65%, 471 mg (over 2 steps), colorless liquid.  
Rf = 0.13 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.71 (s, 1H), 6.05 (s, 1H), 5.61 (s, 1H), 3.72 (s, 3H), 3.39 (s, 2H), 1.32 (s, 
9H). 
13C NMR (126 MHz, CDCl3) δ 176.6, 171.5, 166.5, 134.7, 125.5, 52.6, 38.5, 37.9, 27.2. 
IR (CDCl3, cm-1) ν 3255, 2977, 2876, 2255, 1777, 1735, 1680, 1632, 1480, 1268, 1203, 1080, 1035, 909, 
727, 647.  






Prepared according to general procedure from 2-(1,3-dioxoisoindolin-2-yl)acrylic acid[6] (830 mg, 3.82 
mmol). 
Yield: 45%, 547 mg (over 2 steps), white solid.  
Rf = 0.10 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.53 (s, 1H), 7.93 – 7.88 (m, 2H), 7.81 – 7.74 (m, 2H), 6.35 (d, J = 1.4 Hz, 
1H), 5.94 (d, J = 1.4 Hz, 1H), 1.32 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.4, 166.3, 162.0, 134.8, 131.7, 129.9, 124.2, 123.1, 38.6, 27.1. 
IR (CDCl3, cm-1) ν 3237, 2976, 2937, 2255, 1785, 1722, 1633, 1480, 1468, 1375, 1288, 1078, 905, 886, 
727, 649. 




Prepared according to general procedure from 2-(4-(trifluoromethyl)phenyl)acrylic acid[7] (1.15 g, 5.3 
mmol). 
Yield: 60%, 1.00 g (over 2 steps), white solid.  
Rf = 0.35 (EA/Hex 1:4). 




13C NMR (126 MHz, CDCl3) δ 176.9, 165.7, 140.8, 139.2, 131.1 (q, J = 32.8 Hz), 128.3, 125.9 (q, J = 3.8 
Hz), 124.5, 124.0 (q, J = 272.1 Hz), 38.6, 27.1. 
19F NMR (471 MHz, CDCl3) δ -61.92. 
IR (CDCl3, cm-1) ν 3196, 2977, 1781, 1669, 1615, 1481, 1407, 1325, 1168, 1122, 1068, 904, 849, 727, 649. 




Prepared according to general procedure from commercially available 2-fluoroacrylic acid (233 mg, 2.59 
mmol). 
Yield: 65%, 320 mg (over 2 steps), white solid.  
Rf = 0.39 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.48 (s, 1H), 5.75 (dd, J = 47.0, 3.7 Hz, 1H), 5.24 (dd, J = 15.5, 3.7 Hz, 1H), 
1.33 (s, 9H) 
13C NMR (126 MHz, CDCl3) δ 176.0, 157.2 (d, J = 31.8 Hz), 154.6 (d, J = 268.4 Hz), 101.2 (d, J = 13.1 
Hz), 38.6, 27.1. 
19F NMR (282 MHz, CDCl3) δ -122.1 (dd, J = 47.0, 15.5 Hz). 
IR (CDCl3, cm-1) ν 3227, 2978, 2939, 2256, 1787, 1693, 1662, 1481, 1301, 1203, 1072, 1042, 944, 904, 
728, 634. 






Prepared according to general procedure from commercially available 2-chloroacrylic acid (300 mg, 2.82 
mmol). 
Yield: 49%, 283 mg (over 2 steps), white solid.  
Rf = 0.41 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 6.64 (d, J = 1.7 Hz, 1H), 5.89 (d, J = 1.7 Hz, 1H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.1, 158.7, 129.2, 125.0, 38.6, 27.1. 
IR (CDCl3, cm-1) ν 3222, 2976, 2938, 1785, 1678, 1612, 1479, 1369, 1268, 1144, 1070, 941, 868, 764. 




Prepared according to general procedure from commercially available 2-bromoacrylic acid (300 mg, 1.98 
mmol). 
Yield: 25%, 124 mg (over 2 steps), white solid.  
Rf = 0.47 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.67 (s, 1H), 7.07 (d, J = 1.8 Hz, 1H), 6.14 (d, J = 1.9 Hz, 1H), 1.34 (s, 9H),  
13C NMR (126 MHz, CDCl3) δ 176.1, 158.9, 129.8, 118.2, 38.6, 27.11. 
IR (CDCl3, cm-1) ν 3219, 2975, 2935, 1782, 1677, 1605, 1478, 1462, 1369, 1267, 1132, 1069, 1031, 942, 
868, 717. 






Prepared according to general procedure from 2-methylenepent-4-enoic acid[8] (540 mg, 4.81 mmol). 
Yield: 74%, 750 mg (over 2 steps), white solid.  
Rf = 0.50 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 5.93 (s, 1H), 5.85 (ddt, J = 17.0, 10.4, 6.6 Hz, 1H), 5.50 (m, 
1H), 5.24 – 5.14 (m, 2H), 3.13 – 3.07 (m, 2H), 1.33 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 177.0, 167.0, 139.8, 134.6, 122.5, 118.1, 38.5, 36.3, 27.1. 
IR (CDCl3, cm-1) ν 3223, 2977, 2937, 2875, 1777, 1672, 1625, 1480, 1368, 1227, 1081, 906, 729, 648. 
HRMS (ASAP) m/z [C11H18NO3]+ ([M+H]+ ) calculated 212.1287, found 212.1290. 
 
Synthesis of [CptRhCl2]2 catalyst 
To a solution of di-tert-butylcyclopentadiene (0.48 mmol, 1.25 equiv.) and RhCl3·3H2O (100 mg, 0.38 
mmol, 1.0 equiv.) in MeOH (1.9 mL) were added a few drops of water. The reaction mixture was stirred at 
65 °C for a period of 4 days. The reaction mixture was cooled to 22 °C, and the precipitate was collected 
by vacuum filtration and rinsed successively with cold ethanol and pentane. The solid was then dissolved 
in methylene chloride and the resultant solution was filtered through a plug of celite. The volatiles were 
evaporated under reduced pressure to obtain the desired [CptRhCl2]2 complex. Yield: 40%, 53.5 mg. 1H 
NMR (500 MHz, CDCl3) δ 5.66 (d, J = 1.5 Hz, 2H), 5.37 (t, J = 1.5 Hz, 1H), 1.35 (s, 18H). 13C NMR (126 
MHz, CDCl3) δ 108.82 (d, J = 9.5 Hz), 82.59 (d, J = 8.0 Hz), 81.38 (d, J = 8.0 Hz), 31.1, 30.2. IR (CDCl3, 


















Reactions were conducted on a 0.1 mmol scale using 1a (1.0 equiv) and 2a (2.0 equiv). aDetermined by 
analysis of 1H NMR of the unpurified reaction mixture. Cpt = di-tert-butylcyclopentadienyl, Cp*CF3 = 
tetramethyl(trifluoromethyl)cyclopentadienyl, Cp*tBu = tert-butyltetramethylcyclopentadienyl, Ind* = 







4. General Procedure for -Lactam Synthesis 
Acrylamide 1 (0.1 mmol, 1 equiv), [CptRhCl2]2 (0.0025 mmol, 2.5 mol%) were measured in a 1 dram vial 
with a magnetic stir bar. After the addition of 0.2 mL of trifluoroethanol (TFE) to the vial, alkene coupling 
partner 2 (0.2 mmol, 2 equiv) and cesium acetate (0.025 mmol, 0.25 equiv) in 0.13 mL of TFE were added. 
The reaction mixture was stirred at 22 °C for 16 hours and quenched with saturated aqueous solution of 
NaHCO3 and extracted 3 times with DCM. The combined organic layers were washed with brine and dried 
over anhydrous Na2SO4. The solid was filtered and the filtrate was concentrated by rotary evaporator. A 
crude 1H NMR spectrum was collected with 1,3,5-trimethoxybenzene as the internal standard. Purification 
was performed by flash chromatography using ethyl acetate and hexane as the eluent. 
 
5. Product Characterization 
3-benzyl-5-cyclopentyl-5,6-dihydropyridin-2(1H)-one (3aa) 
 
Yield: 19.2 mg, 75%, 10.2 : 1 rr. off-white solid. 
Rf = 0.35 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.24 – 7.16 (m, 3H), 6.15 (d, J = 3.7 Hz, 1H), 6.02 (s, 
1H), 3.64 (d, J = 15.7 Hz, 1H), 3.58 (d, J = 15.6 Hz, 1H), 3.40 (ddd, J = 12.1, 5.9, 3.1 Hz, 1H), 3.18 (ddd, 
J = 11.7, 8.4, 2.5 Hz, 1H), 2.27 – 2.17 (m, 1H), 1.89 – 1.80 (m, 1H), 1.82 – 1.69 (m, 2H), 1.68 – 1.57 (m, 
2H), 1.56 – 1.45 (m, 2H), 1.19 – 1.06 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.0, 140.8, 139.6, 134.2, 129.3, 128.5, 126.2, 44.4, 42.1, 40.1, 36.4, 31.0, 
30.3, 25.4, 25.2. 
IR (CDCl3, cm-1) ν 3215, 3061, 3026, 2947, 2865, 1673, 1625, 1476, 1451, 1267, 825, 726, 699. 






Yield: 10 mg, 39% ([Cp*RhCl2]2 was used as a catalyst), 1 : 1.1 rr. white solid. 
Rf = 0.56 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.25 (m, 2H), 7.23 – 7.16 (m, 3H), 6.09 (ddt, J = 6.0, 3.0, 1.6 Hz, 
1H), 5.53 (s, 1H), 3.68 – 3.54 (m, 2H), 3.29 (dddd, J = 12.0, 8.6, 5.0, 1.0 Hz, 1H), 2.30 (dddd, J = 17.4, 
6.2, 5.0, 1.3 Hz, 1H), 2.14 (ddq, J = 17.3, 11.9, 2.6 Hz, 1H), 1.97 – 1.87 (m, 1H), 1.87 – 1.79 (m, 1H), 1.77 
– 1.69 (m, 1H), 1.69 – 1.50 (m, 4H), 1.27 – 1.18 (m, 1H), 1.17 – 1.08 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 167.2, 139.6, 135.9, 134.9, 129.4, 128.5, 126.3, 56.3, 44.8, 36.1, 29.8, 29.3, 
29.2, 25.4, 25.4. 
IR (CDCl3, cm-1) ν 3214, 3062, 3027, 2948, 2868, 1673, 1630, 1452, 1426, 906, 728, 699. 




Yield: 19.6 mg, 76%, 9.4 : 1 rr. white solid. 
Rf = 0.44 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.24 – 7.16 (m, 3H), 6.09 – 6.05 (m, 1H), 5.96 (s, 1H), 
3.64 – 3.57 (m, 2H), 3.40 (ddd, J = 12.0, 5.9, 3.1 Hz, 1H), 3.11 (ddd, J = 11.6, 8.5, 2.5 Hz, 1H), 2.44 – 2.35 
(m, 1H), 1.48 – 1.33 (m, 2H), 1.33 – 1.20 (m, 6H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 167.0, 141.6, 139.6, 134.0, 129.3, 128.5, 126.2, 44.7, 36.2, 34.6, 32.1, 31.9, 
26.7, 22.6, 14.1. 
IR (CDCl3, cm-1) ν 3207, 3061, 3027, 2923, 2854, 1674, 1625, 1477, 1453, 1074, 824, 699. 
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Yield: 20.4 mg, 72%, 6.7 : 1 rr. white solid. 
Rf = 0.50 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.26 (m, 2H), 7.24 – 7.16 (m, 3H), 6.08 – 6.02 (m, 1H), 5.54 (s, 1H), 
3.60 (s, 2H), 3.39 (ddd, J = 12.1, 5.8, 3.1 Hz, 1H), 3.08 (ddd, J = 11.6, 8.3, 2.6 Hz, 1H), 2.56 – 2.48 (m, 
1H), 1.73 – 1.61 (m, 5H), 1.37 – 1.06 (m, 6H), 0.93 –  0.77 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.0, 142.0, 139.6, 134.0, 129.3, 128.5, 126.2, 44.9, 39.7, 36.3, 34.8, 33.8, 
33.1, 31.6, 26.6, 26.3, 26.3. 
IR (CDCl3, cm-1) ν 3203, 3064, 3027, 2920, 2848, 2249, 1674, 1626, 1478, 1449, 1419, 904, 727, 648. 




Yield: 16.3 mg, 81%, 10.0 : 1 rr. white solid. 
Rf = 0.22 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.27 (m, 2H), 7.24 – 7.16 (m, 3H), 6.03 – 5.96 (m, 2H), 3.64 – 3.55 
(m, 2H), 3.38 (dddd, J = 11.9, 6.0, 3.4, 0.9 Hz, 1H), 3.07 (ddd, J = 11.7, 9.1, 2.3 Hz, 1H), 2.63 – 2.53 (m, 
1H), 1.05 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 142.6, 139.5, 133.9, 129.4, 128.5, 126.2, 46.6, 36.1, 29.7, 17.5. 
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IR (CDCl3, cm-1) ν 3241, 3061, 3027, 2962, 2926, 2871, 1674, 1626, 1476, 1277, 1076, 700. 




Yield: 21.9 mg, 79%, 11.1 : 1 rr. off-white solid. 
Rf = 0.34 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.26 (m, 4H), 7.26 – 7.18 (m, 4H), 7.14 – 7.08 (m, 2H), 6.12 – 6.07 
(m, 1H), 6.01 (s, 1H), 3.68 – 3.56 (m, 2H), 3.32 (ddd, J = 12.1, 5.3, 2.8 Hz, 1H), 3.12 (ddd, J = 12.2, 6.8, 
3.0 Hz, 1H), 2.81 – 2.72 (m, 1H), 2.72 – 2.59 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 140.6, 139.4, 138.8, 134.7, 129.4, 129.0, 128.7, 128.5, 126.6, 126.3, 
44.0, 38.2, 36.4, 36.2. 
IR (CDCl3, cm-1) ν 3215, 3060, 3025, 2918, 2855, 1672, 1625, 1493, 1476, 1452, 1285, 1076, 1028, 741, 
699, 511. 




Yield: 23.0 mg, 79%, 5.3 : 1 rr. off-white solid. 
Rf = 0.41 (EA/Hex 1:1). 
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1H NMR (500 MHz, CDCl3) δ 7.34 – 7.24 (m, 4H), 7.24 – 7.16 (m, 4H), 7.15 – 7.09 (m, 2H), 6.13 (s, 1H), 
6.08 (d, J = 4.0 Hz, 1H), 3.61 (s, 2H), 3.44 (ddd, J = 12.2, 5.8, 3.0 Hz, 1H), 3.17 (ddd, J = 11.6, 7.9, 2.7 
Hz, 1H), 2.66 – 2.55 (m, 2H), 2.47 – 2.37 (m, 1H), 1.90 – 1.65 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 141.3, 141.0, 139.4, 134.5, 129.4, 128.6, 128.5, 128.4, 126.3, 126.2, 
44.5, 36.2, 33.9, 33.7, 33.2. 
IR (CDCl3, cm-1) ν 3213, 3060, 3025, 2922, 2856, 1672, 1625, 1493, 1477, 1452, 1267, 1074, 1030, 825, 
746, 698. 
HRMS (ASAP) m/z [C20H22NO]+ ([M+H]+ ) calculated 292.1701, found 292.1698. 
 
4-(5-benzyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)butyl acetate (3ag) 
 
Yield: 24.4 mg, 81%, 8.5 : 1 rr. white solid. 
Rf = 0.11 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.25 (m, 2H), 7.23 – 7.17 (m, 3H), 6.08 – 6.02 (m, 2H), 4.03 (t, J = 
6.6 Hz, 2H), 3.63 – 3.57 (m, 2H), 3.41 (ddd, J = 12.1, 5.8, 3.1 Hz, 1H), 3.12 (ddd, J = 12.1, 8.2, 2.6 Hz, 
1H), 2.44 – 2.35 (m, 1H), 2.03 (s, 3H), 1.64 – 1.56 (m, 2H), 1.50 – 1.28 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 171.2, 166.8, 141.0, 139.4, 134.4, 129.3, 128.5, 126.3, 64.2, 44.6, 36.2, 
34.5, 31.8, 28.7, 23.5, 21.1. 
IR (CDCl3, cm-1) ν 3216, 2062, 3027, 2929, 2858, 1734, 1673, 1626, 1476, 1453, 1365, 1236, 1034, 701. 






Yield: 27.6 mg, 79%, 8.8 : 1 rr. yellow oil. 
Rf = 0.21 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.24 (m, 7H), 7.25 – 7.16 (m, 3H), 6.09 - 6.05 (m, 1H), 5.93 (s, 1H), 
4.49 (s, 2H), 3.60 (s, 2H), 3.45 (t, J = 6.4 Hz, 2H), 3.39 (ddd, J = 12.0, 5.8, 3.1 Hz, 1H), 3.11 (ddd, J = 12.1, 
8.3, 2.6 Hz, 1H), 2.46 – 2.35 (m, 1H), 1.67 – 1.54 (m, 2H), 1.52 – 1.33 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 141.3, 139.5, 138.6, 134.1, 129.3, 128.5, 128.5, 127.8, 127.7, 126.2, 
73.1, 70.0, 44.6, 36.2, 34.6, 31.9, 29.8, 23.8. 
IR (CDCl3, cm-1) ν 3214, 3061, 3027, 2929, 2855, 1673, 1626, 1476, 1452, 1363, 1271, 1099, 735, 698. 




Yield: 27.6 mg, 71%, 9.5 : 1 rr. yellow oil. 
Rf = 0.10 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.85 – 7.80 (m, 2H), 7.74 – 7.65 (m, 2H), 7.29 -7.23 (m, 2H), 7.21 – 7.14 
(m, 3H), 6.07 – 6.02 (m, 2H), 3.66 (t, J = 7.2 Hz, 2H), 3.58 (s, 2H), 3.38 (ddd, J = 12.1, 5.9, 3.1 Hz, 1H), 
3.10 (ddd, J = 11.6, 8.3, 2.6 Hz, 1H), 2.42 – 2.34 (m, 1H), 1.71 – 1.59 (m, 2H), 1.52 – 1.38 (m, 2H), 1.38 
– 1.26 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 168.5, 166.8, 141.0, 139.4, 134.3, 134.1, 132.2, 129.3, 128.5, 126.2, 123.3, 
44.5, 37.7, 36.2, 34.5, 31.6, 28.6, 24.3. 
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IR (CDCl3, cm-1) ν 3218, 3061, 3027, 2931, 2858, 2243, 1770, 1705, 1672, 1624, 1395, 1365, 911, 718, 
702. 




Yield: 24.5 mg, 76%, 8.0 : 1 rr. white solid. 
Rf = 0.24 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.27 – 7.18 (m, 3H), 6.14 (s, 1H), 6.10 – 6.06 (m, 1H), 
3.63 (s, 2H), 3.49 – 3.38 (m, 3H), 3.15 (ddd, J = 11.5, 8.2, 2.4 Hz, 1H), 2.49 – 2.36 (m, 1H), 1.91 – 1.79 
(m, 2H), 1.53 – 1.39 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 140.9, 139.4, 134.5, 129.3, 128.5, 126.3, 44.6, 36.2, 34.4, 33.5, 32.6, 
31.2, 25.5. 
IR (CDCl3, cm-1) ν 3216, 3061, 3026, 2927, 2856, 2247, 1672, 1625, 1476, 1453, 1270, 905, 727, 701, 647. 
HRMS (ASAP) m/z [C16H21BrNO]+ ([M+H]+ ) calculated 322.0807, found 322.0798. 
 
ethyl 5-(5-benzyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)pentanoate (3ak) 
 
Yield: 24.9 mg, 79%, 8.0 : 1 rr. white solid. 
Rf = 0.28 (EA/Hex 1:1). 
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1H NMR (500 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.22 – 7.16 (m, 3H), 6.07 – 6.03 (m, 1H), 6.00 (s, 1H), 
4.11 (q, J = 7.1 Hz, 2H), 3.59 (s, 2H), 3.40 (ddd, J = 12.0, 5.9, 3.1 Hz, 1H), 3.11 (ddd, J = 11.6, 8.3, 2.6 
Hz, 1H), 2.45 – 2.36 (m, 1H), 2.27 (t, J = 7.4 Hz, 2H), 1.66 – 1.54 (m, 2H), 1.51 – 1.36 (m, 2H), 1.36 – 
1.27 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.6, 166.9, 141.2, 139.5, 134.3, 129.3, 128.5, 126.2, 60.4, 44.6, 36.2, 
34.4, 34.2, 31.8, 26.5, 24.9, 14.4. 
IR (CDCl3, cm-1) ν 3217, 3062, 3027, 2978, 2930, 2858, 1729, 1673, 1626, 1476, 1453, 1180, 1158, 727, 
701.  




Yield: 19.9 mg, 78%, 7.7 : 1 rr. yellow solid. 
Rf = 0.41 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.24 – 7.18 (m, 3H), 6.10 – 6.03 (m, 2H), 4.71 (s, 1H), 
4.64 (s, 1H), 3.61 (s, 2H), 3.43 (ddd, J = 12.1, 5.8, 3.0 Hz, 1H), 3.14 (ddd, J = 12.1, 8.0, 2.6 Hz, 1H), 2.44 
– 2.35 (m, 1H), 2.06 – 1.95 (m, 2H), 1.69 (s, 3H), 1.65 – 1.47 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 144.9, 141.2, 139.5, 134.3, 129.4, 128.5, 126.2, 110.8, 44.6, 36.2, 
35.1, 34.0, 30.0, 22.4. 
IR (CDCl3, cm-1) ν 3217, 3066, 3026, 2966, 2924, 2856, 1672, 1625, 1476, 1451, 1371, 1265, 1074, 1029, 
886, 825, 753, 699, 511. 






Yield: 18.9 mg, 70%, 6.1 : 1 rr. off-white solid. 
Rf = 0.44 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.24 – 7.16 (m, 3H), 6.15 (d, J = 4.0 Hz, 1H), 5.78 (s, 
1H), 3.62 (s, 2H), 3.35 (ddd, J = 12.0, 6.1, 3.0 Hz, 1H), 3.27 (ddd, J = 11.8, 8.2, 2.7 Hz, 1H), 2.24 – 2.16 
(m, 1H), 1.77 – 1.61 (m, 4H), 1.48 – 1.38 (m, 1H), 1.25 – 1.04 (m, 4H), 1.03 – 0.91 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 140.4, 139.7, 134.3, 129.3, 128.5, 126.2, 42.3, 40.0, 39.9, 36.4, 30.6, 
30.4, 26.4. 
IR (CDCl3, cm-1) ν 3217, 3061, 3026, 2922, 2850, 1673, 1625, 1478, 1449, 1273, 1075, 727, 699. 




Yield: 19.4 mg, 72%, 1 : 7.3 rr. off-white solid. 
Rf = 0.23 (EA/Hex 1:4). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.26 (m, 2H), 7.24 – 7.16 (m, 3H), 6.10 (ddt, J = 5.1, 3.3, 1.6 Hz, 
1H), 5.59 (s, 1H), 3.63 (dd, J = 15.8, 2.0 Hz, 1H), 3.57 (dd, J = 15.8, 1.9 Hz, 1H), 3.37 – 3.28 (m, 1H), 2.29 
– 2.14 (m, 2H), 1.81 – 1.64 (m, 5H), 1.43 – 1.34 (m, 1H), 1.30 – 1.06 (m, 3H), 1.04 – 0.92 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.2, 139.6, 135.9, 134.8, 129.4, 128.5, 126.2, 55.9, 41.9, 36.1, 28.9, 28.8, 
27.4, 26.4, 26.2, 26.1. 
IR (CDCl3, cm-1) ν 3206, 3062, 3027, 2923, 2852, 2244, 1672, 1629, 1450, 1428, 905, 727, 700, 648. 






Yield: 14.2 mg, 55%, 1 : 3.3 rr. white solid. 
Rf = 0.22 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.24 – 7.17 (m, 3H), 6.07 (ddt, J = 6.0, 3.0, 1.6 Hz, 
1H) 5.45 (s, 1H), 3.69 – 3.54 (m, 3H), 2.28 – 2.18 (m, 1H), 2.19 – 2.10 (m, 1H), 1.47 (dd, J = 14.6, 6.7 Hz, 
1H), 1.41 (dd, J = 14.5, 4.1 Hz, 1H), 0.94 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 139.5, 135.9, 134.9, 129.5, 128.5, 126.3, 50.1, 48.7, 36.1, 32.8, 30.6, 
30.1. 
IR (CDCl3, cm-1) ν 3206, 3063, 3027, 2952, 2868, 1674, 1630, 1427, 1365, 904, 726, 649. 




Yield: 23.3 mg, 92%, off-white solid. 
Rf = 0.38 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H), 7.23 – 7.15 (m, 3H), 5.84 (d, J = 4.4 Hz, 1H), 5.72 (s, 
1H), 3.63 – 3.50 (m, 3H), 2.48 – 2.41 (m, 1H), 2.09 (d, J = 3.9 Hz, 1H), 2.03 (d, J = 3.4 Hz, 1H), 1.71 (dt, 
J = 10.4, 2.1 Hz, 1H), 1.61 – 1.47 (m, 2H), 1.31 – 1.15 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ 164.7, 139.8, 137.6, 131.0, 129.3, 128.4, 126.1, 58.3, 46.5, 43.3, 42.7, 36.0, 
32.6, 29.7, 25.8. 
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IR (CDCl3, cm-1) ν 3205, 3060, 3027, 2952, 2911, 2872, 2242, 1680, 1631, 1474, 1452, 1271, 904, 726, 
700, 647. 




Yield: 20.1 mg, 80%, off-white solid. 
Rf = 0.44 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.25 (m, 3H), 7.21 (d, J = 7.8 Hz, 2H), 6.19 (dd, J = 5.8, 3.0 Hz, 1H), 
6.08 - 5.99 (m, 2H), 5.98 – 5.94 (m, 1H), 3.66 – 3.54 (m, 2H), 3.49 (dt, J = 9.3, 1.9 Hz, 1H), 2.76 (s, 1H), 
2.67 (s, 1H), 2.42-2.40 (m, 1H), 1.74 – 1.68 (m, 1H), 1.51 – 1.44 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 165.1, 139.7, 139.0, 137.8, 134.7, 131.8, 129.3, 128.5, 126.2, 54.3, 52.5, 
48.6, 42.9, 38.0, 36.3. 
IR (CDCl3, cm-1) ν 3204, 3060, 3027, 2970, 2920, 2242, 1678, 1631, 1475, 1453, 1276, 905, 725, 699, 647, 
508. 





Yield: 20.2 mg, 75%, yellow solid. 
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Rf = 0.56 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.22 – 7.17 (m, 3H), 6.09 (dt, J = 6.3, 1.6 Hz, 1H), 
5.54 – 5.37 (m, 1H), 3.70 – 3.51 (m, 3H), 2.50 – 2.42 (m, 1H), 1.86 – 1.71 (m, 2H), 1.74 – 1.55 (m, 5H), 
1.56 – 1.34 (m, 4H), 1.34 – 1.24 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 167.1, 142.6, 139.7, 132.3, 129.4, 128.5, 126.2, 54.1, 37.0, 35.8, 29.1, 28.4, 
27.2, 25.4, 25.0, 23.6. 
IR (CDCl3, cm-1) ν 3205, 3061, 3027, 2919, 2852, 2242, 1672, 1628, 1451, 1428, 1293, 905, 726, 699, 647. 




Yield: 21.1 mg, 93%, off-white solid. 
Rf = 0.34 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 7.23 – 7.17 (m, 3H), 6.07 (dt, J = 5.1, 1.5 Hz, 1H), 
5.59 (s, 1H), 3.98 – 3.92 (m, 1H), 3.63 (dt, J = 15.7, 1.6 Hz, 1H), 3.56 (dt, J = 15.8, 1.5 Hz, 1H), 2.66 – 
2.57 (m, 1H), 2.00 – 1.86 (m, 2H), 1.85 – 1.73 (m, 1H), 1.72 – 1.62 (m, 1H), 1.65 – 1.51 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 165.6, 139.7, 139.6, 132.2, 129.4, 128.5, 126.2, 55.5, 38.6, 36.1, 35.1, 32.2, 
23.2. 
IR (CDCl3, cm-1) ν 3205, 3060, 3027, 2955, 2871, 1672, 1627, 1493, 1451, 1304, 1267, 907, 727, 699. 







Yield: 21.1 mg, 88%, >15 : 1 rr. white solid. 
Rf = 0.48 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.23 – 7.17 (m, 3H), 6.09 – 6.03 (m, 1H), 5.97 – 5.90 
(m, 1H), 5.61 (ddd, J = 8.8, 4.4, 2.2 Hz, 1H), 5.49 (s, 1H), 4.07 – 4.02 (m, 1H), 3.65 (d, J = 15.9 Hz, 1H), 
3.57 (d, J = 15.9 Hz, 1H), 2.46 – 2.38 (m, 1H), 2.13 – 2.04 (m, 1H), 2.04 – 1.94 (m, 1H), 1.68 – 1.55 (m, 
2H). 
13C NMR (126 MHz, CDCl3) δ 165.8, 140.1, 139.6, 134.1, 131.4, 129.4, 128.5, 126.2, 125.1, 48.3, 36.1, 
34.1, 24.3, 22.8. 
IR (CDCl3, cm-1) ν 3208, 3060, 3024, 2922, 1673, 1627, 1452, 1429, 1286, 1263, 736, 699. 




Yield: 18.2 mg, 63%, >13.1 : 1 rr. white solid. 
Rf = 0.58 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.27 (m, 2H), 7.29 – 7.18 (m, 6H), 7.21 – 7.13 (m, 1H), 6.24 (dt, J = 
6.0, 1.5 Hz, 1H), 5.42 (s, 1H), 4.69 (d, J = 5.0 Hz, 1H), 3.71 (d, J = 15.7 Hz, 1H), 3.59 (d, J = 15.8 Hz, 1H), 
2.88 (ddd, J = 17.0, 5.2, 2.9 Hz, 1H), 2.76 (ddd, J = 17.1, 11.8, 5.6 Hz, 1H), 2.54 – 2.46 (m, 1H), 1.95 – 
1.84 (m, 1H), 1.81 – 1.73 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 165.7, 140.0, 139.4, 136.7, 134.4, 134.4, 129.6, 129.4, 128.8, 128.5, 128.4, 
127.0, 126.3, 51.7, 36.1, 35.0, 28.8, 22.6. 
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IR (CDCl3, cm-1) ν 3401, 3205, 3060, 3025, 2924, 2244, 1671, 1629, 1493, 1452, 1427, 1266, 906, 726, 
700. 




Yield: 20.4 mg, 74%, 14.7 : 1 rr. yellow solid. 
Rf = 0.46 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.16 (m, 7H), 7.12 – 7.06 (m, 2H), 6.49 (s, 1H), 6.06 – 6.02 (m, 1H), 
4.94 – 4.87 (m, 1H), 3.64 (d, J = 15.9 Hz, 1H), 3.54 (d, J = 15.9 Hz, 1H), 3.37 – 3.29 (m, 1H), 3.22 (dd, J 
= 15.6, 7.9 Hz, 1H), 2.90 (dd, J = 15.5, 5.1 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 165.0, 142.7, 141.3, 139.4, 139.1, 133.7, 129.2, 128.4, 128.4, 127.3, 126.16, 
124.9, 123.9, 58.3, 39.0, 38.2, 36.1. 
IR (CDCl3, cm-1) ν 3203, 3061, 3026, 2906, 2850, 2243, 1674, 1628, 1477, 1453, 907, 729, 698.  




Yield: 15.2 mg. 56%, yellow solid. 
Rf = 0.21 (EA/Hex 1:4). 
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1H NMR (500 MHz, CDCl3) δ 7.33 – 7.25 (m, 2H), 7.26 – 7.14 (m, 3H), 6.0f6 – 6.00 (m, 1H), 5.75 (s, 1H), 
3.64 – 3.55 (m, 2H), 3.28 – 3.19 (m, 1H), 2.20 – 2.11 (m, 1H), 1.60 – 1.47 (m, 1H), 1.49 – 1.21 (m, 7H), 
0.90 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 165.8, 140.1, 139.6, 133.3, 129.3, 128.5, 126.2, 54.7, 38.8, 37.2, 36.1, 34.9, 
20.0, 19.0, 14.3, 14.0. 
IR (CDCl3, cm-1) ν 3205, 3062, 3027, 2956, 2928, 2870, 1674, 1629, 1454, 1430, 699. 




Yield: 11.0 mg. 51%, yellow oil. 
Rf = 0.37 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.23 – 7.16 (m, 3H), 6.11 (dt, J = 5.6, 1.6 Hz, 1H), 
5.43 (s, 1H), 3.76 – 3.70 (m, 1H), 3.67 – 3.60 (m, 1H), 3.5 – 3.52 (m, 1H), 2.36 – 2.29 (m, 1H), 1.13 (d, J 
= 6.8 Hz, 3H), 0.93 (d, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.8, 142.4, 139.6, 133.4, 129.4, 128.5, 126.2, 49.5, 36.0, 33.8, 17.0, 11.9. 
IR (CDCl3, cm-1) ν 3206, 3061, 3027, 2969, 2921, 1671, 1626, 1453, 1424, 903, 725, 649. 






Yield: 11.1 mg, 62%, >15 : 1 rr.  white solid. 
Rf = 0.21 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 6.33 (s, 1H), 6.08 (s, 1H), 3.40 (ddd, J = 12.0, 5.9, 3.3 Hz, 1H), 3.18 (ddd, 
J = 11.8, 9.2, 2.3 Hz, 1H), 2.27 – 2.17 (m, 1H), 1.89 – 1.79 (m, 5H), 1.82 – 1.72 (m, 1H), 1.69 – 1.59 (m, 
2H), 1.58 – 1.48 (m, 2H), 1.29 – 1.08 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.8, 140.1, 130.3, 44.8, 42.1, 40.2, 31.0, 30.4, 25.4, 25.3, 17.0. 
IR (CDCl3, cm-1) ν 3201, 3071, 2948, 2867, 1675, 1631, 1483, 1273, 856, 810.  
HRMS (ASAP) m/z [C11H18NO]+ ([M+H]+ ) calculated 180.1388, found 180.1387. 
 
methyl 2-(5-cyclopentyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl)acetate (3ca) 
 
Yield: 17.3 mg, 69%, 9.3 : 1 rr. yellow oil. 
Rf = 0.16 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 6.48 (d, J = 3.6 Hz, 1H), 5.91 (s, 1H), 3.68 (s, 3H), 3.45 (ddd, J = 12.1, 6.0, 
3.3 Hz, 1H), 3.36 – 3.20 (m, 3H), 2.36 – 2.27 (m, 1H), 1.94 – 1.73 (m, 3H), 1.71 – 1.59 (m, 2H), 1.59 – 
1.47 (m, 2H), 1.29 – 1.10 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 172.0, 166.2, 143.1, 128.0, 52.1, 44.5, 42.0, 40.3, 35.9, 31.0, 30.4, 25.3, 
25.2. 
IR (CDCl3, cm-1) ν 3222, 2949, 2866, 1737, 1677, 1631, 1478, 1339, 1263, 1208, 1159, 1018, 904, 797, 
725, 648. 






Yield: 14.9 mg, 48%, 4.4 : 1 rr. yellow solid. 
Rf = 0.17 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.92 – 7.87 (m, 2H), 7.77 – 7.72 (m, 2H), 6.76 (d, J = 3.7 Hz, 1H), 6.07 (s, 
1H), 3.59 (ddd, J = 12.4, 5.8, 3.3 Hz, 1H), 3.41 (ddd, J = 12.3, 8.6, 2.5 Hz, 1H), 2.65 – 2.58 (m, 1H), 2.09 
– 1.91 (m, 2H), 1.90 – 1.80 (m, 1H), 1.75 – 1.61 (m, 2H), 1.64 – 1.53 (m, 2H), 1.36 – 1.17 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.1, 161.6, 145.3, 134.4, 132.2, 124.8, 123.9, 44.1, 42.0, 40.6, 31.2, 30.4, 
25.4, 25.2. 
IR (CDCl3, cm-1) ν 3226, 3085, 2950, 2867, 1777, 1720, 1684, 1641, 1470, 1378, 1113, 1086, 907, 717, 
531. 




Yield: 19.0 mg, 61%, 12.6 : 1 rr. yellow solid. 
Rf = 0.42 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.63 – 7.53 (m, 4H), 6.76 (d, J = 3.6 Hz, 1H), 6.54 (s, 1H), 3.52 (ddd, J = 
12.2, 5.9, 3.5 Hz, 1H), 3.31 (ddd, J = 12.0, 9.0, 2.5 Hz, 1H), 2.49 – 2.41 (m, 1H), 2.02 – 1.87 (m, 2H), 1.87 
– 1.80 (m, 1H), 1.75 – 1.63 (m, 2H), 1.66 – 1.53 (m, 2H), 1.37 – 1.16 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 165.8, 143.9, 140.3, 134.1, 129.8 (q, J = 32.4 Hz), 129.1, 125.07 (q, J = 3.8 
Hz), 124.34 (q, J = 271.9 Hz), 44.4, 42.0, 40.6, 31.1, 30.5, 25.4, 25.3. 
19F NMR (376 MHz, CDCl3) δ -62.6. 
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IR (CDCl3, cm-1) ν 3206, 3102, 3058, 2960, 2875, 1670, 1613, 1475, 1320, 1164, 1120, 1067, 834.  




Yield: 13.4 mg, 73%, >15 : 1 rr. white solid. 
Rf = 0.26 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 6.68 (s, 1H), 6.07 (dd, J = 12.2, 4.0 Hz, 1H), 3.46 (ddd, J = 12.4, 5.8, 3.0 
Hz, 1H), 3.25 (ddd, J = 12.5, 8.5, 2.5 Hz, 1H), 2.45 – 2.36 (m, 1H), 1.95 – 1.76 (m, 3H), 1.70 – 1.61 (m, 
2H), 1.60 – 1.49 (m, 2H), 1.23 – 1.06 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 161.4 (d, J = 31.6 Hz), 149.4 (d, J = 255.6 Hz), 119.0 (d, J = 10.9 Hz), 
44.5, 42.3 (d, J = 2.1 Hz), 39.0 (d, J = 4.5 Hz), 31.0, 30.4, 25.32, 25.27. 
19F NMR (471 MHz, CDCl3) δ -129.06 (m). 
IR (CDCl3, cm-1) ν 3241, 3097, 2948, 2867, 1693, 1650, 1478, 1233, 1198, 905, 815, 772, 722. 




Yield: 15.2 mg, 76%, >15 : 1 rr. white solid. 
Rf = 0.34 (EA/Hex 1:1). 
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1H NMR (500 MHz, CDCl3) δ 7.01 (s, 1H), 6.74 (d, J = 3.9 Hz, 1H), 3.48 (ddd, J = 12.4, 5.9, 3.3 Hz, 1H), 
3.27 (ddd, J = 12.0, 9.0, 2.4 Hz, 1H), 2.43 – 2.34 (m, 1H), 1.95 – 1.74 (m, 3H), 1.71 – 1.61 (m, 2H), 1.60 
– 1.50 (m, 2H), 1.27 – 1.09 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 162.3, 141.4, 126.9, 44.4, 41.8, 41.6, 31.0, 30.4, 25.3, 25.2. 
IR (CDCl3, cm-1) ν 3202, 3104, 2938, 2867, 1671, 1609, 1480, 1411, 1353, 1260, 1102, 1046, 858, 801, 
547. 




Yield: 20.3 mg, 83%, >15 : 1 rr. yellow solid. 
Rf = 0.34 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 7.01 (d, J = 3.8 Hz, 1H), 6.91 (s, 1H), 3.49 (ddd, J = 12.4, 5.9, 3.4 Hz, 1H), 
3.28 (ddd, J = 12.0, 9.1, 2.4 Hz, 1H), 2.39 – 2.30 (m, 1H), 1.95 – 1.83 (m, 2H), 1.84 – 1.74 (m, 1H), 1.70 
– 1.61 (m, 2H) 1.60 – 1.49 (m, 2H), 1.31 – 1.09 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 162.0, 146.2, 117.9, 44.6, 42.8, 41.7, 31.0, 30.4, 25.3, 25.2. 
IR (CDCl3, cm-1) ν 3199, 3098, 2937, 2865, 1667, 1604, 1477, 1406, 1351, 1259, 904, 728, 537. 






Yield: 14.3 mg, 70%, 6.1 : 1 rr. yellow solid. 
Rf = 0.31 (EA/Hex 1:1). 
1H NMR (500 MHz, CDCl3) δ 6.34 – 6.29 (m, 1H), 5.95 (s, 1H), 5.86 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 
5.11 – 5.03 (m, 2H), 3.40 (ddd, J = 12.1, 5.9, 3.3 Hz, 1H), 3.19 (ddd, J = 11.8, 8.9, 2.4 Hz, 1H), 3.09 – 2.96 
(m, 2H), 2.31 – 2.20 (m, 1H), 1.90 – 1.72 (m, 3H), 1.70 – 1.59 (m, 2H), 1.59 – 1.47 (m, 2H), 1.28 – 1.08 
(m, 2H). 
13C NMR (126 MHz, CDCl3) δ 167.0, 140.2, 136.0, 132.8, 116.5, 44.5, 42.1, 40.2, 34.4, 31.0, 30.4, 25.3, 
25.2. 
IR (CDCl3, cm-1) ν 3216, 3073, 2948, 2866, 1674, 1626, 1477, 1267, 905, 724, 648. 
HRMS (ASAP) m/z [C13H20NO]+ ([M+H]+ ) calculated 206.1545, found 206.1545. 
 
 




3hw was synthesized following general procedure using 1h and 2w[9]. Yield: 18.7 mg, 66%, yellow oil. Rf 
= 0.15 (5% MeOH in DCM). 1H NMR (500 MHz, CDCl3) δ 7.04 – 6.98 (m, 1H), 6.59 (s, 1H), 5.67 (t, J = 
6.6 Hz, 1H), 3.62 (ddd, J = 12.9, 5.6, 2.1 Hz, 1H), 3.52 – 3.45 (m, 1H), 3.28 – 3.21 (m, 2H), 2.98 (s, 3H), 
2.80 – 2.71 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 161.4, 142.5, 120.0, 43.2, 42.1, 40.6, 37.7. IR (CDCl3, 
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cm-1) ν 3270, 2928, 2873, 1667, 1609, 1473, 1446, 1313, 1148, 1102, 980, 761, 521. HRMS (ASAP) m/z 











3hw (0.18 mmol, 1 equiv.), PdCl2(PPh3)2 (0.018 mmol, 10 mol%), and (4-(trifluoromethyl)phenyl)boronic 
acid (0.54 mmol, 3 equiv) were measured in a 10 mL round-bottom flask. After the addition of 1.5 mL of 
dioxane, the mixture was purged with argon for 10 min. Separately, 1.5 mL of 2.0 M Na2CO3 solution in 
water was purged with argon 10 min and added to the flask. Then, the reaction mixture was heated to 60 °C 
and stirred for 1 hour. After completion, organic layer was collected and aqueous layer was extracted three 
times with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous 
MgSO4. The solid was filtered and the filtrate was concentrated by rotary evaporator. Purification was 
performed by flash chromatography using 5% MeOH in DCM as the eluent. Yield: 47.7 mg, 78%, white 
solid. Rf = 0.23 (5% MeOH in DCM). 1H NMR (500 MHz, MeOD-d4) δ 7.67 – 7.59 (m, 4H), 6.89 (d, J = 
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4.3 Hz, 1H), 3.56 (dd, J = 12.7, 5.8 Hz, 1H), 3.41 (dd, J = 12.7, 7.7 Hz, 1H), 3.30 – 3.18 (m, 2H), 2.97 (s, 
3H), 2.88 – 2.81 (m, 1H). 13C NMR (126 MHz, MeOD-d4) δ 166.9, 142.8, 141.7, 136.2, 130.7 (q, J = 32.8 
Hz), 130.4, 125.79 (q, J = 3.9 Hz), 125.74 (q, J = 271.1 Hz), 44.42, 42.64, 39.81, 37.05. 19F NMR (471 
MHz, MeOD-d4) δ -63.2. IR (MeOD-d4, cm-1) ν 3216, 3073, 2948, 2866, 1674, 1626, 1477, 1267, 905, 



















To a 10 mL round-bottom flack, 3hw-1 (0.244 mmol, 1 equiv.) was measure and dissolved in 0.8 mL of 
MeOH (0.3 M). The flask was charged with argon and Rh/C (10 wt%) was quickly added. Then the flask 
was evacuated and refilled with H2 (1 atm) and stirred at 22 °C for 4 h. After completion, the reaction 
mixture was filtered through a Celite plug and washed with EtOAc. The solvent was removed in vacuo and 
purified by flash chromatography using 5-10% MeOH in DCM as the eluent to afford product 5. Yield: 
68.3 mg, 80%, white solid. dr = 5.9 : 1 Rf = 0.11 (5% MeOH in DCM). Major isomer: 1H NMR (500 
MHz, MeOD-d4) δ 7.62 (m, 2H), 7.44 (m, 2H), 3.76 (dd, J = 12.3, 6.1 Hz, 1H), 3.52 – 3.46 (m, 1H), 3.21 – 
3.14 (m, 1H), 3.13 – 3.03 (m, 2H), 2.93 (s, 3H), 2.30 – 2.17 (m, 2H), 1.72 (q, J = 12.9 Hz, 1H). Major 
isomer: 13C NMR (126 MHz, MeOD-d4) δ 174.66, 147.08, 130.47, 130.0 (q, J = 32.2 Hz), 126.35 (q, J = 
3.8 Hz), 125.77 (q, J = 271.0 Hz), 49.24, 46.65, 46.54, 39.68, 35.99, 35.82. 19F NMR (471 MHz, MeOD-
d4) δ -63.04, -63.07. IR (MeOD-d4, cm-1) ν 3289, 2931, 2460, 2242, 2070, 1632, 1324, 1158, 1118, 1067, 

















5 (92.7 mg, 0.265 mmol) was dissolved in THF (4 mL) and 1.32 mL of 1 M BH3·THF (1.32 mmol, 5 equiv.) 
was added. The solution was heated to 60 °C for 3 h and cooled to ambient temperature, then quenched by 
the addition of MeOH. The solvent was removed under reduced pressure and 7 mL of MeOH and 7 mL of 
6 N HCl was added to the residue. The mixture was heated 60 °C for 3 h and the MeOH was removed under 
reduced pressure. Water was added to the mixture, which was then made basic (pH ≈ 14) with 6N NaOH. 
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The basic solution was extracted with ethyl acetate and the combined organic extracts were dried over 
anhydrous MgSO4. The solvent was removed under reduced pressure and 1.3 mL of DCM (0.2 M) was 
added to the crude mixture. After addition of Et3N (0.795 mmol, 3 equiv.) and morpholine-4-carbonyl 
chloride (purchased from sigma and used without purification, 0.530 mmol, 2 equiv.), the reaction mixture 
was stirred at room temperature for 16 hours. After completion volatiles were removed by rotary evaporator 
and purified by column chromatography using 5% MeOH in DCM as the eluent to afford product 6.  Yield: 
63 mg, 53% (over 2 steps), white solid. dr = 4.3 : 1 Rf = 0.24 (5% MeOH in DCM). 1H NMR (500 MHz, 
CDCl3) δ 7.60 – 7.57 (m, 2H), 7.35 – 7.31 (m, 2H), 4.46 (t, J = 6.5 Hz, 1H), 3.97 – 3.90 (m, 1H), 3.86 – 
3.75 (m, 1H), 3.75 – 3.62 (m, 4H), 3.32 – 3.23 (m, 4H), 3.17 – 3.02 (m, 2H), 2.99 (s, 3H), 2.88 (ddt, J = 
12.2, 7.5, 3.8 Hz, 1H), 2.79 (dd, J = 12.7, 11.6 Hz, 1H), 2.52 (dd, J = 13.0, 11.4 Hz, 1H), 2.14 – 2.08 (m, 
1H), 2.05 – 1.94 (m, 1H), 1.37 (q, J = 12.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 163.9, 146.6, 129.7 (q, 
J = 32.5 Hz), 127.6, 125.9 (q, J = 3.7 Hz), 124.3 (q, J = 272.0 Hz), 66.8, 53.6, 50.4, 47.6, 46.7, 42.3, 40.8, 
37.0, 36.1. 19F NMR (471 MHz, CDCl3) δ -61.7. IR (CDCl3, cm-1) ν 3226, 2923, 2855, 1619, 1419, 1323, 


















To a 1 dram screw-capped vial with a magnetic stir bar was added 2-benzyl-N-(pivaloyloxy)acrylamide 
(1a, 0.10 mmol, 1 equiv), [CptRhCl2]2 (0.0025 mmol, 2.5 mol%) or [Cp*RhCl2]2 (0.0025 mmol, 2.5 mol%) 
and cesium acetate (0.025 mmol, 0.25 equiv) and dissolved in 0.33 mL of TFE-d1. Vinyl cyclopentane (2a, 
0.20 mmol, 2 equiv) was added to the vial and the cap was screwed on and the reaction was stirred at 22 °C 
for 30 minutes. The reaction mixture was quenched by saturated NaHCO3 solution and extracted three times 
with dichloromethane. The combined organic layer was dried over MgSO4 and filtered through celite. The 
filtrate was concentrated by rotary evaporation and the crude mixture was analyzed by 1H NMR with 1,3,5-
trimethoxybenzene as an internal standard. When [CptRhCl2]2 was used as a catalyst, no deuterium 
incorporation was observed in the recovered 2-benzyl-N-(pivaloyloxy)acrylamide. In contrast, 27% of 




KIE was measured from two separated reactions, one with 1a containing a C-H bond and one with an 
analogous C-D bond (1a-d2). 1a (or 1a-d2) (0.15 mmol, 1 equiv), [Cp
tRhCl2]2 (0.00375 mmol, 2.5 mol%), 
cesium acetate (0.0375 mmol, 0.25 equiv) and 1,3,5-trimethoxybenzen (0.05 mmol, internal standard) was 
dissolved in 0.5 mL of TFE-d3 and transferred to J-young NMR tube. Vinyl cyclopentane (2a, 0.30 mmol, 
2 equiv) was added to the NMR tube directly and reaction progress was monitored by in situ 1H NMR at 
22 °C. KIE value was calculated by comparing the initial reaction rate (slope) of each reaction (repeated 3 
times each). Observed primary KIE (KH / KD) value of 6.31 suggests C-H bond cleavage occurs during the 







8. X-ray Crystal Structure 
Single crystal X-ray diffraction was performed at the Shared Materials Characterization Laboratory at 
Columbia University. Use of the SMCL was made possible by funding from Columbia University. Data for 
all compounds was collected on an Agilent SuperNova diffractometer using mirror-monochromated Cu K 
or Mo K radiation. Data collection, integration, scaling (ABSPACK) and absorption correction (face-
indexed Gaussian integration or numeric analytical methods) were performed in CrysAlisPro. Structure 
solution was performed using ShelXT. Subsequent refinement was performed by full-matrix least-squares 
on F2 in ShelXL.  For 3aq and 3av, all non-H atoms were located in the initial solutions and refined with 
free anisotropic ADPs. C-H hydrogens were placed in calculated positions and refined with riding isotropic 
ADPs and coordinates. N-H hydrogens were refined freely with isotropic ADPs. Olex2 was used for 
viewing and to prepare CIF files. PLATON CheckCIF. ORTEP graphics were prepared in CrystalMaker.  
Thermal ellipsoids are rendered at the 50% probability level. 
 
 
3aq: Crystallized by vapor diffusion of pentane into benzene. Black, carbon; blue, nitrogen; red, oxygen; 
white spheres, hydrogen. Most C-H hydrogens are omitted for clarity. 
 
 
3av: Crystallized by vapor diffusion of pentane into benzene. Black, carbon; blue, nitrogen; red, oxygen; 




Compound 3aq 3av 
Formula C18H23NO C18H25NO 
MW 269.37 271.39 
Space group P21/c P-1 
a (Å) 10.2414(2) 7.3848(3) 
b (Å) 5.75070(10) 9.6884(5) 
c (Å) 24.6727(6) 11.6917(7) 
α (°) 90 101.377(5) 
β (°) 93.685(2) 103.736(4) 
γ (°) 90 98.276(4) 
V (Å3) 1450.10(5) 780.46(7) 
Z 4 2 
ρcalc (g cm-3) 1.234 1.155 
T (K) 100 100 
λ (Å) 1.54184 .71073 
2θmin, 2θmax 7, 146 7, 59 
Nref 8619 10677 
R(int), R(σ) .0539, .0508 .0455, .0605 
μ(mm-1) 0.582 0.070 
Size (mm) .21 x .06 x .03 .32 x .19 x .10 
Tmax / Tmin 1.26 1.39 
Data 2888 3780 
Restraints 0 0 
Parameters 185 187 
R1(obs) 0.0540 0.0532 
wR2(all) 0.1485 0.1226 
S 1.042 1.037 
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1. General information 
All reactions were carried out using oven-dried glassware with magnetic stirring unless otherwise noted. 
Anhydrous solvents and reagents were purchased from commercial sources and used without further 
purification. Flash chromatography was conducted either manually on SiliCycle® SilicaFlash® P60 (230-
400 mesh) silica gel, SiliCycle® prep TLC (TLG-R10011B-341, thickness 1000um) or automatically via a 
Teledyne Isco Lumen CombiFlash with RediSep Rf Disposable Flash columns. Thin layer chromatography 
(TLC) was performed on Silicycle 250μm silica gel 60 Å plates. Visualization was accomplished with UV 
light (254 nm) and KMnO4. 1H, 19F NMR, and 13C NMR spectra were collected at ambient temperature on 
Bruker 400 MHz or Bruker Avance III 500 MHz spectrometers unless otherwise noted. Chemical shifts (δ) 
are reported in parts per million (ppm), coupling constants (J) are reported in Hz, and multiplicity is 
described using the following abbreviations: singlet (s), broad (b), multiplet (m), doublet (d), triplet (t), 
quartet (q), or combinations thereof. 1H NMR spectra were referenced to 7.26 ppm (CHCl3) or 0.0 ppm 
(TMS). 13C NMR spectra were referenced to 77.16 ppm (CDCl3) and all peaks given are singlet unless 
otherwise noted. Diastereomeric and regioisomeric ratios were measured by integration of 1H NMR spectra 
of product mixtures prior to purification. High resolution mass spectra (HRMS) were obtained from 
Columbia University Mass Spectrometry Facility on a JOEL JMSHX110HF mass spectrometer using the 
ASAP ionization model. Infrared spectra were collected on a Perkin Elmer Spectrum Two FT-IR 
Spectrometer.  
 
2. Preparation of starting materials 
All boronic acids (1a-1r), alkenes 2b, 2c, 2d, 2e, and 2i were purchased from commercial sources and used 
without purification. Alkene 2f,1 2j,2 2k,3 2l4, 2m5 and dioxazolone 3c,6 3d,7 3e,8 3f,7 3g,6 and 3h7 were 
synthesized following literatures. Alkenes 2g, 2h, and dioxazolone 3b were synthesized following the 
procedures below.  
General procedure A: the synthesis of acrylamides (2g-2h) 
To a solution of primary amine (or corresponding HCl salt, 1 equiv) and triethylamine (1.1 equiv) in 
dichloromethane (0.5 M) was added acryloyl chloride (1.1 equiv) in dichloromethane at 0 °C. The mixture 
was stirred at 0 °C for 15 minutes and warmed to room temperature. The reaction was stirred at room 
temperature for 3 hours. The volatiles was removed by a rotary evaporator then ethyl acetate was added 
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and filtered through celite. The filtrate was washed with 1M HCl, saturated NaHCO3 solution, and brine. 
The organic layer was dried over anhydrous MgSO4 and concentrated. The residue was purified by 
chromatography on silica gel (hexane/ethyl acetate) to afford the corresponding acrylamides. 
 
Yield: Prepared according to general procedure A from 1-aminopentane (10 mmol). 78%, 1.11g, colorless 
oil. 
Rf = 0.39 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 6.23 (d, J = 17.1 Hz, 1H), 6.11 (dd, J = 17.0, 10.2 Hz, 1H), 6.05 (s, 1H), 
5.58 (dt, J = 10.0 Hz, 1H), 3.28 (q, J = 7.3, 6.7 Hz, 2H), 1.50 (q, J = 7.2 Hz, 2H), 1.36 – 1.21 (m, 4H), 0.87 
(t, J = 6.8, 3H). 
13C NMR (101 MHz, CDCl3) δ 165.75, 131.22, 125.99, 39.70, 29.33, 29.18, 22.43, 14.04. 
IR (CDCl3, cm-1) ν 3276, 3079, 2957, 2929, 2861, 1656, 1623, 1548, 1407, 1245, 985, 954, 727. 
HRMS (ASAP) m/z [C8H16NO]+ ([M+H]+ ) calculated 142.1232, found 142.1236. 
 
 
Yield: Prepared according to general procedure A from 1-Boc-4-(aminomethyl)piperidine (10 mmol). 65%, 
1.74g, colorless oil. 
Rf = 0.18 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 6.26 (dd, J = 17.0, 1.6 Hz, 1H), 6.10 (dd, J = 17.0, 10.2 Hz, 1H), 6.06 (s, 
1H), 5.61 (dd, J = 10.2, 1.6 Hz, 1H), 4.16 – 3.97 (m, 2H), 3.30 – 3.12 (m, 2H), 2.65 (t, J = 12.7 Hz, 2H), 
1.73 – 1.61 (m, 3H), 1.42 (s, 9H), 1.19 – 1.04 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 165.82, 154.95, 130.86, 126.74, 79.57, 45.10, 43.76, 36.57, 29.92, 28.59. 
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IR (CDCl3, cm-1) ν 3302, 3080, 2976, 2926, 2854, 2244, 1658, 1546, 1424, 1365, 1226, 1167, 1143, 906, 
727, 647. 
HRMS (ESI) m/z [C14H24N2NaO3]+ ([M+Na]+ ) calculated 291.1685, found 291.1699. 
 
Preparation of 3c 
 
Oxalyl chloride (9.8 mmol, 0.98 equiv) and catalytic amount (5 – 10 drops) of DMF were added dropwise 
to a solution of 3,3,3-trifluoropropanoic acid (10 mmol, 1.0 equiv) in THF (0.3 M) at 0 °C. The reaction 
mixture was warmed to room temperature and stirred for 3 hours. After the full conversion of acid, the 
crude material was taken without concentration. In a separate flask, hydroxylamine hydrochloride (11 
mmol, 1.1 equiv) was dissolved in 0.1 M of ethyl acetate/H2O 2:1 biphasic mixture. K2CO3 (20 mmol, 2 
equiv) was added to the solution and cooled to 0 °C. The crude THF solution of acid chloride was added 
dropwise to the mixture and stirred for 1 hour at 0 °C. After completion of the reaction, the reaction mixture 
was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered, and concentrated. The residue was used without further purification. To a 
solution of 3,3,3-trifluoro-N-hydroxypropanamide (3.22 mmol, 1.0 equiv) in DCM (0.2 M), CDI (3.53 
mmol, 1.2 equiv) was added as one portion. After stirring for 1 hour at room temperature, the reaction was 
quenched with 1 M HCl and extracted with DCM three times. The combined organic layer was washed 
with brine and dried over sodium sulfate. The solvent was removed under reduced pressure to afford 3-
(2,2,2-trifluoroethyl)-1,4,2-dioxazol-5-one (3c). No further purification was required. 
 
Yield: 44% (over 2 steps), 2.05 mmol, 346 mg, colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 3.56 (q, J = 9.1 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 158.61 (q, J = 3.9 Hz), 153.03, 122.37 (q, J = 278.2 Hz), 31.48 (q, J = 34.9 
Hz). 
19F NMR (376 MHz, CDCl3) δ -63.40 (t, J = 9.1 Hz). 
 
3. General procedure for the carboamination of alkenes 
[Cp*RhCl2]2 (0.0050 mmol, 5 mol%), sodium bicarbonate (0.03 mmol, 0.3 equiv), and boronic acid (0.25 
mmol, 2.5 equiv) were measured in a 0.5-dram vial with a magnetic stir bar. In a separate vial, dioxazolone 
(0.1 mmol, 1 equiv) and alkene (0.3 mmol, 3 equiv) were dissolved in 0.10 mL of MeOH and transferred 
to the first vial. It was rinsed with an additional 0.07 mL of MeOH and transferred again to the first vial. 
The reaction mixture was then stirred at 25 oC for 16 hours. After the completion of the reaction, the solvent 
was removed by a rotary evaporator. Ethyl acetate was added to the residue and filtered through a short pad 
of celite and washed with ethyl acetate three times. The filtrate was concentrated by rotary evaporator and 
a crude 1H NMR spectrum was collected with 1,3,5-trimethoxybenzene as the internal standard. Purification 
was performed by flash chromatography or preparational TLC using ethyl acetate and hexane or DCM and 

















































5. Product characterization 
 
 
Yield: 68%, 20 mg, white solid. 
Rf = 0.26 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 3H), 7.31 – 7.26 (m, 2H), 7.26 – 7.17 (m, 3H), 7.04 – 6.95 
(m, 2H), 5.93 (d, J = 7.9 Hz, 1H), 5.17 (d, J = 12.1 Hz, 1H), 5.12 (d, J = 12.1 Hz, 1H), 4.92 (dt, J = 7.9, 5.7 
Hz, 1H), 3.18 – 3.03 (m, 2H), 1.98 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 171.62, 169.68, 135.82, 135.17, 129.43, 128.76, 128.72, 128.69, 128.67, 
127.20, 67.40, 53.26, 37.94, 23.27. 
IR (CDCl3, cm-1) ν 3277, 3063, 3031, 2932, 1738, 1652, 1540, 1372, 1209, 1173, 734, 696. 
HRMS (ASAP) m/z [C18H20NO3]+ ([M+H]+ ) calculated 298.1443, found 298.1437. 
 
 
Yield: 62%, 23 mg, white solid. 
Rf = 0.38 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 2H), 7.40 – 7.34 (m, 3H), 7.31 – 7.24 (m, 2H), 7.07 (d, 
J = 7.9 Hz, 2H), 5.98 (d, J = 7.3 Hz, 1H), 5.19 (d, J = 12.0 Hz, 1H), 5.09 (d, J = 12.0 Hz, 1H), 4.97 – 4.90 
(m, 1H), 3.23 – 3.11 (m, 2H), 1.99 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 171.28, 169.74, 140.03 (d, J = 1.6 Hz), 134.89, 129.80, 129.45 (q, J = 32.7 
Hz), 128.92, 128.84, 125.51 (q, J = 3.7 Hz), 124.17 (q, J = 270.9 Hz), 67.66, 53.10, 37.80, 23.28. 
19F NMR (376 MHz, CDCl3) δ -62.51. 
284 
 
IR (CDCl3, cm-1) ν 3276, 3066, 3036, 2939, 1740, 1654, 1541, 1324, 1164, 1122, 1067, 904, 729, 699. 
HRMS (ASAP) m/z [C19H19F3NO3]+ ([M+H]+ ) calculated 366.1317, found 366.1310. 
 
  
Yield: 60%, 20 mg, white solid 
Rf = 0.25 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 3H), 7.33 – 7.19 (m, 2H), 6.96 – 6.84 (m, 4H), 5.97 (d, J = 
7.7 Hz, 1H), 5.19 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.1 Hz, 1H), 4.89 (dt, J = 7.8, 5.7 Hz, 1H), 3.15 – 3.00 
(m, 2H), 1.98 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.49, 169.69, 162.08 (d, J = 245.4 Hz), 135.05, 131.51 (d, J = 3.3 Hz), 
130.91 (d, J = 8.0 Hz), 128.85, 128.81, 115.48 (d, J = 21.3 Hz), 67.50, 53.30, 37.17, 23.28. (Two aromatic 
peaks overlapped).  
19F NMR (376 MHz, CDCl3) δ -115.54 – -115.76 (m). 
IR (CDCl3, cm-1) ν 3278, 3066, 2935, 1738, 1653, 1541, 1508, 1373, 1220, 1176, 905, 828, 729, 698. 
HRMS (ASAP) m/z [C18H19FNO3]+ ([M+H]+ ) calculated 316.1349, found 316.1348. 
 
 
Yield: 65%, 25 mg, white solid. 
Rf = 0.31 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.34 (m, 3H), 7.33 – 7.25 (m, 4H), 6.87 – 6.79 (m, 2H), 5.96 (d, J = 
7.7 Hz, 1H), 5.19 (d, J = 12.0 Hz, 1H), 5.09 (d, J = 12.1 Hz, 1H), 4.89 (dt, J = 7.8, 5.7 Hz, 1H), 3.13 – 2.99 
(m, 2H), 1.98 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ 171.38, 169.70, 134.99, 134.84, 131.73, 131.14, 128.87, 128.85, 128.83, 
121.21, 67.54, 53.11, 37.40, 23.26. 
IR (CDCl3, cm-1) ν 3277, 3063, 3034, 2930, 1739, 1652, 1539, 1488, 1209, 1128, 1071, 813, 749. 
HRMS (ASAP) m/z [C18H19BrNO3]+ ([M+H]+ ) calculated 376.0548, found 376.0555. 
 
 
Yield: 60%, 20 mg, white solid. 
Rf = 0.33 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.33 (m, 3H), 7.33 – 7.27 (m, 2H), 6.94 – 6.86 (m, 2H), 6.78 – 6.70 
(m, 2H), 5.91 (d, J = 7.9 Hz, 1H), 5.17 (d, J = 12.1 Hz, 1H), 5.11 (d, J = 12.1 Hz, 1H), 4.88 (dt, J = 7.9, 5.7 
Hz, 1H), 3.76 (s, 3H), 3.14 – 3.00 (m, 2H), 1.97 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 171.70, 169.69, 158.76, 135.17, 130.40, 128.72, 128.66, 127.68, 114.05, 
67.33, 55.29, 53.38, 37.05, 23.26. (Two aromatic peaks overlapped) 
IR (CDCl3, cm-1) ν 3278, 3063, 3034, 2953, 2934, 2836, 1739, 1653, 1511, 1373, 1246, 1177, 1033, 698. 
HRMS (ASAP) m/z [C19H22NO4]+ ([M+H]+ ) calculated 328.1549, found 328.1549. 
 
 
Yield: 70%, 22 mg, white solid. 
Rf = 0.17 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.23 (m, 5H), 7.02 (s, 1H), 6.87 – 6.79 (m, 2H), 6.77 – 6.62 (m, 2H), 
6.10 (d, J = 8.1 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.12 (d, J = 12.1 Hz, 1H), 4.90 (dt, J = 8.0, 5.9 Hz, 1H), 
3.06 (dd, J = 14.1, 5.8 Hz, 1H), 2.97 (dd, J = 14.1, 6.0 Hz, 1H), 1.97 (s, 3H).  
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13C NMR (101 MHz, CDCl3) δ 171.84, 170.51, 155.65, 135.10, 130.43, 128.78, 128.73, 128.71, 126.90, 
115.70, 67.52, 53.54, 37.22, 23.16. 
IR (CDCl3, cm-1) ν 3298, 3062, 3033, 2930, 1737, 1652, 1514, 1451, 1374, 1213, 905, 730, 699. 
HRMS (ASAP) m/z [C18H20NO4]+ ([M+H]+ ) calculated 314.1392, found 314.1390. 
 
  
Yield: 66%, 28 mg, colorless oil. 
Rf = 0.38 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H), 6.89 – 6.79 (m, 2H), 6.73 – 6.63 (m, 2H), 5.89 (d, J = 
7.9 Hz, 1H), 5.16 (d, J = 12.1 Hz, 1H), 5.11 (d, J = 12.2 Hz, 1H), 4.88 (dt, J = 7.9, 5.7 Hz, 1H), 3.11 – 2.96 
(m, 2H), 1.97 (s, 3H), 0.97 (s, 9H), 0.18 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.71, 169.65, 154.88, 135.24, 130.41, 128.77, 128.72, 128.67, 128.36, 
120.21, 67.36, 53.35, 37.16, 25.79, 23.28, 18.30, -4.29. 
IR (CDCl3, cm-1) ν 3282, 3063, 3033, 2954, 2930, 2888, 2857, 1740, 1655, 1508, 1254, 906, 838, 728, 697. 
HRMS (ASAP) m/z [C24H34NO4Si]+ ([M+H]+ ) calculated 428.2257, found 428.2254. 
 
 
Yield: 55%, 18 mg, white solid. 
Rf = 0.31 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.33 (m, 3H), 7.34 – 7.22 (m, 4H), 6.99 – 6.91 (m, 2H), 6.67 (dd, J 
= 17.6, 10.9 Hz, 1H), 5.94 (d, J = 7.9 Hz, 1H), 5.70 (dd, J = 17.6, 1.0 Hz, 1H), 5.23 (dd, J = 10.9, 0.9 Hz, 
287 
 
1H), 5.17 (d, J = 12.1 Hz, 1H), 5.11 (d, J = 12.1 Hz, 1H), 4.92 (dt, J = 7.8, 5.8 Hz, 1H), 3.17 – 3.03 (m, 
2H), 1.98 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.59, 169.72, 136.58, 136.51, 135.40, 135.12, 129.61, 128.77, 128.74, 
128.70, 126.50, 113.90, 67.43, 53.25, 37.69, 23.27. 
IR (CDCl3, cm-1) ν 3278, 3063, 2930, 2252, 1739, 1654, 1539, 1511, 1373, 1209, 1178, 904, 727, 699, 649.  
HRMS (ASAP) m/z [C20H22NO3]+ ([M+H]+ ) calculated 324.1600, found 324.1605. 
 
 
Yield: 55%, 19 mg, white solid.   
Rf = 0.37 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (m, 3H), 7.32 – 7.27 (m, 2H), 7.26 – 7.22 (m, 2H), 6.97 – 6.91 
(m, 2H), 5.93 (d, J = 7.7 Hz, 1H), 5.18 – 5.09 (m, 2H), 4.92 (dt, J = 7.9, 5.7 Hz, 1H), 3.08 (d, J = 5.7 Hz, 
2H), 1.98 (s, 3H), 1.29 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 171.76, 169.74, 150.05, 135.21, 132.63, 129.10, 128.74, 128.70, 128.66, 
125.60, 67.39, 53.26, 37.39, 34.55, 31.45, 23.29. 
IR (CDCl3, cm-1) ν 3280, 3062, 3033, 2960, 2868, 1740, 1654, 1537, 1515, 1368, 1190, 906, 730, 697. 
HRMS (ASAP) m/z [C22H28NO3]+ ([M+H]+ ) calculated 354.2069, found 354.2072. 
 
  
Yield: 51%, 16 mg, yellow oil. 
Rf = 0.23 (EA/Hex 1:1). 
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1H NMR (400 MHz, CDCl3) δ 7.48 – 7.38 (m, 2H), 7.42 – 7.31 (m, 3H), 7.31 – 7.28 (m, 2H), 7.08 – 7.02 
(m, 2H), 6.03 (d, J = 7.5 Hz, 1H), 5.22 (d, J = 12.0 Hz, 1H), 5.08 (d, J = 11.9 Hz, 1H), 4.92 (dt, J = 7.5, 5.8 
Hz, 1H), 3.16 (qd, J = 13.8, 5.9 Hz, 2H), 1.99 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.07, 169.75, 141.57, 134.82, 132.27, 130.22, 129.01, 128.99, 128.86, 
118.76, 111.11, 67.70, 53.00, 38.13, 23.24. 
IR (CDCl3, cm-1) ν 3283, 3064, 3035, 2936, 2228, 1736, 1656, 1534, 1505, 1374, 1268, 1211, 1175, 905, 
731, 698. 
HRMS (ASAP) m/z [C19H19N2O3]+ ([M+H]+ ) calculated 323.1396, found 323.1390. 
 
  
Yield: 64%, 21 mg, white solid. 
Rf = 0.20 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H), 7.73 – 7.66 (m, 2H), 7.41 – 7.31 (m, 3H), 7.32 – 7.27 (m, 2H), 
7.17 – 7.10 (m, 2H), 6.05 (d, J = 7.7 Hz, 1H), 5.20 (d, J = 12.1 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.96 (dt, 
J = 7.7, 5.9 Hz, 1H), 3.19 (qd, J = 13.8, 5.9 Hz, 2H), 1.99 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 191.90, 171.23, 169.76, 143.15, 135.40, 134.90, 130.15, 129.97, 128.90, 
128.89, 128.83, 67.63, 53.06, 38.20, 23.24. 
IR (CDCl3, cm-1) ν 3284, 3062, 3034, 2932, 2831, 2738, 2251, 1738, 1695, 1656, 1606, 1534, 1374, 1306, 
1211, 1170, 905, 730, 698. 





Yield: 65%, 23 mg, yellow oil. 
Rf = 0.19 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.90 (dt, J = 7.7, 1.5 Hz, 1H), 7.79 (t, J = 1.8 Hz, 1H), 7.41 – 7.32 (m, 3H), 
7.36 – 7.24 (m, 3H), 7.19 (dt, J = 7.7, 1.5 Hz, 1H), 6.04 (d, J = 7.8 Hz, 1H), 5.28 – 5.09 (m, 2H), 4.94 (dt, 
J = 7.7, 5.9 Hz, 1H), 3.89 (s, 3H), 3.20 (dd, J = 13.8, 6.0 Hz, 1H), 3.13 (dd, J = 13.9, 5.7 Hz, 1H), 1.99 (s, 
3H). 
13C NMR (101 MHz, CDCl3) δ 171.42, 169.79, 166.94, 136.35, 134.99, 133.92, 130.58, 130.49, 128.77, 
128.73, 128.68, 128.46, 67.57, 53.28, 52.25, 37.79, 23.22. (Two aromatic peaks overlapped) 
IR (CDCl3, cm-1) ν 3282, 3064, 3034, 2951, 1719, 1655, 1537, 1436, 1283, 1202, 1109, 908, 747, 733, 697. 
HRMS (ASAP) m/z [C20H22NO5]+ ([M+H]+ ) calculated 356.1498, found 356.1502. 
 
  
Yield: 74%, 23 mg, yellow oil. 
Rf = 0.45 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.01 – 7.33 (m, 3H), 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 1H), 7.08 – 6.95 
(m, 3H), 6.04 (d, J = 8.0 Hz, 1H), 5.17 (d, J = 12.2, 1H), 5.12 (d, J = 12,2 Hz, 1H), 4.91 (dt, J = 8.0, 6.0 
Hz, 1H), 3.22 (ddd, J = 13.9, 6.0, 1.2 Hz, 1H), 3.12 (ddd, J = 13.9, 6.1, 1.1 Hz, 1H), 1.96 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.52, 169.79, 161.48 (d, J = 245.2 Hz), 135.17, 131.80 (d, J = 5.1 Hz), 
129.12 (d, J = 8.3 Hz), 128.73, 128.64, 128.60, 124.32 (d, J = 3.9 Hz), 123.02 (d, J = 16.0 Hz), 115.49 (d, 
J = 22.5 Hz), 67.56, 52.67, 31.52 (d, J = 1.8 Hz), 23.17. 
19F NMR (376 MHz, CDCl3) δ -117.50 (m). 
IR (CDCl3, cm-1) ν 3277, 3064, 3036, 2936, 1739, 1654, 1539, 1493, 1454, 1373, 1271, 1209, 1230, 1176, 
1132, 755, 697. 





Yield: 37%, 12 mg, colorless liquid.  
Rf = 0.26 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 6H), 7.21 – 7.05 (m, 3H), 6.01 (d, J = 8.2 Hz, 1H), 5.17 (d, 
J = 12.2 Hz, 1H), 5.12 (d, J = 12.2 Hz, 1H), 4.96 (ddd, J = 8.2, 7.1, 6.3 Hz, 1H), 3.32 (dd, J = 13.9, 6.3 Hz, 
1H), 3.18 (dd, J = 13.9, 7.1 Hz, 1H), 1.95 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.65, 169.76, 135.18, 134.62, 134.17, 131.46, 129.78, 128.73, 128.69, 
128.61, 128.50, 127.08, 67.52, 52.70, 35.55, 23.23. 
IR (CDCl3, cm-1) ν 3275, 3064, 2939, 1742, 1653, 1543, 1444, 1373, 1269, 1177, 1134, 1052, 751, 697. 
HRMS (ASAP) m/z [C18H19ClNO3]+ ([M+H]+ ) calculated 332.1053, found 332.1052. 
 
 
Yield: 52%, 23 mg, white solid. 
Rf = 0.46 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.54 – 7.49 (m, 2H), 7.42 – 7.33 (m, 3H), 7.33 – 7.25 (m, 2H), 
6.07 (d, J = 7.2 Hz, 1H), 5.14 (s, 2H), 4.93 (ddd, J = 7.2, 6.4, 5.3 Hz, 1H), 3.32 (dd, J = 13.9, 6.3 Hz, 1H), 
3.21 (dd, J = 13.9, 5.3 Hz, 1H), 2.00 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.93, 169.87, 138.76, 134.58, 131.84 (q, J = 33.3 Hz), 129.72 (d, J = 3.9 
Hz), 129.03, 128.94, 128.63, 123.31 (q, J = 272.7 Hz), 121.24 (p, J = 3.9 Hz), 67.95, 53.19, 37.62, 23.13. 
19F NMR (376 MHz, CDCl3) δ -62.87 (s). 
IR (CDCl3, cm-1) ν 3271, 3068, 2957, 1741, 1654, 1545, 1378, 1276, 1171, 1129, 900, 700, 682. 
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HRMS (ASAP) m/z [C20H18F6NO3]+ ([M+H]+ ) calculated 434.1191, found 434.1189. 
 
  
Yield: 65%, 22 mg, colorless oil. 
Rf = 0.28 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H), 6.97 (td, J = 8.6, 6.3 Hz, 1H), 6.78 – 6.67 (m, 2H), 
6.03 (d, J = 7.9 Hz, 1H), 5.14 (s, 2H), 4.89 (dt, J = 7.9, 6.0 Hz, 1H), 3.19 (ddd, J = 14.1, 6.1, 1.2 Hz, 1H), 
3.07 (dd, J = 14.1, 5.9 Hz, 1H), 1.97 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.41, 169.77, 162.26 (dd, J = 248.4, 12.1 Hz), 161.42 (dd, J = 247.8, 
11.9 Hz), 135.05, 132.37 (dd, J = 9.6, 6.2 Hz), 128.77, 128.75, 128.70, 118.91 (dd, J = 16.3, 3.8 Hz), 111.46 
(dd, J = 21.2, 3.7 Hz), 103.93 (dd, J = 25.7, 26.0 Hz), 67.66, 52.61, 31.10, 23.18. 
19F NMR (376 MHz, CDCl3) δ -111.23 (p, J = 7.7 Hz), -113.16 (q, J = 8.7 Hz). 
IR (CDCl3, cm-1) ν 3278, 3066, 3029, 2939, 1740, 1654, 1540, 1504, 1374, 1273, 1174, 1136, 1094, 965, 
850, 747, 697. 
HRMS (ASAP) m/z [C18H18F2NO3]+ ([M+H]+ ) calculated 334.1255, found 334.1255. 
 
 
Yield: 52%, 18 mg, white solid.  
Rf = 0.26 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 8.6 Hz, 1H), 7.89 – 7.80 (m, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.55 
– 7.41 (m, 2H), 7.34 – 7.23 (m, 4H), 7.20 – 7.09 (m, 3H), 5.99 (d, J = 7.8 Hz, 1H), 5.10 – 4.97 (m, 3H), 
3.65 – 3.49 (m, 2H), 1.91 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ 171.88, 169.84, 135.03, 134.01, 132.46, 132.37, 128.93, 128.67, 128.58, 
128.49, 128.06, 127.63, 126.42, 125.90, 125.41, 123.72, 67.36, 53.47, 35.22, 23.23. 
IR (CDCl3, cm-1) ν 3277, 3062, 2953, 2251, 1739, 1652, 1539, 1511, 1372, 1176, 905, 778, 728, 698. 
HRMS (ASAP) m/z [C22H22NO3]+ ([M+H]+ ) calculated 348.1600, found 348.1603. 
 
 
Yield: 65%, 22 mg, white solid. 
Rf = 0.37 (EA/Hex 1:1). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 3H), 7.34 – 7.29 (m, 2H), 6.64 (d, J = 7.9 Hz, 1H), 6.49 (d, 
J = 1.7 Hz, 1H), 6.42 (dd, J = 7.9, 1.7 Hz, 1H), 5.95 (d, J = 8.0 Hz, 1H), 5.91 (s, 2H), 5.18 (d, J = 12.1 Hz, 
1H), 5.12 (d, J = 12.1 Hz, 1H), 4.87 (dt, J = 7.8, 5.7 Hz, 1H), 3.07 – 2.98 (m, 2H), 1.99 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.59, 169.70, 147.87, 146.81, 135.14, 129.40, 128.79, 128.74, 128.71, 
122.53, 109.71, 108.41, 101.09, 67.43, 53.42, 37.68, 23.31. 
IR (CDCl3, cm-1) ν 3281, 3065, 3034, 2927, 2893, 1738, 1654, 1537, 1501, 1489, 1443, 1371, 1246, 1191, 
1037, 904, 729, 699. 
HRMS (ASAP) m/z [C19H20NO5]+ ([M+H]+ ) calculated 342.1341, found 342.1337. 
 
 
Yield: 68%, 16 mg, white solid. 
Rf = 0.30 (EA/Hex 2:3). 
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1H NMR (400 MHz, CDCl3) δ 7.33 – 7.19 (m, 3H), 7.14 – 7.07 (m, 2H), 5.93 (d, J = 7.8 Hz, 1H), 4.86 (dt, 
J = 7.9, 5.8 Hz, 1H), 4.17 (qd, J = 7.2, 1.2 Hz, 2H), 3.19 – 3.05 (m, 2H), 1.98 (s, 3H), 1.24 (t, J = 7.1 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 171.79, 169.72, 136.02, 129.42, 128.62, 127.18, 61.62, 53.26, 38.02, 23.25, 
14.21. 
IR (CDCl3, cm-1) ν 3283, 3063, 3030, 2982, 2932, 1737, 1656, 1542, 1374, 1212, 1028, 701. 
HRMS (ASAP) m/z [C13H18NO3]+ ([M+H]+ ) calculated 236.1287, found 236.1284. 
 
 
Yield: 63%, 17 mg, yellowish oil.  
Rf = 0.31 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.18 (m, 3H), 7.18 – 7.05 (m, 2H), 5.97 (d, J = 7.7 Hz, 1H), 4.76 (dt, 
J = 7.8, 6.0 Hz, 1H), 3.09 (d, J = 6.0 Hz, 2H), 1.98 (s, 3H), 1.41 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 170.94, 169.64, 136.32, 129.62, 128.49, 127.08, 82.53, 53.65, 38.18, 28.07, 
23.34. 
IR (CDCl3, cm-1) ν 3285, 3064, 3030, 2978, 2931, 1732, 1655, 1544, 1498, 1369, 1257, 1226, 1154, 755, 
738, 699. 
HRMS (ESI) m/z [C15H21NO3Na]+ ([M+H]+ ) calculated 286.1419, found 286.1433. 
 
 
Yield: 65%, 18 mg, white solid.  
Rf = 0.28 (EA/Hex 2:3). 
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1H NMR (400 MHz, CDCl3) δ 7.41 – 7.19 (m, 8H), 7.03 – 6.95 (m, 2H), 6.04 (d, J = 7.8 Hz, 1H), 5.12 (dt, 
J = 7.7, 6.0 Hz, 1H), 3.34 – 3.20 (m, 2H), 2.01 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.50, 169.89, 150.38, 135.72, 129.63, 129.57, 128.86, 127.49, 126.33, 
121.37, 53.44, 38.08, 23.23. 
IR (CDCl3, cm-1) ν 3267, 3033, 2936, 1760, 1653, 1537, 1491, 1372, 1190, 1162, 1121, 908, 734, 699, 494. 
HRMS (ESI) m/z [C17H18NO3]+ ([M+H]+ ) calculated 284.1287, found 284.1281. 
 
 
Yield: 70%, 13 mg, white solid. 
Rf = 0.27 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.28 (m, 3H), 7.31 – 7.24 (m, 2H), 6.17 (d, J = 8.6 Hz, 1H), 5.14 
(ddd, J = 8.7, 7.4, 5.8 Hz, 1H), 3.08 (m, 2H), 1.98 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.56, 134.03, 129.57, 129.14, 128.09, 118.30, 41.66, 38.88, 22.89. 
IR (CDCl3, cm-1) ν 3270, 3032, 2932, 2856, 2244, 1954, 1658, 1531, 1497, 1372, 1289, 749, 700. 
HRMS (ASAP) m/z [C11H13N2O]+ ([M+H]+ ) calculated 189.1028, found 189.1029. 
 
 
Yield: 71%, 20 mg, white solid. 
Rf = 0.42 (EA/Hex 2:3). 
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1H NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.57 (d, J = 7.9 Hz, 2H), 7.34 – 
7.24 (m, 6H), 7.21 – 7.16 (m, 1H), 7.05 (t, J = 7.3 Hz, 1H), 4.66 (td, J = 8.9, 5.3 Hz, 1H), 3.02 (dd, J = 
13.7, 5.3 Hz, 1H), 2.84 (dd, J = 13.7, 9.4 Hz, 1H), 1.79 (s, 3H).  
13C NMR (101 MHz, DMSO-d6) δ 170.34, 169.26, 138.81, 137.72, 129.14, 128.68, 128.06, 126.33, 123.37, 
119.34, 54.86, 37.76, 22.39. 
IR (DMSO-d6, cm-1) ν 3446, 2249, 2123, 1767, 1665, 1548, 1222, 1052, 1024, 1006, 820, 757, 621. 
HRMS (ASAP) m/z [C17H19N2O2]+ ([M+H]+ ) calculated 283.1447, found 283.1446. 
 
 
Yield: 59%, 16 mg, yellow solid. 
Rf = 0.29 (EA/Hex 1:1). 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 7.27 – 7.16 (m, 3H), 6.70 (d, J = 8.1 Hz, 1H), 6.15 (t, 
J = 5.7 Hz, 1H), 4.64 (td, J = 8.3, 6.4 Hz, 1H), 3.24 – 3.11 (m, 1H), 3.10 – 2.94 (m, 3H), 1.96 (s, 3H), 1.40 
– 1.18 (m, 4H), 1.23 – 1.06 (m, 2H), 0.85 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.96, 170.11, 137.01, 129.39, 128.67, 127.00, 54.93, 39.59, 39.03, 29.01, 
28.99, 23.25, 22.38, 14.02. 
IR (CDCl3, cm-1) ν 3277, 3085, 3030, 2956, 2929, 2859, 1638, 1552, 1497, 1372, 743, 698. 





Yield: 74%, 30 mg, yellow oil. 
Rf = 0.22 (EA 100%). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.12 (m, 5H), 6.63 (d, J = 8.1 Hz, 1H), 6.43 (t, J = 5.6 Hz, 1H), 4.68 
(td, J = 8.5, 6.3 Hz, 1H), 4.00 (s, 2H), 3.22 – 3.08 (m, 1H), 3.03 (dd, J = 13.4, 6.3 Hz, 1H), 2.96 (dd, J = 
13.4, 8.7 Hz, 1H), 2.86 (s, 1H), 2.66 – 2.45 (m, 2H), 1.96 (s, 3H), 1.43 (s, 9H), 1.41 – 1.21 (m, 3H), 1.01 – 
0.84 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 171.19, 170.17, 154.86, 136.81, 129.37, 128.72, 127.06, 79.52, 54.95, 
44.91, 43.75, 38.98, 36.21, 29.64, 28.56, 23.26. 
IR (CDCl3, cm-1) ν 3281, 2972, 2923, 2849, 1686, 1640, 1547, 1421, 1365, 1277, 1226, 1168, 1141, 734, 
698. 
HRMS (ESI) m/z [C22H33N3NaO4]+ ([M+Na]+ ) calculated 426.2369, found 426.2367. 
 
  
Yield: 61%, 14 mg, white solid. 
Rf = 0.42 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.35 (m, 2H), 7.32 – 7.22 (m, 3H), 4.79 (d, J = 8.7 Hz, 1H), 4.29 (t, 
J = 8.6 Hz, 1H), 3.19 (d, J = 8.6 Hz, 1H), 2.70 (s, 1H), 2.41 – 2.35 (m, 1H), 1.84 – 1.64 (m, 3H), 1.62 (s, 
3H), 1.57 – 1.38 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.17, 140.13, 128.54, 128.40, 126.47, 56.52, 52.12, 42.61, 40.28, 35.54, 
30.09, 26.39, 23.24. 
IR (CDCl3, cm-1) ν 3293, 3061, 2955, 2872, 1646, 1549, 1496, 1451, 1373, 1290, 1154, 905, 726, 700, 494. 





Yield: 89%, 25 mg, white solid. 
Rf = 0.42 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.26 (m, 7H), 7.30 – 7.20 (m, 2H), 5.56 (s, 1H), 5.31 – 5.23 (m, 2H), 
4.49 (t, J = 8.5 Hz, 1H), 3.34 (d, J = 7.9 Hz, 1H), 1.58 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.86, 146.12, 143.36, 138.74, 128.93, 128.84, 127.64, 127.30, 127.27, 
120.84, 119.13, 84.45, 84.30, 54.24, 50.12, 22.98. 
IR (CDCl3, cm-1) ν 3428, 3308, 3040, 3006, 1656, 1495, 1371, 904, 727, 703, 648. 
HRMS (ASAP) m/z [C18H18NO2]+ ([M+H]+ ) calculated 280.1338, found 280.1337. 
 
 
Yield: 55%, 21 mg, white solid. 
Rf = 0.26 (EA/Hex 2:3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.35 (m, 1H), 7.35 – 7.28 (m, 2H), 7.28 – 7.20 (m, 4H), 7.19 – 7.13 
(m, 2H), 5.26 (s, 1H), 5.18 (d, J = 9.4 Hz, 1H), 4.91 (s, 1H), 4.46 – 4.29 (m, 1H), 3.20 (d, J = 8.1 Hz, 1H), 
1.51 (s, 3H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 169.62, 156.59, 146.57, 143.71, 138.95, 128.83, 128.68, 127.54, 127.29, 
127.16, 121.79, 120.04, 99.74, 81.11, 67.68, 66.46, 53.64, 50.12, 28.44, 22.96. (Measured at 60 °C.) 
IR (CDCl3, cm-1) ν 3315, 3028, 2979, 2927, 1698, 1667, 1367, 1336, 1278, 1255, 1158, 909, 729. 





Yield: 43%, 11 mg, colorless oil. 
Rf = 0.37 (EA/Hex 2:3). 
(major diastereomer) 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.58 (m, 2H), 7.48 – 7.42 (m, 2H), 7.42 – 7.32 
(m, 5H), 7.32 – 7.25 (m, 1H), 5.37 – 5.32 (m, 1H), 3.50 (dd, J = 8.6, 5.0 Hz, 1H), 2.69 (dd, J = 8.6, 1.2 Hz, 
1H), 2.02 (s, 3H), 1.27 (s, 3H). 
(major diastereomer) 13C NMR (101 MHz, CDCl3) δ 171.48, 146.83, 134.92, 130.58, 129.25, 128.74, 
128.57, 127.14, 126.65, 37.19, 30.92, 30.24, 23.36, 18.07. 
IR (CDCl3, cm-1) ν 3303, 3056, 3024, 2927, 1651, 1601, 1495, 1444, 1370, 1268, 907, 763, 732, 700. 
HRMS (ASAP) m/z [C18H20NO]+ ([M+H]+ ) calculated 266.1545, found 266.1544. 
 
 
Yield: 38%, 13 mg, white solid. 
Rf = 0.32 (EA/Hex 2:3). 
(major diastereomer) 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.42 (m, 6H), 7.39 – 7.30 (m, 3H), 5.34 (s, 1H), 
3.41 (dd, J = 8.7, 4.7 Hz, 1H), 2.65 (dd, J = 8.7, 1.1 Hz, 1H), 2.01 (s, 3H), 1.23 (s, 3H). 
(major diastereomer) 13C NMR (101 MHz, CDCl3) δ 171.57, 145.93, 134.53, 131.83, 130.53, 130.46, 
129.37, 127.32, 120.50, 37.15, 30.69, 30.17, 23.32, 17.94. 
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IR (CDCl3, cm-1) ν 3302, 3054, 3026, 2931, 2979, 1653, 1492, 1444, 1369, 1090, 1009, 825, 734, 702, 532. 
HRMS (ASAP) m/z [C18H19BrNO]+ ([M+H]+ ) calculated 344.0650, found 344.0644. 
 
 
Yield: 73%, 27 mg, white solid. 
Rf = 0.30 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.35 (m, 3H), 7.34 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 7.01 – 6.92 
(m, 2H), 6.19 (d, J = 7.6 Hz, 1H), 5.20 (d, J = 12.1 Hz, 1H), 5.14 (d, J = 12.1 Hz, 1H), 4.94 (dt, J = 7.7, 5.6 
Hz, 1H), 3.24 – 3.09 (m, 2H), 3.04 (q, J = 10.5 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 170.94, 162.13 (q, J = 3.6 Hz), 135.23, 134.94, 129.44, 128.85, 128.84, 
128.77, 127.42, 123.97 (q, J = 276.9 Hz), 67.74, 53.59, 41.69 (q, J = 29.7 Hz), 37.68. (Two aromatic peaks 
overlapped) 
19F NMR (376 MHz, CDCl3) δ -62.86 (t, J = 10.5 Hz) 
IR (CDCl3, cm-1) ν 3313, 3066, 3032, 2957, 1740, 1664, 1542, 1388, 1261, 1240, 1213, 1191, 1136, 905, 
733, 699. 
HRMS (ASAP) m/z [C19H19F3NO3]+ ([M+H]+ ) calculated 366.1317, found 366.1319. 
 
 
Yield: 53%, 18 mg, white solid. 
Rf = 0.23 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.30 (m, 3H), 7.33 – 7.27 (m, 2H), 7.24 – 7.19 (m, 3H), 7.03 – 6.96 
(m, 2H), 5.87 (d, J = 7.8 Hz, 1H), 5.17 (d, J = 12.2 Hz, 1H), 5.11 (d, J = 12.1 Hz, 1H), 4.95 (dt, J = 7.9, 5.8 
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Hz, 1H), 3.19 – 3.04 (m, 2H), 2.20 – 2.12 (m, 2H), 1.62 – 1.50 (m, 2H), 1.35 – 1.24 (m, 2H), 0.88 (t, J = 
7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.76, 171.72, 135.89, 135.20, 129.45, 128.75, 128.72, 128.68, 128.65, 
127.17, 67.39, 53.04, 38.01, 36.40, 27.73, 22.42, 13.88. 
IR (CDCl3, cm-1) ν 3288, 3063, 3031, 2956, 2930, 2869, 1740, 1648, 1537, 1497, 1454, 1210, 1174, 742, 
697. 
HRMS (ASAP) m/z [C21H26NO3]+ ([M+H]+ ) calculated 340.1913, found 340.1908. 
 
  
Yield: 54%, 22 mg, white solid. 
Rf = 0.25 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.08 (m, 13H), 7.04 – 6.95 (m, 2H), 5.86 (d, J = 7.9 Hz, 1H), 5.17 
(d, J = 12.1 Hz, 1H), 5.11 (d, J = 12.1 Hz, 1H), 4.94 (dt, J = 7.9, 5.9 Hz, 1H), 3.19 – 3.03 (m, 2H), 2.59 (t, 
J = 7.5 Hz, 2H), 2.16 (dd, J = 7.9, 6.6 Hz, 2H), 1.92 (p, J = 7.6 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 172.37, 171.67, 141.50, 135.84, 135.17, 129.41, 128.74, 128.71, 128.67, 
128.59, 128.49, 127.19, 126.06, 67.40, 53.07, 37.97, 35.70, 35.14, 27.01. (Two aromatic peaks overlapped) 
IR (CDCl3, cm-1) ν 3290, 3062, 3028, 2930, 2859, 1738, 1648, 1534, 1496, 1453, 1175, 907, 734, 696. 
HRMS (ASAP) m/z [C26H28NO3]+ ([M+H]+ ) calculated 402.2069, found 402.2067. 
 
    
Yield: 56%, 25 mg, white solid. 
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Rf = 0.44 (EA/Hex 2:3). 
1H NMR (500 MHz, CDCl3) δ 7.95 – 7.85 (m, 2H), 7.79 – 7.73 (m, 2H), 7.41 – 7.32 (m, 3H), 7.31 – 7.27 
(m, 2H), 7.19 – 7.13 (m, 3H), 7.03 – 6.90 (m, 2H), 6.24 (d, J = 7.6 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.12 
(d, J = 12.0 Hz, 1H), 4.91 (dt, J = 7.8, 5.5 Hz, 1H), 4.38 (d, J = 16.1 Hz, 1H), 4.30 (d, J = 16.1 Hz, 1H), 
3.18 – 3.07 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 171.00, 167.76, 165.66, 135.39, 134.99, 134.38, 132.13, 129.58, 128.84, 
128.80, 128.79, 128.68, 127.24, 123.80, 67.62, 53.53, 40.80, 37.69. 
IR (CDCl3, cm-1) ν 3346, 3066, 3033, 2947, 1774, 1716, 1419, 1393, 1192, 954, 904, 730, 716, 701. 
HRMS (ASAP) m/z [C26H23N2O5]+ ([M+H]+ ) calculated 443.1607, found 4431608. 
 
 
Yield: 61%, 21 mg, colorless oil. 
Rf = 0.22 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.33 (m, 3H), 7.33 – 7.28 (m, 2H), 7.24 – 7.19 (m, 3H), 7.03 – 6.96 
(m, 2H), 5.86 (d, J = 7.9 Hz, 1H), 5.75 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.12 (d, 
J = 12.1 Hz, 1H), 5.02 – 4.92 (m, 3H), 3.20 – 3.05 (m, 2H), 2.19 – 2.15 (m, 2H), 2.07 - 2.02 (m, 2H), 1.76 
– 1.66 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 172.45, 171.68, 137.90, 135.86, 135.19, 129.44, 128.76, 128.73, 128.69, 
128.67, 127.20, 115.48, 67.41, 53.06, 38.00, 35.76, 33.11, 24.64. 
IR (CDCl3, cm-1) ν 3293, 3064, 3031, 2931, 1742, 1648, 1539, 1498, 1454, 1175, 744, 698. 





Yield: 53%, 17 mg, white solid. 
Rf = 0.27 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 3H), 7.32 – 7.28 (m, 2H), 7.25 – 7.19 (m, 3H), 7.07 – 6.98 
(m, 2H), 6.10 (d, J = 7.8 Hz, 1H), 5.18 (d, J = 12.2 Hz, 1H), 5.12 (d, J = 12.1 Hz, 1H), 4.95 (dt, J = 7.9, 5.8 
Hz, 1H), 3.18 – 3.07 (m, 2H), 1.36 (tt, J = 7.9, 4.6 Hz, 1H), 1.02 – 0.91 (m, 2H), 0.79 – 0.68 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 173.24, 171.74, 135.92, 135.21, 129.51, 128.74, 128.71, 128.66, 128.64, 
127.15, 67.35, 53.34, 38.10, 14.75, 7.52, 7.45. 
IR (CDCl3, cm-1) ν 3302, 3063, 3029, 3006, 2941, 2838, 1739, 1650, 1599, 1498, 1455, 1203, 1150, 1066, 
732, 699. 
HRMS (ASAP) m/z [C20H22NO3]+ ([M+H]+ ) calculated 324.1600, found 324.1601. 
 
 
Yield: 57%, 22 mg, colorless oil. 
Rf = 0.33 (EA/Hex 1:4). 
1H NMR (400 MHz, CDCl3) δ 7.44 – 7.31 (m, 3H), 7.34 – 7.28 (m, 2H), 7.28 – 7.18 (m, 3H), 7.04 – 6.95 
(m, 2H), 5.86 (d, J = 7.8 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.12 (d, J = 12.1 Hz, 1H), 4.95 (dt, J = 7.9, 5.8 
Hz, 1H), 3.19 – 3.05 (m, 2H), 2.24 – 2.12 (m, 2H), 1.74 – 1.59 (m, 5H), 1.54 – 1.42 (m, 2H), 1.28 – 1.05 
(m, 4H), 0.94 – 0.79 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 173.03, 171.73, 135.89, 135.21, 129.46, 128.76, 128.73, 128.68, 128.64, 
127.18, 67.39, 53.05, 38.00, 37.34, 34.16, 33.17, 33.11, 33.03, 26.65, 26.33.  
IR (CDCl3, cm-1) ν 3298, 3070, 3029, 2921, 2850, 1740, 1648, 1536, 1498, 1451, 1174, 905, 730, 698. 
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HRMS (ASAP) m/z [C25H32NO3]+ ([M+H]+ ) calculated 394.2387, found 394.2384. 
 
6. Mechanistic studies 
Possible aziridine intermediate 
 
[Cp*RhCl2]2 (0.0050 mmol, 5 mol%) and sodium bicarbonate (0.03 mmol, 30 mol%) were measured in a 
0.5-dram vial with a magnetic stir bar. In a separate vial, dioxazolone 3a (0.1 mmol, 1 equiv) and ethyl 
acrylate 2b (0.3 mmol, 3 equiv) were dissolved in 0.10 mL of MeOH and transferred to the first vial. It was 
rinsed with an additional 0.07 mL of MeOH and transferred again to the first vial. The reaction mixture was 
then stirred at room temperature for 16 hours. After the completion of the reaction, the solvent was removed 
by rotary evaporator. Ethyl acetate was added to the residue and filtered through a short pad of celite and 
washed with ethyl acetate three times. The filtrate was concentrated by rotary evaporator and a crude 1H 
NMR spectrum was collected with 1,3,5-trimethoxybenzene as the internal standard. As a result, neither 
aziridine nor ring-opening products by methanol were observed. This result suggests Rh(III)-catalyzed 













Reversibility of -hydride elimination 
  
               
Benzyl cinnamate 7 was prepared according to literature procedures.9 [Cp*RhCl2]2 (0.0050 mmol, 5 mol%) 
and sodium bicarbonate (0.03 mmol, 30 mol%), and naphthalene-1-boronic acid 1q (0.25 mmol, 2.5 equiv)  
were measured in a 0.5-dram vial with a magnetic stir bar. In a separate vial, benzyl cinnamate 7 (0.1 mmol, 
1 equiv) was dissolved 0.10 mL of MeOH and transferred to the first vial. It was rinsed with an additional 
0.07 mL of MeOH and transferred again to the first vial. Sequentially benzyl acrylate 2a (0.3 mmol, 3 
equiv) and dioxazolone 3a (0.1 mmol, 1 equiv) were added to the reaction mixture using a micropipette. 
The reaction mixture was then stirred at room temperature for 16 hours. After the completion of the reaction, 
the solvent was removed by a rotary evaporator. Ethyl acetate was added to the residue and filtered through 
a short pad of celite and washed with ethyl acetate three times.  The filtrate was concentrated by rotary 
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evaporator and a crude 1H NMR spectrum was collected with 1,3,5-trimethoxybenzene as the internal 
standard).  
 
Reversibility of proto-demetalation step 
 
                     
Benzyl 3-phenylpropanoate 8 was prepared according to literature procedures.10 [Cp*RhCl2]2 (0.0050 
mmol, 5 mol%) and sodium bicarbonate (0.03 mmol, 30 mol%), and naphthalene-1-boronic acid 1q (0.25 
mmol, 2.5 equiv)  were measured in a 0.5-dram vial with a magnetic stir bar. In a separate vial, Benzyl 3-
phenylpropanoate 8 (0.1 mmol, 1 equiv) were dissolved 0.10 mL of MeOH and transferred to the first vial. 
It was rinsed with an additional 0.7 mL of MeOH and transferred again to the first vial. Sequentially benzyl 
acrylate 2a (0.3 mmol, 3 equiv) and dioxazolone 3a (0.1 mmol, 1 equiv) were added to the reaction mixture 
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using a micropipette. The reaction mixture was then stirred at room temperature for 16 hours. After the 
completion of the reaction, the solvent was removed by a rotary evaporator. Ethyl acetate was added to the 
residue and filtered through a short pad of celite and washed with ethyl acetate three times.  The filtrate was 
concentrated by rotary evaporator and a crude 1H NMR spectrum was collected with 1,3,5-
trimethoxybenzene as the internal standard. While both reactions give the desired product (4q) from 1-
naphthyl boronic acid (2q) in good yield, carboamination products (4a) from these side products (7 or 8) 




The same experiments were conducted without benzyl acrylate (2a) and without both naphthalene-1-
boronic acid (1q) and benzyl acrylate (2a). As a result, carboamination products are not observed after the 










Reaction progress monitoring 
        
 
[Cp*RhCl2]2 (0.0050 mmol, 5 mol%) and sodium bicarbonate (0.03 mmol, 30 mol%), and phenylboronic 
acid 1a (0.25 mmol, 2.5 equiv) were measured in a 0.5-dram vial with a magnetic stir bar. In a separate 
vial, benzyl acrylate 2a (0.3 mmol, 3 equiv) and dioxazolone 3a (0.1 mmol, 1 equiv) were dissolved in 0.10 
mL of MeOH. It was rinsed with an additional 0.07 mL of MeOH and transferred again to the first vial.  10 
separate reactions were set up and each time the solvent was removed by rotary evaporator and ethyl acetate 
was added to the residue and filtered through a short pad of celite and washed with ethyl acetate three times.  
The filtrate was concentrated by rotary evaporator and a crude 1H NMR spectrum was collected with 1,3,5-
trimethoxybenzene as the internal standard. 
 
Synthesis of benzyl acrylate-3,3-d2 (2a-d2) 
Benzyl acrylate-3,3-d2 (2a-d2) was synthesized following literature11 using 
(benzyloxycarbonylmethyl)triphenylphosphonium bromide and paraformaldehyde-d2. To a solution of 
(benzyloxycarbonylmethyl)triphenylphosphonium bromide (10 mmol, 1 equiv) in a 2:1 mixture of 
Et2O/H2O (40 mL/20 mL), K2CO3 was added portionwise over 15 minutes. After stirring 24 hours at 35 °C, 


























organic layer was dried with MgSO4 and filtered. To this solution, paraformaldehyde-d2 (10.5 mmol, 1.05 
equiv) was added and refluxed for 24 hours. After careful removal of the solvent, the crude material was 
purified by column chromatography using pentane and Et2O. Yield: 48%, colorless oil. 1H NMR (500 MHz, 
CDCl3) δ 7.44 – 7.30 (m, 5H), 6.18 (bs, 1H), 5.22 (s, 2H). 
 
Intermolecular competition KIE 
 
[Cp*RhCl2]2 (0.010 mmol, 5 mol%), sodium bicarbonate (0.06 mmol, 30 mol%), and phenylboronic acid 
1a (0.50 mmol, 2.5 equiv) were measured in a 1-dram vial with a magnetic stir bar. In a separate vial, 2a 
(0.15 mmol, 1.5 equiv) and 2a-d2 (0.15 mmol, 1.5 equiv) were dissolved in 0.20 mL of MeOH containing 
1,3,5-trimethoxybenzene as standard and transferred to the first vial. It was rinsed with an additional 0.13 
mL of MeOH and transferred again to the first vial. After the addition of dioxazolone 3a (0.20 mmol, 1 
equiv), the reaction mixture was stirred at room temperature for 30 min. 20 uL aliquot was taken and diluted 
with 0.5 mL of MeCN-d3 then analyzed by 1H NMR. The KIE value was calculated based on the area of 
the 4.92 ppm (contribution from both molecules, 4a and 4a-d2) and at 3.12 ppm (contribution solely from 
4a). The experiment was repeated three times and an average KIE value of 0.72 indicates sp2 → sp3 
hybridization change during the turnover limiting step, which suggests alkene migratory insertion as the 








Intermolecular parallel KIE 
 
KIE was measured from two separated reactions, one with benzyl acrylate (2a) containing two C-H bonds 
and benzyl acrylate-3,3-d2 (2a-d2) containing two C-D bonds. [Cp*RhCl2]2 (0.010 mmol, 5 mol%), sodium 
bicarbonate (0.06 mmol, 30 mol%), and phenylboronic acid 1a (0.50 mmol, 2.5 equiv) were measured in a 
1-dram vial with a magnetic stir bar. In a separate vial, 2a (or 2a-d2) (0.60 mmol, 3 equiv) were dissolved 
in 0.20 mL of MeOH containing 1,3,5-trimethoxybenzene as standard and transferred to the first vial. It 
was rinsed with an additional 0.13 mL of MeOH and transferred again to the first vial. Dioxazolone 3a 
(0.20 mmol, 1 equiv) was added to the reaction mixture using a micropipette and the reaction mixture was 
stirred at room temperature. To monitor the reaction progress, 20 uL aliquot was taken every 5 min and 
diluted with 0.5 mL of MeCN-d3. KIE value was calculated by comparing the initial reaction rate (slope) 
of each reaction (repeated 3 times each) by using 1H NMR. Observed inversed secondary KIE (KH/KD) 





Syn addition of alkenes 
Synthesis of benzyl acrylate-3-d1 (2a-d1) 
 
(E)-3-bromoacrylic acid was synthesized following literature.12 To a solution of (E)-3-bromoacrylic acid 
(1.0 g, 6.62 mmol) in D2O (1.0 M), 5.0 g of 20% sodium amalgam was added as one portion at 0 °C. After 
stirring 5 min at 0 °C for 5 min, the reaction mixture was warmed to room temperature and stirred additional 
30 min. The reaction mixture was decanted and washed with water. The reaction mixture was acidified to 
pH ≈ 1 with 6 M HCl, then extracted with diethyl ether 3 times. The combined organic layer was washed 
with brine and dried over MgSO4 and solvent was removed by a rotary evaporator. (E)-acrylic-3-d acid was 
used without further purification (around 20% of over reduction product was observed). To a mixture of 
K2CO3 (1.1 equiv) and benzyl bromide (1 equiv) in DMF (1.0 M), (E)-acrylic-3-d acid was added dropwise 
at room temperature. After stirring for two hours at room temperature, the reaction mixture was diluted 
y = 1.56x + 2.2
R² = 0.9911


























with diethyl ether and washed with water and brine. The organic layer was dried with MgSO4 and 
concentrated. The crude material was purified by column chromatography using pentane and diethyl ether 
as eluent. 2a-d1. Yield: 20% (over two steps). Colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.30 (m, 
5H), 6.44 (d, J = 17.3 Hz, 0.86H), 6.17 (dt, J = 17.2, 1.5 Hz, 1H), 5.84 (d, J = 10.5 Hz, 0.15H). 
 
To a solution of [Cp*RhCl2]2 (0.05 mmol, 5 mol%), sodium bicarbonate (0.30 mmol, 30 mol%), and 
phenylboronic acid 1a (2.5 mmol, 2.5 equiv) in MeOH (1.7 mL, 0.6 M), 2a-d1 (3.0 mmol, 3.0 equiv) and 
3a (1.0 mmol, 1 equiv) were added at room temperature and stirred overnight. The volatiles were removed 
by rotary evaporator and ethyl acetate was added and filtered through short pad of celite. After removing 
solvent using rotary evaporator, the crude material was purified by column chromatography using ethyl 
acetate and hexane as eluent to obtain 4a-d1. Yield: 73%, white solid. 1H NMR (500 MHz, CD3CN) δ 7.40 
– 7.22 (m, 8H), 7.18 – 7.14 (m, 2H), 6.67 (s, 1H), 5.12 – 5.06 (m, 2H), 4.63 (t, J = 7.8 Hz, 1H), 3.07 (d, J 







6 M HCl (0.1 M) was added to 4a-d1 (1.38 mmol) and refluxed for 4 hours. After removing volatiles, diethyl 
ether was added, and the white solid was collected by filteration. The resulting solid was washed with 
diethyl ether and dried under high vacuum. The deprotected product was dissolved in MeOH (0.25 M) and 
SOCl2 (1.5 equiv) was added dropwise at 0 °C. The reaction mixture was warmed to room temperature and 
heated at 50 °C for 3 hours. The volatiles were removed by a rotary evaporator and diethyl ether was added. 
After stirring for 10 min at 0 °C, the white solid was filtered and washed with diethyl ether to give crude 
deuterated phenylalanine methyl ester hydrochloride. The crude material (1 equiv) and 2-picolinic acid (1.1 
equiv) were dissolved in DCM (0.2 M) and HOBt hydrate (1.1 equiv) and DIPEA (3.0 equiv) were added 
at room temperature. The reaction mixture was cooled to 0 °C and EDCI (1.1 equiv) was added. After 
stirring for 5 min, the reaction mixture was warmed to room temperature and stirred overnight. Water was 
added and extracted with DCM three times. The combined organic layer was washed with water and brine 
and dried with Na2SO4. After removing the solvent, the crude material was purified by column 
chromatography using ethyl acetate and hexane as eluent to obtain 4a’-d1. Yield: 69% (over three steps). 
White solid. 1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 
8.16 (dt, J = 7.8, 1.1 Hz, 1H), 7.83 (td, J = 7.7, 1.7 Hz, 1H), 7.42 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H), 7.33 – 






9a-d1 was prepared following the literature.13 In a 20 mL vial, Pd(OAc)2 (2 mol%, 0.018 mmol) and 
PhI(OAc)2 (2 equiv. 1.78 mmol) were measured in the glovebox. In a separate flask, 4a’-d1 (1 equiv, 0.89 
mmol) was dissolved in toluene (0.125 M) and transferred to the first vial. After purging with Ar for 10 
min, the vial was sealed and heated at 60 °C for 24 hours. The reaction mixture was concentrated and 
purified by column chromatography using ethyl acetate and hexane as eluent. 11a-d1. Yield: 81%, white 
solid. 1H NMR (500 MHz, toluene-d8) δ 8.85 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 4.8 Hz, 1H), 8.09 (d, J = 7.9 
Hz, 1H), 7.15 – 7.16 (m, 2H), 6.89 – 6.81 (m, 2H), 7.04 – 6.96 (m, 2H), 6.64 (ddd, J = 7.6, 4.7, 1.2 Hz, 







11a was synthesized from phenylalanine using same procedure described above. 11a. White solid.  1H 
NMR (500 MHz, toluene-d8) δ 8.86 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 4.5 Hz, 1H), 8.09 (d, J = 7.9 Hz, 1H), 
7.09 (td, J = 9.6, 7.8, 6.0 Hz, 2H), 6.89 – 6.81 (m, 2H), 6.62 (dd, J = 7.7, 4.8 Hz, 1H), 5.75 (dd, J = 10.9, 
3.2 Hz, 1H), 3.17 (s, 3H), 3.05 (dd, J = 16.4, 10.9 Hz, 1H), 2.95 (dd, J = 16.3, 3.2 Hz, 1H). The relative 
stereochemistry was assigned based on the literature.14 Benzylic proton with 10.9 Hz coupling constant was 
assigned as cis proton and proton with 3.2 Hz was assigned as trans proton which confirms the syn-



















(1)  Chanthamath, S.; Takaki, S.; Shibatomi, K.; Iwasa, S. Highly Stereoselective Cyclopropanation of 
α,β-Unsaturated Carbonyl Compounds with Methyl (Diazoacetoxy)Acetate Catalyzed by a Chiral 
Ruthenium(II) Complex. Angew. Chemie Int. Ed. 2013, 52, 5818–5821. 
(2)  Yang, W.; Luo, R.; Yang, D. Iridium-Catalyzed Asymmetric Ring-Opening of 
Oxabenzonorbornadienes with N-Substituted Piperazine Nucleophiles. Molecules 2015, 20, 
21103. 
(3)  Lautens, M.; Fagnou, K.; Zunic, V. An Expedient Enantioselective Route to Diaminotetralins:  
Application in the Preparation of Analgesic Compounds. Org. Lett. 2002, 4, 3465–3468. 
(4)  Phan, D. H. T.; Kou, K. G. M.; Dong, V. M. Enantioselective Desymmetrization of Cyclopropenes 
by Hydroacylation. J. Am. Chem. Soc. 2010, 132, 16354–16355. 
(5)  Cheng, X.; Zhu, L.; Lin, M.; Chen, J.; Huang, X. Rapid Access to Cyclopentadiene Derivatives 
through Gold-Catalyzed Cycloisomerization of Ynamides with Cyclopropenes by Preferential 
Activation of Alkenes over Alkynes. Chem. Commun. 2017, 53, 3745–3748. 
(6)  Lei, H.; Rovis, T. Ir-Catalyzed Intermolecular Branch-Selective Allylic C–H Amidation of 
Unactivated Terminal Olefins. J. Am. Chem. Soc. 2019, 141, 2268–2273. 
(7)  Hong, S. Y.; Park, Y.; Hwang, Y.; Kim, Y. B.; Baik, M.-H.; Chang, S. Selective Formation of γ-
Lactams via C–H Amidation Enabled by Tailored Iridium Catalysts. Science (80-. ). 2018, 359, 
1016 LP – 1021. 
(8)  Farr, C. M. B.; Kazerouni, A. M.; Park, B.; Poff, C. D.; Won, J.; Sharp, K. R.; Baik, M.-H.; 
Blakey, S. B. Designing a Planar Chiral Rhodium Indenyl Catalyst for Regio- and 
Enantioselective Allylic C–H Amidation. J. Am. Chem. Soc. 2020, 142, 13996–14004. 
(9)  Lutjen, A. B.; Quirk, M. A.; Barbera, A. M.; Kolonko, E. M. Synthesis of (E)-Cinnamyl Ester 
Derivatives via a Greener Steglich Esterification. Bioorg. Med. Chem. 2018, 26, 5291–5298. 
(10)  Chen, H.; Xu, X.; Liu, L.; Tang, G.; Zhao, Y. Phosphorus Oxychloride as an Efficient Coupling 
Reagent for the Synthesis of Esters, Amides and Peptides under Mild Conditions. RSC Adv. 2013, 
3, 16247–16250. 
(11)  Wenzel, S. C.; Williamson, R. M.; Grünanger, C.; Xu, J.; Gerth, K.; Martinez, R. A.; Moss, S. J.; 
Carroll, B. J.; Grond, S.; Unkefer, C. J.; et al. On the Biosynthetic Origin of Methoxymalonyl-
Acyl Carrier Protein, the Substrate for Incorporation of “Glycolate” Units into Ansamitocin and 
Soraphen A. J. Am. Chem. Soc. 2006, 128, 14325–14336. 
(12)  Ouellet, R. ,3’a-Dihydroxycyclopent-1’. 1976, No. 10, 2–11. 
(13)  He, G.; Lu, C.; Zhao, Y.; Nack, W. A.; Chen, G. Improved Protocol for Indoline Synthesis via 
Palladium-Catalyzed Intramolecular C(Sp2)–H Amination. Org. Lett. 2012, 14, 2944–2947. 
(14)  McComas, C. C.; Gilbert, E. J.; Van Vranken, D. L. Stereochemistry of 3-Alkylindole 
Dimerization:  Acyclic 1,1‘-Tryptophan Dimers. J. Org. Chem. 1997, 62, 8600–8603. 
318 
 





























































































































































































































































































































































































Rhodium(III)-Catalyzed Three-Component 1,2-Diamination of Unactivated 
Terminal Alkenes 
Sumin Lee, Young Jin Jang, Erik J. T. Phipps, Honghui Lei and Tomislav Rovis* 
 




Copy of 1H and 13C NMR Spectra 363 
 
  
367 
 
 
 
 
 
368 
 
 
 
 
 
369 
 
 
 
 
 
370 
 
 
 
 
 
371 
 
 
 
 
 
372 
 
 
 
 
 
373 
 
 
 
 
 
374 
 
 
 
 
375 
 
 
 
 
 
376 
 
 
 
 
 
377 
 
 
 
 
 
378 
 
 
 
 
 
379 
 
 
 
 
380 
 
 
 
 
381 
 
 
 
 
 
